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DEVELOPMENT OF THE ANALYTI CAL METHODOLO GY FOR 
PYRIMETHAMINE AND I TS APPLICATION TO S TUDIES OF PARTI ­
TIONING AND BINDING IN THE SUBCOMPARTMENTS OF BLOOD 
Abstract 
A dis sertation submitted in partial ful f i l lment of the 
requirements for the degree of Doctor of Phil osophy at 
Virginia Commonwealth Univers ity 
Anita Chaptal Rudy , Ph . D . 
Virginia Commonwealth Univers ity , 1 9 8 7  
Director : Wesley J. Poynor , Ph . D . 
An original H PLC assay was devel oped for pyrimeth-
amine ( PYR) in plasma , RBCs , and buffer for the purpose.  
o f  studying its plasma protein b inding and RBC part i -
t i oning . 
Equil ibrium dialysis ( E D )  was used to study pro-
tein binding . Isotonic phosphate buf fer used in ED did 
not prevent small volume shi fts . The pH o f  the plasma 
affected the protein binding of PYR a lthough it was not 
s ignificant for the comparison of binding at pH 7 . 4  vs . 
8 . 0. PYR at 1 0 0 0  ng/ml averaged 9 3 . 1 % bound to plasma 
prote ins . Binding to pure human albumin was 86.5% at 
l ower levels of al bumin and PYR ( 3 5 0  ng/ml ) . There was 
a s i gnificant dif ference ( p < . 03) in the p lasma b inding 
at two levels in the therapeut ic range , with more free 
at higher levels . There was a l s o  concentration depen-
dent binding at higher concentrations ; the drug did not 
follow to law o f  mas s  action when b inding increased at 
h igher concentrat ions . Th i s  i s  a solub i l ity phenomenon . 
Linear regress ion o f  the e f fect o f  albumi n  concentr�tion 
on plasma binding yielded the equation percent f ree = 
-0 . 4 6 7 ( albumin giL) + 23 . 5 .  The b i n di ng to pure albumin 
was only sl ightly above that p re dicted by th i s  equat ion 
( 8 3 . 1 % ) . The f i rst and second stoich i o metric binding 
constants a re K1 = 2 . 8 3  X 1 0 4 and K2 = 1 . 7 4 X 1 0 4 M- l 
f rom nonl inear regression o f  data . The re was no binding 
to no rmal levels o f  aI-acid glycoprotein . 
PYR is preferent ially bound to p l a s ma p roteins i n  
comparison to RBCs . The mean RBC/p l a s ma ratio was 
0 . 4 2 ( 1 0 . 2% CV , n=5 ) . When p l a s ma was removed and pH 
7 . 4  isoton ic bu ffer substituted, mean RBC/buffer rat i o  
w a s  5 . 2  ( 1 1 . 8 %  CV , n=2) . Mean percent bound to hemoly­
sate was 4 2 . 5%  ( 19 %  CV , n=1 0 ) .  Binding to hemogl ob in 
d i d  not account for a l l  the RBC uptake . The refore ,  PYR 
binds to RBC membranes . 
xv;; 
Chapter 1 
Introduct ion 
Pyrimethamine ( PYR) has been used a s  an ant imalar­
ial  s ince its introduction in the 1 9 5 0 s  ( 4 5 ) . More 
recently , it has ga ined recognition in f ight ing pl a smo­
d i a  resi stent to other ant imalarial drugs ( 9 6 , 1 0 9 ) . I n  
comb ination with a sul fonamide , it i s  t h e  o n l y  agent f o r  
use in toxopl asmo s i s  ( 1 2 8 ) . It i s  a l s o  used for pneumo­
nia caused by Pneumocystis carin i i  in acqu i red 
immunodefic iency syndrome ( 9 6 ) . In addition , PYR has 
had s ome success in neoplastic diseases o f  the central 
nervous system such as meningea l  l eukemia ( 1 9 ). 
Yet , for a drug that has been on the market for s o  
l ong and is used throughout the world for malaria ( 9 6 ) ,  
r elatively l ittle i s  known about i t s  pharmacokinet ics 
(I, 2 ,  70, 109, 112, 113, 125). Surprisingly, stud ies 
examining its protein b inding ( 2 , 1 9 ) and red cell  
uptake are almost nonexistent ( 1) . 
The l ack o f  analytical methodol ogy i n  the early 
years o f  its marketing is partly respons ible for the 
scarcity o f  pharmacokinetic studies . Recently , a s  
described in Chapter 2 ,  there have been several a s s a ys 
pub l i shed . 
In general , studies o f  the uptake o f  drugs by 
e rythrocytes or red bl ood cel l s  ( RBCs ) have also been 
infrequent in the pharmaceutics l iterature . The s e  
studies a r e  so infrequent that standard procedures have 
not been estab l i shed . Analytical art i facts whi ch w i l l  
be di scussed in Chapter 2 are frequently found in RBC 
studies . 
In the same way , convent ional methods for deter­
mining protein b indi ng -are l imited . S everal authors 
have questioned the va l idity o f  the maj ority o f  pub ­
l i shed prote in b inding studies ( 1 4 ,  1 6 , 2 5, 7 6 ,  1 1 9 ) . 
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There fore , several important factors involved i n  
measuring RBC up take were selected f o r  study . The s ame 
factors were a l s o  evaluated relat ive to pl asma prote i n  
b inding because RBC uptake and protein b inding a r e  s o  
closely rel ated . PYR was chosen as a model drug because 
it i s  a l ipoph i l i c  weak base that i s  l ikely to have 
s igni f icant RBC uptake and the protein b inding o f  thi s  
drug has not been studied extens ively . RBC uptake i s  
e s sential for a nt imalarial activity . Thi s  is an uncom­
mon chance to study a very acces sible t i s sue compart­
ment ( the RBC ) in which the mal arial parasite and , 
there fore , the s ite o f  action is l ocated . I nformation 
about the relationship between plasma and RBC l eve l s  
wou l d  b e  enl ightening for pharmacodynami c  studies . 
Chapter 2 
Literature Survey 
In thi s  chapter , a rev iew is presented of the 
phys icochemical properties and pharmacokinet ics of PYR, 
l i quid chromatography , the analys i s  o f  protein b ind ing 
data , ideal and nonideal cases o f  protein binding , s ome 
o f  the art i facts assoc iated with the c o l l ection o f  
protein bind i ng data , and the concepts o f  red bl ood c e l l  
( REC ) part itioning and b inding as they app ly in thi s  
work . 
2 . l Phys icochemical properties o f  PYR 
The phys icochemical propert ies o f  PYR 
( 2 , 4 -diamino-5- (3-chlorphenyl ) - 6 -ethylpyrimidine ) from 
Cava l l ito et al . ( l 9 )  are g iven in Tab l e  l . It is a 
strongly l ipoph i l i c  weak base . The structure is g iven 
b e l ow Tab l e  l . 
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Tabl e  1 .  Phys icochemical pro perties o f  PYR 
Molecular we ight 2 4 8 . 7 1 g/mol e  
Aqueous s o l ub i l ity : practically insol ub l e  « 1  in 
1 0 , 0 0 0  part s )  
Log P ( partition coefficient , octano l/water) 2 . 6 9 
pKa 7 . 3 4 
pKa ( Re f . 2 )  7 . 1 3 
pKa (Re f .  9 0 )  7 . 0  
C1 PYR 
Figure 1 .  structure o f  pyrimethamine ( PYR) . 
4 
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2 . 2  Pyrimethamine pharmacokinet ics 
PYR i s  an ant imalarial that was one o f  a series o f  
compounds synthes i z ed by Falco ( 4 5) i n  the late 1 9 4 0 's .  
I t  proved to be better than proguanil a s  an antima l a r i a l  
agent . Its pharmacokinet ics were not examined unt i l  
recently due t o  l ack o f  analyt ical knowl edge . The b a s i c  
pharmacokinet ics o f  PYR a r e  l i sted in Tab l e  2 .  Com-
p lete absorption o f  the dose o f  PYR was a s s umed in each 
s t udy in Tab l e  2 .  smith and Ihrig ( 1 1 3 ) determined the 
b ioava ilabil ity to be 1 . 0  in monkeys . Human bio­
ava i l ab i l ity has not been reported in the l iterature . 
Ref. No. of 
subjects 
( 1) 7 
(2 ) 6 
( 19) 4 
(70) 11 
( 109) 6 
( 125) 14 
TABLE 2. PHARMACOKINETICS O F  PYR 
Ana l yt i c a l  Dose 
method ( mg) 
TLC 25 
TLC 25 
TLC 1 0 0  
HPLC 12 . 5  
HPLC 25 
M i cro 25 
Cmax 
( ng/ml) 
E l im inat i o n  Vd 
h a l f - l ife 
C l e arance 
( ml/h/kg) 
(h) 
234 ± 21 83 ± 14 
81 :!:. 14 
600 -10 0 0  8 5  
( 79- 9 3) 
314 
+ 90 . 
8 0  
( 35 -17 5) 
123 :!:. 27 
214 96 
( 127-39 8) ( 46-15 0) 
2 . 93 24 . 8  
± 0 . 52 ± 3 . 8 
L/kg 
2 . 46 
±O . 6  
L/kg 
14 . 
±2 . 5 
7 5 . 9  20 . 5  
:!:. 28 . 6  :!:. 7 . 2 
L 
Mean ± standard d ev i a t i o n  or ranges of va lues are given . 
Vd = vo lume of d i stribut ion of centr a l  compartment . 
Cmax = maximum p l a sma concentra t i o n  
Analyti c a l  methods a r e  d i scus sed i n  S ecti o n  2 . 3  
Model 
1 com­
pa rt­
ment 
2 com­
pa rt­
ment 
l inear 
l inear 
2 com­
part­
ment 
2 com­
part­
ment 
0'1 
7 
The study o f  the protein b inding o f  PYR yields 
i n format ion about its dispos i t i on .  Ahmad and Rogers ( 2 )  
reported the pl asma prote in b inding o f  PYR a s  8 2 . 3  +/ -
2 . 6 % ( n=8 ) in vitro and 8 4 . 9  +/ - 2 . 5% ( n=9 ) ex vivo . 
Cava l l ito and others ( 1 9 )  reported the p l a sma prote in 
b inding o f  PYR a s  87  +/ - 1 %  ( n=3 ) . Percent b inding 
info rmation about PYR i s  of l imited value . More exp l i ­
c i t  information regarding the protein b inding o f  PYR i s  
necessary f o r  later reference in thi s  work ( S ection 
6 . 5 . 6 ) , thus a more deta i l ed description o f  the protein 
b inding o f  a s imilar compound i s  provided here . 
The study by Cava l l ito et a l . ( 1 9 )  included 
metoprine , 2 , 4 -diamino-5- ( 3 , 4 -dichl orophenyl ) - 6 -methy l ­
pyrimid ine , which i s  a mammal i an dihydro folate reductase 
inhib itor and a structura l anal og o f  PYR . Metoprine 
b i nd ing was studied in greater deta i l  than PYR b inding 
and because the ir structures di ffer by only one chl o ­
rine , t h e  two drugs may have s imilar b inding character­
istics . Plasma and serum samples were sp iked with 
rad i o l abel led met oprine . After equ i l ibration with 
protein fract ions in the samples , the prote in fract i ons 
were separated by el ectrophore s i s , and rad ioact ivity was 
associated with the albumin band . However, in equ i l i ­
brium dialysis experiments where pure protein fract ions 
were dissolved in phosphate buf fer at concentrat ions 
found in human pl asma , it was discovered that metop r i ne 
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bound to other pl asma proteins as wel l . 
Tab l e  3 .  Binding o f  metoprine to pl asma proteins ( 1 9 )  
Protein concentration Binding K X 1 0 3 
gl1 0 0  ml % ( S D )  
Albumin 1 . 8  58 . ( 1 .  0 )  5. 9 6  
j3-gl obul in 0 . 2  8 . 2  ( 3 . 9 )  1 0 . 3  
-y-globul in 0 . 5  3 . 4  p.O) 2 . 2 5 
j3- lipoprotein 0 . 1  5. 6 ( 1 . 2 )  3 1 1 .  0 
fibrinogen 0 . 2  0 . 9  ( 1 .  0 )  5. 7 
K = a f f i nity constant 
In fact , the a f f inity c onstant , K, for b inding t o  
j3- l ip oprotein fracti on was 50 t imes that for albumin . 
Tab l e  3 gives a summary o f  met oprine b inding at 1 �g/ml 
wh ich may be s imilar to PYR binding in pure fract i ons of 
protein . 
In the only ment i on o f  RBC l eve l s  in the l itera­
ture , Ahmad and Rogers ( 1 ) , as  an as ide , stated that the 
p l a sma and RBC concentra tions for PYR were s imilar . In 
the ir study , PYR c ompet itively displ aced daps one from 
p l a sma binding s ites . 
More recent papers on PYR concern its kinet ics in 
anima l s  ( 2 2 , 2 3 , 2 4 )  rather than in humans . 
2 . 3  Determinat i on of PYR in Biol ogica l Fluids 
I t  has been stated (2 1 )  that the pharmacokinet ics 
o f  PYR are not wel l  understood due t o  the lack of sens i -
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t ivity o f  previous analyt ical methods . On examination 
of the minimum detectabl e  l imits in Tabl e  4 ,  the l evel 
of detection i s  wel l below the trough on multiple dos ing 
( 2 0  ng/ml ) and the pharmacokinetics o f  PYR should be 
abl e  to be studied . However , these analyt ical methods 
were not uti l i z ed extens ively to d i scern the basic 
pharmacokinet ics in humans . The more sen s i t ive methods 
have b een used to study the pharmacokinet ics o f  PYR in 
anima l s  ( 2 2 , 2 3 , 2 4 ) . 
Previous methods o f  quant i fication included thos e  
l i sted in Table 4 .  The earl iest senst ive assay was 
devel oped by DeAngel is et a l . ( 3 0 )  in 1975. DeAngel i s  
e t  a l . ( 3 0 )  quant itated PYR o n  TLC ( thin-layer chroma­
tography ) plates with a uv absorbance scanning method . 
A method us ing HP-TLC ( h igh performance-TLC ) by Ahmad et 
a l . ( 1 )  had high coefficients o f  variation . Normal 
phase h igh pressure l i quid chromatography ( NP-HPLC ) 
methods were devel oped by two groups . Jones et al . ( 70 )  
used ultraviolet ( UV )  detect ion and nonl inear standard 
curves whi l e  T imm et a l . ( 1 18 )  used fluorescence detec­
t i on and had l inear cal ibrat ion curves . I n  both cases 
the d i sadvantages were the volat i l e  mob i l e  phases of  
normal phase chromatography . Jones et a l . ( 71 ) deve l ­
oped a sensitive gas l i quid chromatograph ic method ( GLC ) 
with a range of 5 -40 0 ng/ml . Weidekamm et a l . ( 1 2 5) , to  
the i r  advantage , used the antimicrob ial activity of PYR 
1 0  
i n  the ir microb iological assay . Three reverse pha s e  ion 
pair chromatographic ( RP-IPC ) procedures were deve l oped . 
Coleman et a l . ( 2 1 )  had a micro-analytical technique 
requ iring only 2 0�1 o f  samp l e  in a study o f  the pharma­
cokinet ics o f  PYR in mice . Edstein ( 3 8 ,  3 9 )  was abl e  to 
quantitate PYR with metabol ites and other drugs usua l ly 
given in comb ination products . The ma in d i fference i n  
these assays w a s  that one used a c i d  extraction a n d  the 
other used base extraction . Optimi z at i ons o f  the 
extractions in these a ssays were for the other drugs o f  
interest , not PYR . Midskov ( 8 9 )  h a s  reviewed the other 
assays . He deve loped the most sens itive analytical  
method with a 1 ng/ml detect ion l imit ; but it i s  comp l i ­
cated , and h i s  Spherisorb columns only l asted 6 0 0  inj ec­
t ions . 
Table 4 l ists the assays d i s cussed above . The 
detection l imits are l i sted a s  determined by the authors 
even though authors used d i f ferent definitions o f  mini­
mum detection l imit . The min imum detect i on l imits have 
been standard i z ed for detect ion in 1 . 0  ml o f  plasma . 
Tab l e  4 .  Previous methods o f  gyant i f ication o f  PYR 
Method Author Min Det Lim (ngim l )  
T L C  UV DeAngel i s  et a l . ( 3 0  ) 1 0  ( I S )  
NP-HPLC Jones et a l . ( 7 0 )  1 0  ( l S )  
HP-TLC Ahmad et al . ( 1 )  2 S  ( 2 S )  
GLC Jones et al . ( 7 1 )  S ( S )  
NP-HPLC 'l.'imm et al . ( 1 1 8 ) 1 0  ( S )  
Microb io Weidekamm et al . ( 12 S )  1 3  ( 2 6 )  
RP- IPC Col eman et al . ( 2 1 )  3 3 0  ( 6 . 6 )  
RP- IPC Edstein ( 3 8 )  S ( S )  
RP- IPC Edstein ( 3 9 )  S ( S )  
RP-HPLC Midskov ( 8 9 ) 1 ( 1 )  
M i n  Det Lim = Minimum detect ion l imit ( standard i z ed 
detection l imit in 1 . 0  ml o f  plasma ) 
1 1  
2 . 4  Liquid chromatography 
1 2  
In  order t o  devel op a n  HPLC assay f or PYR , knowl ­
edge of the basic principles of l i quid chromatography 
are necessary . 
S eparati on by HPLC depends on the d istribut i on of 
s amp l e  mol ecul es bet ween the mob i l e  pha s e  and stat i onary 
phase . D i f ferent molecular spec ies are thus retained t o  
d i f ferent degrees . From c omp onents in the original 
samp l e  that are introduced into the mob i l e  phase , bands 
f orm in the c olumn . Ideally bands should emerge c om­
p l etely separated . Bands tend t o  broaden the l onger 
they stay on the c olumn (5 5 ) .  
I n  l i quid chromatography , res olut i on ,  R, i s  def­
ined as the di stance between the centers of adj acent 
peaks divided by the average base width of peaks . R i s  
a measure of separati on .  R can a l s o  be defined a s  the 
p r oduct of efficiency ( N ) , capacity ( k') , and selecti­
vity ( a ) . 
E f ficiency , N ,  is the number of theoret ical p lates 
demonstrated by a c olumn and i s  a measure of c olumn 
qua l ity. High values of N demonstrate a superi or c ol umn 
and better separat i on ab i l ity . 
N 5.S-1 ( V/W1/ 2 ) 2 (1) 
where w l/ 2  is the width at hal f the peak he ight and V i s  
the retent i on volume . E f f iciency can be expres sed a s  
p l ates p e r  meter in order t o  c ompare c olumns of di ffer-
1 3  
ent length . N can be influenced by the manner in wh ich 
a column i s  packed , s i z e  and di stribution of part i c l e  
s i z e s , type o f  support structure , and qua l ity o f  packing 
materia l . 
Capacity , k', is a parameter describ ing the reten­
tion o f  molecular spec ies . It is the rat i o  o f  the mol e s  
o f  s olute in the stationary phase divided b y  the moles 
in  the mob i l e  phase . 
k' ( 2  ) 
where VI and Vo are the retent ion volume o f  the reta ined 
s o lute ( analyte ) and void volume respective l y  and t l and 
to are the retent ion t imes of the analyte and unreta ined 
s olute respect ively . 
Sel ectivity , a, i s  a rat i o  o f  capacities and a 
comparison o f  the relative retent ion o f  two component s . 
I t  rel ates the ir peak to peak separat ion . 
a 
k2 V2 - Vo 
Larger a values mean greater separat ion ( 55) .  
2 . 4 . 1  Ion nai r chromatogr aphy 
( 3  ) 
Ion pair c hro matography ( I PC ) is one kind o f  HPLC . 
It can be used for ionic or ionizable compounds . I P C  
espec ially h a s  advantages f o r  basic compounds that a r e  
i on i z ed at the p H  in which s i l ica based columns a r e  
stab l e . The theory o f  IPC , factors contro l l ing reten­
tion , typ ical counterions and app l ications of RP- IPC 
have been reviewed ( 58 )  
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2 . 5  E quations for the express ion of binding e qui l ibria 
The top i c  o f  PYR protein b inding was introduced i n  
s ection 2 . 2 .  The following i s  a discussion o f  the 
theoretical concepts of protein b inding . 
In the study o f  protein b inding , equations have 
been developed to express the interaction between drug 
and protein molecul es . Briefly , the b inding o f  drugs to 
proteins in the ideal case follows the l aw o f  mas s  
a c t i o n  where : 
[ P ]  + [ D ]  [ PD ]  
[ PD ]  
K 
[ P ]  [ D ]  
[ PD] 
r 
[ P ]  
( 4 )  
(5 ) 
(6) 
where r = number o f  moles o f  drug bound [ PD ]  per mo l e  o f  
total protein , [ P ] , and [ D ]  = the molar unbound drug 
concentrat ion , and K is the affinity or association 
constant . [PD] i s  the concentration o f  the protein-drug 
comp l ex . The bas i c  a ssumptions for th i s  model are that 
b i nding s ites on the protein are identical and affinity 
1 5  
does not change a s  occupancy increases ( independent 
s ites ) ( 7 6 ) . The relationship for r below is ident i c a l  
to t h e  Langmui r  i sotherm , an e xpress ion f o r  adsorpt ion 
( 7 8 ) . Eq . ( 7 )  i s  a more useful equation for e xpres s ing 
protein b inding data ( 1 0 6 )  where m i s  the number o f  
classes of  b inding s ites . 
m 
L 
niKi [ D] 
r = ----------
1 + Ki [ D] 
( 7 )  
i=l 
Eq.  ( 7 )  was l inear i z ed by Wol f f  in 1 9 2 9  and s ince then 
other names have been attached to thes e  equat ions ( E q .  8 
and 9 )  and graphical representat ions o f  them ( 2 7 , 7 6 ) , 
1 1 
r nK [ D ]  
r nK - rK 
[ D] 
1 
+ ( 8 )  
n 
( 9 )  
Two l inear p l ots are represented by Eq . ( 8 ) , which i s  
known as the double-reciprocal plot, and Eq. (9 ) , wh ich 
i s  known as the S catchard p l ot ( 1 0 6 ) . The l inear 
equa t i o ns a nd the i r  plots as dep icted in Fig . 2 a ssume 
that a l l  s ites are identical and the i r  a f f inities do not 
change with increasing occupancy . Thi s  is cal l ed the 
s ite approach . E q .  ( 7 )  is o ften referred to as the 
S catchard model ( 4 7 )  also . 
The alternative to the s ite approach is the ther-
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mOdynamic o r  stoichiometric model a s  described b y  Klotz 
with Eg.  ( 1 0 ) .  The binding constants refl ect the nature 
of interactions between s ites with increas ing occupancy . 
A semil ogarithmic p l ot o f  r versus l og free drug concen­
trations is not l inear , but i s  S -shaped ( F ig . 2 )  ( 7 4 ) . 
K1 [ D ]  + 2 K1K2 [ D ]
2 + . . .  + N ( K1 . . .  KN ) [ D ] N 
r = ------------------------------------------- ( 1 0 )  
1 + K1 [ D ]  + K1K2 [ D ]
2 + • . .  + ( K1 . . .  KN ) [ D ] N 
The S catchard approach as sumes the independence o f  
s ites and that they a l l  exist init i a l ly . The stoich i o ­
metric approach is val id whether or not s ites a r e  pre­
s ent and irrespect ive o f  cooperativity or ant i cooperat i ­
vity o f  binding . At l ow l igand concentrat ion i f  [ Db ] i s  
sma l l  compared to [ a lbumin ] ,  Eg. ( 1 0 )  s imp l i fies to r 
[ D ] Kl and therefore Kl = ( [ Db ] / [ D ] ) / [ a lbumin ] . This 
equat ion is very useful when the only information i s  
percent bound . In contrast , the scatchard model does 
not s impl i fy (63). 
Klotz (75, 77) has also questioned the use of 
nonl inear Scatcha rd pl ots to yield definite intercepts 
as b inding parameter est imates . The parameter estimate s  
a r e  meaningless unless suffic ient data have been c o l ­
l ected such that p l ott ing in a Klotz p l ot surpasses  a n  
i n f l ex i on po int o n  a n  S -shaped curve . S imp ly put , there 
i s  usual ly a need for higher l igand concentrat ions than 
most authors use , and the r versus log [ D] p l ot prov ides 
the best graph for ascertaining the s aturation l eve l s  
( 7 5 , 7 6 ) . The s ite approach completely col l apses when 
there is more than one binding constant for each s ite 
( when s ite a f f inities change with the extent o f  occu­
pancy ) even though the equat ion i s  widely used in such 
s i tuations ( 7 7 ) . 
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Nevertheles s , the shape o f  the Scatchard plot 
reveals useful information about the from o f  the b i nding 
model one should choose for fitt ing the data . For 
instance , a positive s l ope indicates that a s  l igands 
b ind , the probab i l ity of more l igand b inding increa s e s . 
positive cooperativity is the term for the enhancement 
of tendency to bind , an a l l o steric e f fect in the b i nd i ng 
proces s . A negative s l ope or negative cooperat ivity 
s igni f ies a decrease in the probab i l ity o f  more b inding 
a s  each l igand b inds . Scatchard p l ots should have an 
continuously negative s l ope i f  the data satisfy the 
a s sumption o f  independent and pre-exi stence o f  s ites . 
Even though apparent Ki ' s  obtained from data may not 
provide direct informat ion about the nature o f  the 
b inding s ite , Scatchard p l ots prov ide adequate initial 
est imates for nonl inear iterat ive search methods in 
which the search procedure has constraints s o  that 
meaningless values are not found ( 4 6 ) . 
In Fig . 2 ,  the parameter estimates that can be 
obta ined from these graphs are given . 
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Figure 2. Various protein binding plots. 
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2 . 6  statistical cons iderat ions o f  protein b inding data 
fitting 
As di scussed in the previous section , the Scat­
chard p l ot has been the method o f  cho ice for plotting 
data . Curvature indicates the existence o f  more than 
one type o f  b inding s ite ( 8 6 ) . When the S catchard p l o t  
g ives a curved l ine , extrapo l at i ons to t h e  intersect ions 
o f  the axes do not give reasonably accurate estimates o f  
b inding parameters and should not b e  used ( 6 3 ) . Klotz 
and Hunston ( 7 7 )  stated that a s s ignment o f  the b indi ng 
constants in these c i rcumstances is incorrect . As 
stated above , the S catchard model can be fit to data for 
which the parameters estimates from fits to the Scat­
chard model cannot be interpreted as b inding constants 
( 4 7 ) . Others c l a im that the non- integer n determined by 
statistical analyses i s  phys ically meaningless and it 
indicates a more comp l i cated model . They bel ieve that 
one needs to know total saturation . Error is greater i n  
both the l ow and h igh concentration range , but the 
Scatchard plot has l ow error . Dowd and Riggs ( 3 5 )  have 
found both l inear plots to be obj ectional and that the 
doub l e  reciprocal p l ot i s  the worst because it heavily 
we ights experimental points at l ow concentrations o f  
free drug [ D ] . The Scatchard model does not suffer from 
this d i sadvantage and at that t ime , 1 9 6 5 , it was the 
method o f  cho ice for pl otting data accord i ng to Dowd 
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and Riggs . 
To give . the high concentrations more nearly equ a l  
weight ing when evaluating b y  the method o f  least 
squares , it has been suggested that each point be 
weighted in proport ion to the concentration o f  free drug 
present ( 7 8 ) . In  that way , we ight ing accounts for the 
nonuni formity o f  the dependent variab l e  ( 9 1 ) . 
Another crit icism o f  the S catchard p l ot is that 
fitt ing it with l inear regression de fies  one of the main 
a ssumptions o f  least squares , namely , that error exists 
in one variab l e  only ( 3 6 ,  9 9 ) . Luecke and Wos i l a it ( 8 4 )  
have described a general procedure t o  f ind a maximum 
l ikel ihood estimate when both the independent a nd depen­
dent variables are subj ect to error . Riggs et a l . ( 9 9 )  
used geometric regress ion to solve thi s  problem . 
2 . 7  Nonideal cases o f  protein b i nd i ng 
In most reviews o f  protein b inding , methods for 
the analys is o f  ideal data are presented , as I have 
d i s cussed above . However ,  some authors have reported 
nonideal systems ( 9 ,  1 5 , 7 6 ) , and thi s  review of prote i n  
b inding will  b e  completed with examples o f  nonide a l  
b i nding s ituations . 
Brodersen et al . ( 1 5 )  have called serum a lbumin a 
nonsaturabl e  carrier . They reported that the b inding o f  
ligands t o  serum albumin showed n o  s igns o f  satura t i on 
for the 15 l igands studied . saturation would have been 
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supported by the occurence o f  an inflexion po int i n  the 
b inding isotherm where the rati o  of bound l igand to 
albumin i s  pl otted aga inst l og free l igand concentration 
( F ig .  2 ) . The adaptab i l ity o f  the tert iary structure 
of a lbumin may account for the f a i lure to observe s atu­
ration . 
They also state that it is genera l l y  not meaning­
ful to  dist inguish spec i f ic from nonnspec i fi c  b inding 
because bound drug molecules are merely transported by 
albumin . The e ffect o f  the drug i s  not related to 
b inding to a spec i f i c  or nonspec i f i c  s ite on the albumin 
a s  it would be in the case o f  a drug b inding to a recep­
tor that produces an action . In the l atter case , only , 
the term speci f i c  b inding appl ies . Also , the term h igh 
versus l ow affin ity is not j ust i f ied ( 1 5 ) . 
The fact that binding classes o f  diverse a f f in i ty 
have been found supports the idea that b inding to albu­
min i s  heterogeneous . In cases o f  heterogeneous s ites , 
one cannot assume independence o f  s ites ( 7 7 ) , and thus 
the Scatchard model should not be used to fit the data . 
S ome o f  the numerous b inding phenomena that exist are 
adsorption to the prote in surface , dissolution o f  the 
l igand in the interior o f  the carrier molecu l e , and 
b inding to heterogeneous s ites . They woul d  a l l  give 
S catchard curves as seen with albumin b inding and could 
p o s s ibly be fit by the S catchard equat ion ( E q .  (9» , but 
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the conclusion o f  the presence o f  s ites with cert a i n  
a f f inities i s  unj ust i fied unless supported b y  add i t i on a l  
evidence . The stoichiometric approach has the advantage 
of avo iding dubious c l a ims o f  the existence of s ites 
( 6 3 )  • 
There are at least two sources o f  curvature in the 
l inear p l ots : ( 1 )  the presence of more than one c l a s s  o f  
b inding s ites and ( 2 )  el ectrostati c  e ffects . Curvature 
in the doub l e-reciprocal p l ot may occur when the b inding 
o f  drug molecules to a protein exert addit ional e l e c ­
trostatic repul s ion toward oncoming drug molecules ( 7 4 ) . 
That is , the a f f inity o f  one s ite may be altered a s  
other molecules are bound a t  other s ites ( 7 7 ) . 
The Scatchard equation produces a stra ight l ine 
only when one class  o f  b inding s ites i s  present . I n  
cases where m classes o f  s ites exist , each class i 
having ni s ites and assoc iation constants Ki , curvature 
exists ( 8 6 ) . Curvature may be an indication o f  interac­
t i ons between initially identical s ites where ass ign­
ments o f  s ite constants are incorrect ( 7 7 ) . 
Binding may fall  below the idea l , as in the c a s e  
o f  attenuated a f f inites , and a curve would appear below 
the l ine in the Scatchard plot ( F ig .  2 ) . In the Klotz 
plot decreas ing a f f inities or fixed d i fferent a f finities  
make it l ook l ike there is no inflexion po int , and the 
l ine occurs below the ideal S -shaped curve . Thi s  lack 
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o f  inflexion po int i n  the b inding i sotherm suggests a 
l ack o f  saturat ion . When the b inding curve fal l s  b e l ow 
the ideal , the a f f inities may be f ixed but be from 
d i f ferent classes of s ites or the s ites may be i n i t i a l l y  
identical but s ome a f finity decreases with increas ing 
occupancy ( negative cooperativity ) . Thes e  two s itua­
t ions cannot be d i f ferenti ated ( 7 6 ) . 
S ager et a l . ( 1 0 4 )  invest igated the b inding o f  
propranolol  t o  albumin , l ipoproteins , and a lpha l -acid 
glycoprotein ( AAG) . Scatchard plots o f  the b inding o f  
proprano lol t o  albumin and AAG a t  the same t ime showed 
curvature . Binding to l ipoproteins produced Scatchard 
p l ots where the s l ope of the curve was not s igni f icantly 
d i f ferent from z ero and the y- intercept was 0 . 7 5 .  The i r  
conclusion w a s  that the drug w a s  n o t  bound but distrib­
uted to l ipoproteins independent o f  propranolol  concen­
tration . Binding was variab l e  between subj ects and 
correlated with AAG concentrat ion . 
The case o f  multiple classes o f  s ites has been 
reviewed by Bl anchard et a l . ( 9 ) . Due to the consider­
able variation in the determination o f  both free and 
bound drug concentrat ion , it may not be possible to 
determine more than the f i rst c l a s s ical assoc iation 
constant . The ir equat ion accounts for a c l a s s  o f  b indi ng 
s ites that possess an inf inite ( nonsaturab l e )  b inding 
capac ity with z ero a f f in ity . That c l a s s  o f  s ites pro-
duces a horiz ontal a symptote on a Scatchard plot . Km 
becomes very sma l l  indicating " z ero " a f f inity . 
m- l 
niKi [ D ] 
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r I ------------ + nmKm [ D ]  ( 1 1 )  I 
i=l 
+ Ki [ D ]  
When m = 2 i n  E q .  ( 7 )  ( the case o f  two classes o f  
s ites ) , b inding data pl otted a s  i n  a S catchard plot i s  
nonl inear . However , many parameter fitting programs 
f a i l  to converge when K2 approaches 0 and n2 approaches 
infinity . Accordingly ,  they suggest the use o f  thi s  
equation : 
r ( 1 2 )  
where the n2 K2 [ D ]  term describes the horiz ontal 
a symptote and Eq. ( 1 2 )  becomes a three parameter model 
where n2 K2 [ D ]  is  fit as C in the fol l owing rearrange-
ment . 
--------- + C ( 1 3 ) 
At l ow r values , l igands assoc iate with h igh a f f in ity-
l ow capacity s ites . At saturation , molecules part i t ion 
into a class o f  high capac ity- l ow a f f in ity s ites . 
In another recent attempt to s imp l i fy the analys i s  
o f  b inding data , Larsen e t  a l . ( 8 2 ) have promulgated a 
two-constant equation for multiple a lbumin b inding 
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i sotherms . Their equation is not a saturation funct i o n  
b u t  accounts for decl ining a f finities a s  l igand concen-
trat ion increases . 
R ( C )  ( 1 4 )  
where R ( C ) = r and C = free l igand concentration and K1 
and K2 are the first and second stoichiometric b inding 
constants . The d i sadvantage o f  this equation i s  that it 
cannot be appl ied to s ituations involving cooperat ivity . 
2 .B Methods o f  blood c o l l ect ion 
Analys is o f  data can only produce results as good 
a s  the data themselves ( 7 5 ) . There has been a great 
deal of interest in the possible alterat ion o f  drug 
protein b inding by the method of bl ood c o l l ection ( lB ,  
2 5 ,  7 3 , 1 1 1 , 1 1 5 , 1 3 0 ) . In fact , there are many arti -
factual changes associated with protein b inding measure-
ments ( 1 3 0 ) . These changes have espec i a l l y  been a s s o c i -
ated with basic drugs ( 5 1 ) . 
In the fol l owing pages , several o f  these s ources 
of error will be di scussed . 
2.B.1 Heparin 
Flushing the cannulas with heparin ra ises the 
l evel o f  non-esteri f ied free fatty acids ( NE FA )  by 
increas ing l ipoprote in l ipase activity ( 4 9 ) . One study 
in dogs ( 1 1 1 )  reported that intravenous p l a sma concen-
trat ion-time curves for propranolol be fore and after 
heparin admini strat ion were superimposible even though 
NEFA concentrat ions s l ightly increased a fter heparin . 
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Wood et a l . ( 1 3 0 )  examined the b inding o f  propra­
nolol  a fter the alternating cyc l e  o f  heparini z ed s a l ine 
administration and bl ood sampl ing . Thi s  cyc l e .  was 
repeated every 8 min for 6 doses . They measured propra­
nolol and NEFA l eve l s  and constructed a cumulative 
dose-response curve for heparin ( 5 0 to 1 2 0 0  IU ) . The 
protein b inding was measured . The free fraction 
increased from 9 . 9 % to 1 2 . 4 % a fter only 50 IU o f  heparin 
had been administered . There was a s ign i ficant 
( p < 0 . 0 0 1 ,  r=0 . 9 8 8 )  correlation between the change in 
free fraction and the l og cumulative dose o f  heparin . 
There was also a correlation between the log cumulative 
heparin dose and change in NEFA ( p < 0 . 0 0 1 ,  r= 0 . 9 9 6 ) . Most 
s ign i f icantly , there was a correlation between change in 
NEFA l evels and change in free fract ion o f  proprano l o l  
( p < O . O O l ,  r=0 . 9 8 8 ) . They a l s o  reported that heparin in 
vitro does not alter the b inding o f  propranolol . There 
was a s igni f icant d i f ference between free fract ions o f  
propranolol i n  samples drawn through a Butterfly® 
cannula and direct venipuncture whi l e , at the same t ime , 
there was no dif ference in NEFA level s .  The e l evation 
in the free fract ion may a f fect drug disposition acutely 
by making more drug ava i lable for di stribut ion out of 
the p l a sma space and into the red bl ood cel l s  and t i s -
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sues . As a resul t ,  volume o f  di stribut ion may incre a s e  
a n d  pl asma l eve l s  may fall . The overall  e f fect on drug 
metabol ism w i l l  a l s o  depend on whether or not the c l ear­
ance i s  a ffected ( restrictive or nonrestrictive e l imina­
t i on )  . 
Guentert and Oie ( 6 0 )  found that the e f fect o f  
inj ected heparin was dose dependent and that its e f fect 
on " protein binding could be prevented merely by reduc­
ing its concentrat ion . "  Only 5 U of heparin/ml is 
suffic ient to prevent coagulation in v itro . In cert a i n  
cases , altered protein b inding c a n  have a pro found 
e f fect on pharmacokinet ic parameters such as cl earance 
and apparent volume o f  distribut ion as wel l  as the 
interpretat ion o f  such data ( 8 3 ) . 
Brown et a l . ( 1 8 )  examined the e f fects o f  s everal 
potent ial l ipoprotein l ipase inhibitors to f ind a suit­
able one to suppress heparin-induced change s . E DTA and 
pyrophosphate were ineffective . Paraoxon ( di ethyl 
p-nitrophenyl phosphate ) ,  mepacrine , and DFP ( d i i s opro­
pyl fluorophosphate )  decreased l idoca ine b inding . Only 
protamine reduced the e ffects o f  heparin without a l ter­
ing p l a sma b inding . They suggested an E DTA/protamine 
mixture . The reversal o f  the heparin e f fect by prota­
mine/ E DTA supported the hypothes i s  that heparin ' s  e ffect 
invo lves the release o f  l ipoprotein l ipase and hepat i c  
triglyceride l ipase . Thes e  l ipases cont inue to rel ease 
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NEFA during equ i l ibrium dialys i s . There were apparent 
shortcomings in the s e l ection o f  an inhibitor . Prota­
minejEDTA a f fected proprano lol b inding but not d i a z epam 
or l idocaine binding ; thus s e l ection of the appropriate 
inhibitor would depend on the particular l igand . 
Heparin induced a decreas e  in quinidine prot e i n  
b inding more in vivo than in vitro ( 7 3 ) . 
2 . 8 . 2  Tri s C 2 -butoxyethyl l phosphate CTBEPl 
Cotham and Shand ( 2 5 )  were the f i rst to postulate 
that there was a chemical in Vacuta inerN ( Becton 
Dickinson and Co . , Rutherford , NJ ) stoppers that reduced 
the plasma b inding of propranol o l  and that the increased 
free drug could re-partit ion into RBCs . Kes s l e r  and 
others ( 7 3 )  reported a decreas e  in quinidine b inding in 
bl ood in Vacuta inersN . Contact with the rubber stopper 
produced highly variable ( 0  to 3 . 5  fold) e l evat ions in 
free quinidine fraction . Later isol ated from Vacutain­
ersN  was tris ( 2 -butoxyethyl ) phosphate ( TBEP)  which has 
been shown to inhibit protein b inding o f  alprenol o l  and 
imipramine to alpha 1-acid glycoprotein ( 1 0 ) . Fremstad 
( 5 1 )  also showed reduced b inding o f  quinidine and its 
redistribut ion into RBCs . He ment ioned th i s  e f fect 
occurred with other basic drugs . 
Stargel et al . ( 1 1 5 )  found that l idocaine b inding 
in in plasma fell s igni f i cantly from 5 6 %  to 2 8 %  when 
VacutainerN tubes were used in b l ood col l ection . 
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Lidocaine concentrat ion i n  serum f e l l  s igni fi cantly f rom 
6 . 5  to 4 . 9  �g/ml . The e f fect was seen only when whol e  
b lood was introduced into the tube s . Thi s  ind i cated 
that RBCs were involved . The relative a f f inity o f  TBEP 
i s  greater than the a f f in ity o f  l idocaine for b indi ng 
s ites in the plasma. 
The plast i c i z e r  TBEP is not used anymore ( 9 3 ) . 
Recently , it was shown that the new red-top VacutainerN 
tubes and the ant icoagul ant sodium c itrate did not 
a f f ect the protein binding of l idocaine in bl ood ( 1 1 4 ) . 
However , there is the possibil ity that other chemical s , 
perhaps a replacement for TBEP , a f fect protein bind i ng . 
2 . 8 . 3  Col l ection tubes 
After the removal o f  TBEP from most stoppers by 
Becton Dickinson and Co . , Nyberg and Martensson ( 9 3 ) 
tested e ight types o f  bl ood coll ection tubes and two 
types of pl asma separators on the stab i l ity of three 
tricyc l i c  ant idepres sants and the ir monodemethylated 
metabo l ites . Tubes with serum separator gel or f i lters 
were unsuitable and were responsible for losses of 
greater than 4 0 % . Thes e  losses were due to contact 
between the contents and the caps of the tubes , not 
re-di stribut ion between red cel l s  and p l a sma . The 
losses may have been from drug bind ing to the stoppers . 
E DTA-conta ining Venoj ectN l avender and Vacuta inerN 
l avender tubes gave the most stab l e  p l a sma samples but 
only by a sma l l  margin . Royal blue tubes were a l s o  
unsuitab l e . They found minimal e ffects on serum or 
p l a sma concentrat ions from freez ing and thawing or 
storage at -2 0 ° . 
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Potter and S e l f  ( 9 7 )  attributed variab i l ity in 
cycl o sporin A whol e  bl ood l eve l s  c o l l ected in heparin 
tubes to the microaggregations o f  RBCs and sma l l  fibrin 
clots seen under microsop ic examinat ion . The clots 
woul d  not disintegrate with gent l e  mixing . commerc i a l  
tubes containing EDTA produced homogenous suspens ions o f  
RBCs a n d  variab i l ity w a s  much less  than that from hepar­
in-conta ining tubes . Freez ing the samp l e s  coll ected in 
heparin tubes and thawing be fore assay reduced vari a ­
b l ity .  
2 . 8 . 4  The pH adjustment for protein b i nding 
In the e f fort to reproduce phys i o l ogic condit ions , 
p l a sma pH has been adj usted to 7 . 4  in prote in b inding 
stud ies . The pH adj ustment has been carried out by 
adding sma l l  volumes ( 5 - 1 0  �l ) o f  phosphoric acid ( 6 1 )  
o r  by t itrat ion with HCI ( 17 )  immediately be fore equ i l i ­
brium dialys i s . 
More correct ly ( this pract ice is more phys io­
logic ) , others ( 5 2 ,  1 0 4 ) gassed plasma with 5% C02 
before dialys i s . However ,  pH i s  o ften not ment i oned in 
protein binding experiments . Brors and Jacobsen ( 1 6 ,  
1 7 ) reviewed the many drugs that have been found t o  have 
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pH-dependent serum b inding . Due to the l o s s  o f  C02 
( 9 8 ) , pH o f  serum l e ft open to the atmosphere or froz en 
and thawed is pH 8 or h igher . The pH o f  thawed serum 
a fter storage at - 2 0 °  was 7 . 7  - 7 . 6  at 3 h .  Us ing 
PerspexN cel l s  sealed with tape , when serum was adj usted 
with HCl to 7 . 4  and then dialyzed at 2 2 °  aga inst sodium 
phosphate buf fers , the serum pH increased to 7 . 5 5 - 7 . 6  
at 3 h .  When serum was dialyzed aga inst ungassed Krebs 
Ringer bicarbonate buffer , the serum pH increased to 
7 . 7 4 a fter 1 h and 8 . 3 7 a fter 3 h.  At 3 7 °  the incre a s e s  
w e r e  greater than at 2 2 ° .  Dialys i s  against a l l  buffers 
produced mean pH 7 . 8  for serum a fter 3 h .  Even when 
serum was adj usted to pH 7 . 4  ( with HCl ) prior to dialy­
sis against Krebs Ringer bicarbonate buffer , the serum 
pH rose to 7 . 8 5 a fter 1 h and 8 . 4 5 a fter 3 h ( 1 7 ) . 
The unstabl e  serum pH is caused by loss o f  CO2 
during dialys i s  result ing in a decrease in hydrogen ion 
and bicarbonate concentrat ions in serum . The pH 
increase was greater at l ower buf fer mo larity and at 
higher temperatures .  The authors b e l i eve that a l a rge 
part of  pub l i shed data on drug b inding in serum contains 
such errors in pH and exceed acceptab l e  l imits for 
analytical errors ( 17 ) . 
2 . 8 . 5  O smot ic volume shi fts o f  fluid 
In equ i l ibrium dialys i s , it is important to mea­
sure shi fts in water across the membrane ( 5 6 ,  6 4 , 1 1 9 ) . 
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Dialys i s  cel l s  cons ist o f  a membrane separating a c e l l  
into two cell -halves . Dieterle et a l . ( 3 4 )  and Giacom­
ini et a l . ( 5 6 )  measured the protein concentration i n  
each cel l -ha l f  be fore and a fter dialys i s  to determine 
the volume shi ft . Authors ( 5 6 , 6 4 , 1 1 9 ) have presented 
equations for correcting for volume shi fts . Hu and 
curry ( 6 4 )  have stated that the use of isotonic buf fers 
in  E D  reduces the magnitude o f  volume shi fts . 
2 . 8 . 6  Mass bal ance cons iderat ions 
From the experimental viewpo int , the determination 
o f  protein b inding by equ i l ibrium dialys i s  has many 
inherent art i factual errors . The l ack o f  contro l s  
concerning mass balance is the maj or cause o f  thes e  
variations ( 1 4 ) . O ften , the conservation o f  mas s  i s  
probably assumed but i s  n o t  addressed in reports in  the 
l iterature ( 6 4 ) . Two deta i l s  frequently l e ft out o f  
most reports are correct ions for b inding t o  dialys i s  
�embranes and apparatus and drug decompos ition ( 1 4 ,  6 4 ) . 
A method ( 1 4 )  and an equation ( 6 4 )  that correct for l o s s  
o f  drug dur ing dialys i s  have been presented . 
2 . 9  Red bl ood c e l l  part ition ing 
Binding to plasma proteins has been d i scus s ed 
above . However ,  drugs b ind to other bl ood const ituents 
a s  wel l . Early work in pharmacol ogy revealed that many 
drugs had an unusual a f finity for RBCs . Maren et al . 
( 8 5 )  observed that a number o f  aromat ic N4 -subst ituted 
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sulfonamides which were carbonic anhydras e  inhibitors 
showed a high RBC/plasma concentration rat i o . Thei r  
comparison o f  d i f ferent categories o f  sul fonamides 
enabl ed them to describe a " d i f fusible component " and 
bound components . Compounds fit into three patterns o f  
distribut ion i n  the bl ood : ( 1 )  drugs l ike aceta z o l amide 
with strong b inding to red cel l s  ( probably to carbonic 
anhydras e )  and a d i f fusible component that followed a 
concentration gradient and was dependent on ionization 
and plasma protein b inding ; ( 2 )  compounds that accumu­
l ated in RBCs but were not firmly bound ; and ( 3 )  com­
pounds with no a f f inity for RBCs . The d i f fusible comp o ­
nent w a s  the drug that d i f fused freely i n t o  the RBC , w a s  
n o t  bound , and could be easily washed o u t  b y  rins ing t h e  
RBCs with an isotonic buffer . N1_ subst ituted drugs were 
not bound to RBCs , whereas unsubstituted ones were 
bound . They dismissed the role o f  l ipid solub i l ity 
a fter finding incons i stencies , pl aced i on i z at ion at a 
moderate importance ,  and decided that plasma b inding was 
the maj or determinant o f  d i f fusion . They also  examined 
b inding to hemoglobin . 
In contrast to Maren et a l . ,  the c l a s s i c  studies 
o f  S chanker et al . ( 1 0 8 )  found that l ipid solub i l i ty and 
degree o f  ion i z ation were the maj or propert ies of bases 
that determined their rate o f  passage into RBCs and that 
the unbound , union i z ed molecules were distributed 
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according t o  a Donnan equi l ibrium . They a l s o  looked a t  
b inding to nond i f fusible c e l l  components such a s  hemo­
globin ( 1 0 7 ) . 
S chanker et a l . ( 1 0 7 ) found that organic anions 
entered the cel l more rap idly than organic cations of 
s imilar low l ipid solubil ity and suggested a possible 
exp l anat ion . They proposed that anions entered through 
both the l ipoid regions and the positively charged 
aqueous pores . 
Korten and Mi l l er ( 8 0 )  found that the anion form 
o f  barbiturates doesn ' t  s ign i f i cantly part ition into 
b i o l ogical membranes us ing the RBC membrane model . The 
potency and pharmacodynamics of barbiturate anesthetics 
depend on their ab i l ity to d i f fuse through membranes . 
Many basic drugs have been found to have h igher 
concentrations in RBCs . Ahtee and Paasonen ( 3 )  noted 
that the uptake o f  three phenothiaz ines by RBCs was 
rel ated to the ir tranqu i l i z ing activ ity . The b inding o f  
chl o rproma z ine and imipramine t o  RBC membranes has been 
studied by Bickel ( 8 ) . 
2 . 9 . 1  E f fects o f  pH on RBC Partitioning 
More o ften than not , researchers refer to any drug 
in the bl ood that is not in the plasma as be ing " bound " 
by RBCs . I n  a sense , this is true because the drug i s  
n o t  free in the bl ood . To be more correct , however , 
they should distinguish between the bound and di ffusible 
3 5  
components a s  Maren et a l . did i n  1 9 6 0  ( 8 5 ) . 
Using the RBC as a model , S chanker et a l . ( 1 0 8 ) , 
determined that two properties , l ip i d  solub i l ity and 
degree o f  ion i z ation , o f  basic drugs were very important 
in determining the ir rate o f  distribution into cel l s . I n  
general , weak electrolytes d i f fuse according t o  the 
l ipid solub i l ity of the union i z ed spec ies which depends 
on the ion i z at i on o f  the molecule at the pH o f  the 
extracel lular med ium . The degree o f  i on i z at ion o f  the 
compounds i s  important because it defines the proport ion 
o f  drug in the l ipid solub l e  ( union i z ed )  form according 
to the Henderson-Hasselbach equat ion . 
There is normal l y  a pH gradient across the cel l s  
i n  the human body , with more acidity ( h igher part i a l  
pres sure o f  C02 ) intracel lularly . T h e  range ins ide RBCs 
i s  normally pH 7 . 1 3 -7 . 2 9 ( 5 9 ) . The pH gradi ent i s  
greater i n  c irrho s i s  and a fter nephrectomy . I n  anoxi a ,  
acidosis i s  more marked in the extracellular fluid 
compared to the intracellular fluid ( 1 2 2 ) . 
I f  the pH o f  the cell  and medium d i f fer , b a s i c  
mol ecules wi l l  favor the a c i d i c  s ide o f  t h e  membrane 
( 9 4 )  and the total concentration o f  drug wi l l  not be the 
s ame on d i fferent s ides of the membrane . The concentra­
t i on of unbound drug may be s omewhat higher on the 
ins ide compared to the outs ide o f  cel l s  ( 1 1 7 ) . I t  i s  
a l s o  poss ible that the union i z ed forms o f  weak acids and 
bases w i l l  have d i f ferent concentrations on d i fferent 
s ides o f  the membrane if the membrane i s  permeable to 
the i on i z ed conj ugate partners ( 1 0 1 ) . 
The pH dependent di stribut ion o f  any drug shou l d  
n o t  b e  influenced b y  the concentrat ion o f  that drug 
( 5 2 ) . According to Schanker et a l . ( 1 0 8 ) , what i s  not 
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accounted for by the pH d i fferent ial i s  due to b inding . 
Measuring the cel l/medium concentration rat io enab l e s  us 
to d i scriminate between d i f fusible and bound component s . 
with certa in restrictions , the concentration rati o  o f  
unbound d i f fusible anion i s  0 . 7 .  For cations , the rat i o  
i s  1 . 3 8 as di scussed more thoroughly below . A common 
pract ice is to as sume that i f  the rat i o  i s  greater than 
1 . 0 ,  b i nding i s  occurring ( 4 1 ) , but one must cons ider 
that bases have a higher free concentrat ion in cel l s  due 
to ion-trapping and that partit ioning depends on pKa . 
The fol l owing equat ion , first derived by Jacobs 
( 6 8 ) , describes the distribut ion o f  a weak base between 
two s olutions separated by a cell membrane permeab l e  
only to the union i z ed mol ecul e :  
Ccell  
Cmedium 1 + 1 0 ( pKa-pHmedium ) 
( 1 5 )  
By substituting into the equation the intracellu-
l a r  and extracellular pH value s , one obta ins rat i o s  
which a r e  ident ical to those calcul ated for t h e  Donnan 
distribut ion o f  the hydrogen ion because strong b a s e s  
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are mainly in the cationic form a t  thes e  pH value s . The 
higher the extracellular pH , the greater the c e l l/medi um 
rat io for the hydrogen ion and strong bases . When 
experimentally determined pH values for the medium are 
6 . 7 ,  7 . 4 ,  and 8 . 0 , the intracellular pH values for the 
RBC are 6 . 6 7 ,  7 . 2 6 ,  and 7 . 6 9 ,  and the cel l/medium rat i o s  
f o r  PYR f o r  these pairs o f  pH values would be 1 . 0 5 ,  
1 . 1 3 ,  and 1 . 12 .  S o ,  for PYR , with pKa 7 . 1 3 that i s  near 
phys iologic pH , the theoret ical cel l/medium concentra­
tion rat io does not para l l e l  the ratios o f  the hydrogen 
ion ( 1 . 0 7 ,  1 . 3 8 ,  2 . 0 4 ) . 
The importance o f  mainta ining phys iologic pH i n  
the medium o f  bl ood cell  suspens ions cannot be under­
stated when doing in vitro determination of RBC b inding 
and partitioning . 
Considering l ipoph i l icity ,  Korten and M i l l e r  ( 8 0 )  
have shown that part ition coe f f i c ients determined with 
RBCs correlate more closely with phys i o l ogical permeab­
i l ity constants than do those determined with organi c  
s olvents . The solvents failed to refl ect part i t i on i ng 
into biomembranes adequately . The pH partition hypothe­
sis described above was confirmed by Korten and M i l l e r . 
Taylor and Turner ( 1 1 6 )  a l s o  confirmed that part i ­
t ion coefficients overest imated d i f ferences in in vivo 
membrane permeab i l ity .  They found s imilar RBC/ free 
p l a sma drug concentration rat ios for three adrenerg i c  
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b l ockers which had greatly d i ffering l ipoph i l ic ity 
according to the ir organic s olvent partition coe f f i ­
c i ents . They also  noted that for l ipoph i l i c  drugs , 
partit ioning into the membrane is o f  greater importance 
than the accumulation o f  weak bases due to the l ower 
intracel lular pH . 
Bickel ( 8 )  has noted a common trend for l ipoph i l i c  
drugs capable o f  hydrophob ic interact ions . They tend t o  
interact with RBe , microsoma l , a n d  mitochondrial mem­
branes as wel l  as l ipoprote ins , alpha and beta gl obu­
l ins , white bl ood cel l s , and p l atelets . 
2 . 9 . 2  Drug disposition and RBe part itioning 
In 1 9 7 3 , Garrett and Lambert ( 5 3 )  expres s ed the 
need for the determination o f  protein b inding and RBe 
part i t i oning to provide a real istic phy s icochemical and 
phys i o l ogical pharmacokinetic descript ion of drug dispo­
s it i on in the body . Others observed the need for the 
invest igat ion of RBe uptake of drugs because o f  s im i l ar­
ities to plasma prote in b inding ( 4 3 , 4 4 , 5 2 , 5 3 , 8 1 ,  
8 7 ) . Drug b inding in the bl ood can a f fect drug distri­
bution , activity , and e l iminat ion ( 4 3 , 4 4 , 7 2 ) . The 
importance of the ir work i s  the recogn ition that only 
the unbound fract ion o f  drug i s  abl e  to e l icit pharmaco­
l ogical actions . As a result , e f forts to elucidate the 
relationship between plasma protein b inding , t i s sue 
distribution , and RBe uptake have been undertaken by 
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many sc ientists . 
In 1 9 7 3 ; b inding to and partit ioning into RBCs was 
shown to alter the del ivery o f  drug to its site of 
e l iminat ion by Evans and Shand ( 4 4 ) . One way to cata­
gori z e  drugs is by the ir metabol ism . In this case , 
c l a s s i f ication o f  drug metabol i sm can be based on 
hepatic clearance . Hepat ic cl earance is e ither 
restricted to the free drug in the c i rcul ation ( restric­
t ive cl earance ) or includes both free and protein bound 
drug ( nonrestrict ive cl earance ) .  I n  the i r  op inion , thi s  
c l a s s i fication should a l s o  include reference to the 
reservoir of  drug in the RBCs . Drug in the RBCs may b e  
removed during passage through e l iminating organs a s  i n  
the cases o f  propranol o l  ( 4 3 ) , quinidine ( 5 2 ) , cyc l oph­
o sphamide ( 1 2 3 ) , and chlorothiaz ide ( 1 1 0 ) . The c l ear­
ance o f  ch1orothiaz ide from the b l ood was found to 
d i f fer between intravenous and oral admini strat ion due 
to the influence of the t ime-dependent distribut i o n  to 
the RBCs . 
2 . 9 . 3  RBC part ition ing relative to protein binding 
The unbound d i f fusible concentrations o f  drugs i n  
t h e  p l a sma a r e  determined b y  protein b inding . The idea 
that drug distribut ion into the t i s sues i s  dependent on 
the unbound concentrat ion in the p l a sma l ed to the 
examination of the interact ion between p l a sma protein 
b inding and RBC partitioning ( 1 1 ,  4 3 , 4 4 , 6 9 , 8 1 ) .  
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S everal authors noted a l inear relationship 
between the RBC/ P drug concentration rati o  and free drug 
in the plasma ( 4 3 , 5 4 , 6 2 , 6 5 , 6 9 , 8 1 ,  1 1 6 ) . Evans and 
Shand ( 4 4 )  and Taylor and Turner ( 1 1 6 )  a l s o  reported a 
l inear relationship between WB/P ratios and free drug 
concentration . with thi s  information , the degree o f  
protein b inding i n  plasma drug could b e  determined g iven 
a RBC/P concentration ratio .  
I n  contrast , Derendorf et a l . ( 3 1 )  found a l ack o f  
correlation between prote in binding and RBC partition ing 
for morphine , nal oxone , and naltrexone . 
2 . 9 . 4  Variables from analytical techn iques 
2 . 9 . 4 . 1  Mass bal ance considerations 
Binding to serum albumin has been studied exten­
s ively . The phenomena o f  RBC partitioning and b inding 
are much more complex and the measurement o f  these 
processes is ultimately more compl icated . The entry and 
rate of entry of molecules is governed by physiocochemi­
cal propert ies o f  the molecules and the RBC membrane . 
Drugs may be bound by the RBC membrane or intrace l l u l a r  
components such as hemoglobin or carbon ic anhydras e , and 
may exist in the intracellular fluid or cytopl a sm in a 
freely d i f fusibl e , unbound form ( 9 5 ) . 
Many invest igators use the rough est imate that i f  
the whol e  bl ood/plasma ( WB/ P )  drug concentrat ion rat i o  
i s  greater than ( 1 -hematocrit ) ( 4 1 )  or i f  t h e  WB/ P rat i o  
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exceeds 1 . 0  ( 8 8 ) , the drug i s  distributed t o  the RBCs . 
However , there is a d i f ference in the ratios depending 
on whether the drug i s  a weak acid o r  a weak base . 
S chanker et a l . ( 1 0 8 )  calculated the RBCj P concentrat ion 
ratio o f  unbound d i f fusible anion at pH 7 . 4  and found it 
to be 0 . 7 .  For cations such a s  weak bases , the rat i o  i s  
near 1 . 4 .  The rat ios given by Schanker et al . are near 
the actual ratios for anions and cations . However ,  for 
more prec ise estimates o f  the RBCj P rat ios , one mus t  
cons ider t h e  pKa values o f  indiv idual weak a c i d s  and 
bases . The theoret ical RBCjP rat ios w i l l  be more tho­
roughly discussed in s ections 5 . 4  and 6 . 4 .  
It is a common pract ice in studying RBC part i t i on­
ing to calculate the RBC l evel based on the assays of 
the pl asma ( or supernatant in buffer suspensions o r  
serum ) and the who l e  bl ood knowing t h e  hematocrit and 
as suming mas s  bal ance in the bl ood ; the amount in the 
p l a sma i s  subtracted from the who l e  bl ood content and 
the rema inder i s  as sumed to be in the RBCs . O ften th i s  
i s  done without even assaying the who l e  bl ood b y  assum­
ing it to contain the sp iked bl ood concentration ( 1 2 ,  
4 3 , 5 3 , 6 2 , 6 5 , 6 6 ) . Thi s  i s  done due to the ease o f  
as say ing p l a sma compared t o  assaying who l e  b l ood o r  
RBCs . 
However , thi s  procedure does not account for the 
in  vitro art i facts such as drug degradat ion or 
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metabol i sm , b inding t o  glass , o r  part i t i oning into white 
b l ood cel l s  or p latelets . Erythromycin proprionate 
hydrolyzes to erythromycin during storage at room t em­
perature and in the frozen state . Thus erythromycin 
l evel s  are increased ( 1 2 1 ) . Hemoglobin catalyzes the 
format ion o f  the sul foxide o f  chlorproma z ine and may 
l ead to a trapp ing e f fect and di screpanc ies in b i nding 
experiments ( 8 ) . Drayer et a l . ( 3 7 )  found that pro­
cainamide , para-aminosal icy l i c  acid , and dapsone 
were acetylated by who l e  bl ood , and the de-acetylated 
metabol ite o f  dapsone was also metabol i z ed back to 
dapsone . For these reasons , it is necessary to confirm 
who l e  bl ood l eve l s  by as say at the same t ime as one 
measures levels in the fract ions of b l ood . 
2 . 9 . 4 . 2  E f fect o f  trapped pla sma 
S ome authors have measured the RBC and p l a sma 
l evels after separating them by centri fugation ( 6 ,  4 8 , 
6 2 , 8 1 ) . For thi s  method , it is necessary to account 
for trapped p l asma or the volume of extracellular f l u i d  
in t h e  packed cel l m a s s  ( 4 1 ,  5 0 , 7 9 , 1 0 8 ) . Thes e  
researchers assumed constant packing o f  cel l s . However , 
p l a sma trapped in the red cell column in a centri fuge 
tube is h igh:y variable . It varies with centri fugal 
force which depends on the radius o f  the centri fuge , the 
di stance from the center of the head to the midd l e  o f  
the packed cel l column , and the speed o f  the centri fuge 
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a s  wel l  a s  the viscos ity o f  the medium . Packing a l s o  
depends o n  the t ime centri fuged and fluctuat ions in the 
accel eration and decelerat ion . As the packed cel l 
volume increases the percentage o f  p l a sma trapped in the 
RBC column increases due to the reduct ion in e ffective 
radius o f  centri fugat ion . It i s  better to spin s amp l e s  
f o r  a l onger period o f  t ime , 5 5  minutes ,  to reduce 
variat ions ( 2 0 ) . 
In the case o f  measuring concentrations in the 
centri fugal ly separated RBC fraction of bl ood , great 
errors can result from not account ing for trapped 
p l a sma . Thi s  s ource o f  error increases as the p l a sma 
protein b inding increases , the trapped plasma increa s e s , 
and in l ow percentage RBC partitioning , creating f a l s e l y  
e l evated RBC leve l s . It is possible the fract ional 
amounts in the RBCs and plasma could add up to greater 
than the true who l e  bl ood concentrat ion . 
Researchers have attempted to correct for p l a sma 
trapp ing . Kornguth and Kunin ( 7 9 )  determined the 
trapped extracel lular antibiotics in the RBC fract ion by 
measuring the hematocrit o f  the RBC fracti on as did Roos 
and Hinderl ing ( 1 0 2 ) . Parsons and Val lner ( 9 5 )  erro­
neously a ssumed a constant 9% trapped extracellular 
fluid ( ECF ) in the RBCs and subtracted it from the 
percent hematocrit to get the true cell  volume . Th i s  
w a s  a preventabl e  source o f  error . They borrowed the 
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value 9 %  +/ - 0 . 5  s . d .  ( n= 3 1 )  from S chanker e t  a l . ( 1 0 8 )  
who determined i t  under d i fferent conditions than i n  the 
Parsons and Val lner lab . S chanker et a l . determined the 
volume of ECF by re-centri fuging the packed RBCs in 
cap i l l ary tubes at 1 2 , 0 0 0  X g .  Thi s  data cannot be 
extrapol ated to other labs or instruments contrary t o  
t h e  belief o f  Parsons and Val lner . 
A more sophist icated measurement o f  trapped p l a sma 
i s  by the addition o f  Evans b lue dye ( 2 0 ) , tritiated 
inul in ( 5 2 ) , or tritiated cobalt blue ( 5 0 )  which can 
then be measured in the fract ion of separated RBCs . 
Fremstad ( 5 2 )  reported that plasma space was more accu­
rately determined by l abe l l ed inulin rather than by 
hematocrit centri fugation and that the hematocrit over­
est imated the RBC volume due to plasma trapp ing . One 
study corrected the hematocrit value by a factor of 0 . 9 8 
to account for plasma trapped in the packed cel l s  ( 6 2 ) . 
However ,  according to Rustad ( 1 0 3 ) , the hematocrit 
should be corrected by a factor o f  0 . 9 7 to a l l ow for 
trapped plasma in the RBC column in micro-hematocrit 
techniques . 
For practical purposes , prel iminary experiments 
may reduce the need for measuring trapped p l a sma in 
every s amp l e  by providing consistency . For instance , 
the variation o f  the centri fugal force on venous bl ood 
s amp l e s  was shown to a f fect the concentrat ion o f  chI oro-
quine in the plasma . However ,  there was l ittle varia­
t i on in plasma leve l s  when samples were centri fuged 
above 1 0 0 0  g forces ( 7 ) . 
2 . 9 . 4 . 3  E ffect o f  the med ium on RBC l evel s  
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The medium in which RBCs are suspended has been 
shown to a f fect the RBC l eve l s  of drugs . For chloro­
quine and its metabol ite , desethyl -chl o roquine , serum 
l eve l s  were 2 and 4 t imes higher than p l a sma l evel s .  
Bergqvist et a l . ( 7 )  specul ated that the h igher concen­
trat ions were due to release of drug from l eucocytes and 
thrombocytes during the cl ott ing proces s . Another 
antimalarial agent , quinidine , was shown to have h igher 
concentrations in serum ( 2 9 )  
Binding data has o ften been obtained us ing washed 
cel l s  or cell membranes ( ghost s )  in buf fer . Washing 
cel l s  has been shown to alter b inding properties e ither 
by removing l ip ids or adsorbed proteins from membranes 
or by " removing the influence o f  p l a sma water" to 
increase or decrease binding ( 5 2 ) . Kornguth and Kuni n  
( 7 9 )  found that using pl asma a s  the medium rather than 
buffer enhanced the egress of antibiotics . 
Ehrnebo et a l . ( 4 0 )  found that for the bas ic drug 
pentazoc ine the b l ood cell/pl asma water rat io in who l e  
b l ood w a s  h igher than the b l ood cel l/buffer rat i o . I n  
the i r  study bl ood cel l s  included l eucocytes a n d  p l ate­
l et s  a s  wel l  as RBCs . Washed RBCs had a greater b inding 
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ab i l ity than unwashed RBCs in who l e  bl ood . In another 
study ( 4 1 ) , pentobarb ital and phenytoin were bound to 
washed bl ood cel l s  more than cel l s  in who l e  bl ood and 
the change was not due to pH d i fferences . The b lood 
cel l/water rat i o  also decreased in washed cel l s  when 
human serum albumin ( 4  g/ 1 0 0ml ) was present , suggest ing 
an a lteration of RBC membrane b inding propert ies due to 
an interact ion with the albumin . 
Others specul ated that plasma b inding s ites st i l l  
attached t o  RBCs a fter washing were probably respon s i b l e  
f o r  a sma l l  deviation from the theoretical l inear rel a ­
t i onship between the hematocrit and the RBC/buf fer rat i o  
f o r  phenytoin . The influence o f  p l a sma water was 
greater at higher hematocrits ( 8 1 ) . W i l l i ams ( 1 2 6 )  has 
shown that bovine albumin i s  adsorbed by a finite number 
o f  s ites on the surface o f  the human RBC , and it com­
petes with other endogenous and possibly exogenous 
molecules and that the albumin i s  not easl iy removed by 
washing with sal ine . In fact , they are not displ aced by 
the human albumin fraction ( Cohn fract ion 5 )  proteins . 
Cru z e  and Meyer ( 2 6 )  found that bovine a lbumin was 
an inadequate subst itute for human serum a lbumin .  
Another source o f  error i s  the e f fect o f  pH o f  the 
medium on the cel l to medium ratio . As discussed ear­
l ier , the pH grad ient across the membrane a f fects the 
concentrat ion gradient for weak acids and bases . P l a sma 
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becomes more alkal ine upon s itting uncovered due t o  the 
escape of C02 and the re-equ i l ibration of C02 in the 
p l a sma with it in the atmosphere ( 1 0 0 ) . The C02 from 
RBCs i s  repl aced by the intracellular movement of chl o ­
r i d e  ions known a s  the " chloride shi ft " . The basic 
buffer anions in the whol e  bl ood are b icarbonate , hemo­
g l ob in ,  and plasma proteinate ( 3 3 ) . In fact , 9 5 %  of the 
exces s  or deficit o f  carbonic acid i s  buf fered intrace l -
lularly ( 1 0 1 ) . 
G iven who l e  bl ood having 1 0 0 %  ( 0 . 0 3 8 5  gEqj L/pH 
unit ) o f  the buffer capacity o f  the bl ood , these are the 
percentages contributed to buffer capac ity by each 
constituent : cel l s  7 9 , pl asma 2 1 ,  p l a sma b i carbonate 
6 . 1 , plasma protein 1 3 . 6 ,  plasma phosphate 1 . 5 .  Hemo­
globin contributes about hal f o f  the total cellular 
buffer capacity ( 4 2 ) . For thi s  reason , p l a sma pH r i s e s  
rapidl y ,  whi l e  RBCs have the buffer reserve to ma inta in 
normal pH . 
Invest igators have s everal ways o f  adj ust ing the 
pH of bl ood samples . The most common method i s  by 
performing centri fugat ion and equ i l ibrium dialys i s  in a 
5 %  ( v/v)  C02 atmosphere ( 5 2 ) . It is possible to bubbl e  
carbon dioxide i n  a i r  or nitrogen through samples t o  
adj ust the ir p H  ( 6 7 ) . Citric acid was added to s amp l e s  
to study the e f fect o f  p H  o n  the part it ion coe f f i c i ent 
of fentanyl between RBCs and plasma ( 1 2 ) . 
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The pH can b e  confirmed by measuring the pH o f  
s amp l es a t  the beg inn ing and end o f  experiments ( 6 2 ,  
1 0 2 ) . Trung et al . ( 1 2 0 )  recommended that tubes o f  b l ood 
or p l a sma samples be covered with PTFE ( p olytetra fluor­
oethyl ene ) tape during all procedures because drug 
b inding could be affected . 
Disease states may a ffect the pH o f  the b l ood . 
Anuria l owers plasma pH . The quinidine b l ood 
c e l l s/plasma rat i o  was l ower in anuric rats and unbound 
qu inidine concentrat ions in plasma were l ower a s  deter­
mined by equil ibrium dialys i s . Anuria reduced the 
di stribut ion to bl ood cel l s  ( 5 2 ) . 
Care has to be taken to prevent hemolys i s . Even a 
stir bar can produce s igni f icant hemolys i s  ( 2 6 ) . P l a sma 
from bl ood banks has been shown to b ind qu inidine l e s s  
than fresh serum or plasma probably due to preseratives 
or anticoagul ants ( 1 2 9 ) . 
3 . 1  Background 
Chapter 3 
De finition o f  the Probl em 
RBC partitioning is closely rel ated to protein 
b inding . Due to the infrequent measurement o f  drugs in 
RBCs in studies reported in the b iopharmaceut ics l itera­
ture , methods to study them have not become rout ine . 
Many analyt ical variables a f fect these studies in add i ­
t i o n  to the ones that a ffect protein b inding studies . 
Recently , sources o f  error in protein b inding studi e s  
have been ment ioned more and more frequently , even 
though plasma protein b inding has been widely studied 
for many years . 
It is important to characteri z e  the prote in b ind­
ing and RBC partitioning of a drug for the understanding 
of the drug ' s  dispo s ition . Thi s  i s  espec i a l l y  true for 
drugs l ike PYR because RBC uptake i s  important for 
antima l arial act ivity and because it i s  a weak base and 
weak bases tend to have s ign i f icant RBC l eve l s . Even 
though PYR has been used for many years , studies of its 
binding and partitioning are lacking in the l iterature . 
For these reasons , PYR was chosen as a model drug . 
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3 . 2  Hypothes i s  
S everal factors such a s  the p H  o f  ·the media , the 
additives in evacuated col l ection tubes , and albumin 
l eve l s  may sign i f i cantly a f fect the protein b inding and 
RBC partitioning o f  PYR . 
3 . 3  Obj ect ives 
( 1 )  To reproduce an HPLC assay for PYR in p l a sma , 
RBCs , and buffer . 
( 2 )  To investigate variables such as pH , types o f  
evacuated col lection tubes , and a lbumin l eve l s  o n  RBC 
partitioning and pl asma protein b inding . 
( 3 )  To determine b inding o f  PYR in pl asma and t o  
p l a sma albumin , AAG , and Rb . 
3 . 4  Proposed methodology 
( 1 )  Edstein ' s  IPC-RPLC a ssay w i l l  be reproduced . 
I f  thi s  method is not suf f i c i ent , an original HPLC 
method will  be devel oped . 
( 2 )  Plasma and RBCs will  be spiked with PYR . Al l 
studies will be in vitro . 
( 3 )  statistical data analys is w i l l  be done us ing 
the SAS System vers ion 5 ( 1 0 5 )  on the VAX- l l/ 7 8 0  CPU at 
Virginia Commonwealth Univers ity . 
Chapter 4 
Experimental 
4 . 1  Reagents .  chemica l s .  and equ ipment 
4 . 1 . 1  Chemicals and reagents 
Methanol , acetonitri le , methy l ene chloride , 
n-butyl chloride , and hexane were a l l  HPLC grade and 
purchased from F i sher S c ient i f i c  co . ,  Fair Lawn , NJ . 
water : Deion i z ed/ organic- free water was d i st i l l ed 
in a model One Liter MP- 1 apparatus ( Corning Glass 
Works , Corning , NY ) . Thi s  water was used to make a l l  
buffers and mob i l e  phases . 
PYR : Pur i f ied PYR ( 5 - ( 4 -chl orophenyl ) -
2 , 4 -diamino- 6 -ethylpyrimidine ) was a g i ft o f  Dr . Carl 
S igel and the Burroughs Wel l come Co . ( Research Triang l e  
Park , NC ) . Precisely 5 0 . 0 0 mg o f  PYR was weighed out 
and p l aced in a 1 0 0  m1 volumetr ic f l ask . HPLC grade 
methanol was added to the 1 0 0  ml mark to make a stock 
solut ion o f  5 0 0  �g/ml PYR in methanol .  It  was kept 
refr igerated at 4 '  in s i l an i z ed ( 0 . 2 - 0 . 3 5 %  AquaS il� , 
Pierce Chemical Co . ,  Rockford , IL)  l ight res i stant , l ow 
act inic Pyrex glassware ( Corning Glass Works , Corning , 
NY ) . S olutions in methanol containing 0 . 1 0 ,  0 . 1 2 ,  0 . 1 5 , 
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0 . 2 ,  0 . 3 ,  0 . 5 ,  0 . 7 ,  1 , 0 ,  2 . 0 ,  3 . 0 , and 5 . 0  �g/ml PYR 
were made by dilution of (us ing volumetric p ipets and 
volumetric flasks ) th is stock solution . For the IPC­
HPLC method , stock solutions from 0 . 1 2 5  to 1 0 . 0  �g/ml 
were made . 
Plasma control s  were made by us ing a volumetr i c  
p ipet to pl ace 6 m l  o f  PYR in methanol ( 6 �g/ml ) in a 
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5 0  m l  volumetric flask , evaporat ing i t  under nitrogen 
unti l  almost dry , and reconst itut ing with exp ired bl ood 
bank plasma . After thorough mixing , us ing a syringe , 
volumes of the spiked plasma were pl aced in 5 0  ml volu­
metric flasks and pl asma was added to the 50 ml marks . 
From these spiked contro l s , other control s  were made by 
s imilar di lutions with plasma to make 7 2 0 , 4 2 0 ,  3 3 0 ,  
1 5 0 , 1 2 8 , 6 8 , 3 5 ,  and 3 2  ng/ml contro l s . Each control 
was d ivided into 3 plastic vials . Two vials were fro z en 
for l ater use and one vial was kept in the re frigerator . 
Buffer control s were made by evaporat ing PYR from 
a standard methanol solution in a volumetric flask and 
adding f i l tered phosphate bu ffer to the mark . Other 
solutions were made by making di lutions of thi s  solution 
to make 4 0 ,  1 0 0 , 1 4 0 , 2 8 0 , 4 8 0 , and 7 0 0  ng/ml contro l s . 
Each control was divided into 3 plastic vials  which were 
kept in the dark . 
All methanol solutions o f  PYR were kept in s i l an­
i z ed g l a s sware in the dark except for s olut ions used for 
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sp iking biological samples . They were kept in s i lani z ed 
culture tubes which were kept in the dark except during 
use . 
Quinine HCI ( Q ) : Quinine HCI , the internal stan­
dard for the IPC-HPLC as say was from an unknown manufac­
turer . Individual stock solutions o f  Q were prepared in 
methanol at concentrat ions o f  1 . 0  to 5 . 0  �g/ml and 
stored at 4 '  in low actinic glass that had been s i l an­
i z ed with AquaS ilN • 
N-acetylproca inamide ( NAPA ) HCL : Prec isely 5 0 . 0  mg 
o f  the internal standard NAPA HCI , 9 9 %  pure , purchased 
from Aldrich Chemical Co . (Mi lwaukee , WI ) , was placed in 
a 5 0  ml volumetric flask . Methanol was added to the 5 0  
m l  mark t o  make a solution o f  1 . 0  mg/ml NAPA HCI . 
D i lutions of thi s  stock so lution were made to make a 0 . 8  
�g/ml solution with which to spike plasma samp l e s . 
S odium salt of l -pentanesul fonic acid ( S PS ) : S PS 
was purcha3ed from S igma Chemical Co . , s t . Lou i s , MO . 
Potass ium hydroxide ( KOH ) : A solution o f  4 . 0  M KOH 
was p repared by plac ing 2 2 . 4  g of pel l ets ( Baker Ana­
l y z ed Reagent grade , J .  T .  Baker Chemical Co . , Ph i l l ip s ­
burg , NJ ) in a 1 0 0  m l  volumetric f l a s k  a n d  adding water 
to the 1 0 0  ml mark . Thi s  so lution was later diluted by 
adding 5 2  ml of 4 M KOH to 2 1 0  ml of water to make a 
total volume o f  2 6 2  ml o f  0 . 8  M KOH . 
S odium carbonate : A solution o f  sod ium carbonate 
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was made by adding 1 0 . 6  g o f  Na2 C03 ( Baker Analyzed 
Reagent grade ) to a volumetric flask and adding water t o  
t h e  5 0  ml mark to make 2 M sodium carbonate . Later , 
this was diluted to 0 . 5  M by adding 3 volumes o f  water . 
Bu ffers : S olutions o f  0 . 0 3 M monobasic potas s ium 
phosphate ( KH2 P04 ) were prepared by plac ing 4 . 0 8 g o f  
HPLC grade KH2 P04 ( F i sher S cient i f i c  Co . ,  Fair Lawn , NJ ) 
in a volumetric flask and adding water to the 1 0 0  ml 
mark . Solutions o f  0 . 0 3 M diba s i c  potass ium phosphate 
( K2 HP04 ) were prepared by plac ing 5 . 2 2 g of K2HP04 
( Baker Analyzed Reagent grade ) in a 1 0 0 0  ml volumetr i c  
flask and adding enough water to make 1 0 0 0  mI . These 2 
solutions were added together to get the des ired pH o f  
6 . 9 5 for the mob i l e  phase . 
I sotonic phosphate buffer ( I PB ) : I PB was prepared 
by making 2 isotonic buffer solutions and adding them 
together to get the des ired pH . The amounts o f  9 . 4 6 5  g 
o f  diba s i c  sodium phosphate ( ACS grade , F i sher S c i en­
t i f i c  Co . )  and 3 . 9 8 3  g of sodium chloride ( ACS grade , 
F i sher sc ient i f i c  co . )  were weighed out and p l aced in a 
1 0 0 0  ml volumetric flask . To th i s  flask was added 
enough water to make a 1 0 0 0  ml isotonic solution ( pH 
9 . 0 ) . The amounts 9 . 0 7 3  g o f  monobas i c  potas s ium phos ­
phate ( ACS grade , F i sher S c ient i f i c  co . )  a n d  5 . 0 0 5  g 
sod ium chloride were weighed out and placed in a 1 0 0 0  ml 
volumetric flask . To this flask was added enough water 
to make a second 1 0 0 0  ml i sotonic solut i on ( pH 4 . 4 ) . 
The approximate volume : volume rati o  o f  the 2 buffer 
solutions for pH 7 . 4  IPB was 8 5 : 1 5 .  
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Phosphoric acid ( 8 5 %  wjw )  was made b y  Mal l inckrodt 
( st .  Louis , MO ) and purchased through S c ient i f i c  Prod­
ucts ( McGaw Park , I L ) . 
4 . 1 . 2  Instrumentation 
Th i s  i s  a l i st o f  the chromatographic instruments :  
( 1 )  Model 1 1 0  A Altex pump ( Beckman Instruments ,  I nc . , 
Berkel ey , CAl 
( 2 )  Model 4 4 0  s ingl e  wavelength UV detector at 2 5 4  nm 
and us ing a 2 8 0  nm s l it at a sensitivity o f  0 . 0 0 5  o r  
0 . 0 1 a . u . f . s .  ( Waters Associates , Inc . , Mil ford , MA ) 
( 3 )  Syringe- loading inj ector 7 1 2 5  with a 1 0 0  �l l oop 
( Rbeodyne , Berke l ey , CA l 
( 4 )  A 2 cm X 2 mm I . D . upt ight precolumn packed with 
Perisorb RP- 1 8  3 0 - 4 0  micron pel l i cular packing ( Upchurch 
s c i ent i fic , Oak Harbor , WA ) 
( 5 )  1 0  mv Recordal l  Series 5 0 0 0  OmniScribe ( Fisher 
s c ient i f i c , Fair Lawn , NJ ) chart recorder 
( 6 )  Series 7 0 0  1 0 0�l syringe ( Hami lton Co . , Reno , NV ) 
Other equipment : 
( 7 )  Hor i z ontal shaker ( Eberbach Corp . , Ann Arbor , MI ) . 
( 8 )  Centri fuge , IEC model UV or desk top model HN-S 
( International Equipment co . , Needham MA ) . 
( 9 )  Evaporator with water bath , Meyer N-Evap model I I I  
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( Organomation Ass oc . , Northborough , MA) . 
( 1 0 )  water bath , model MW- 1 1 3 0A- 1 ( Blue M E l ectric Co . , 
Blue I s l and , I L ) . 
( 1 1 )  Hemato-Kit for convert ing the I E C  model HN-S cen­
tri fuge into a micro -hematocrit machine (VWR S c i ent i f i c , 
San Franc isco , CA) . 
( 1 2 )  Spectrophotometer , Model DB-GT , ( Beckman Instru­
ments , Ful lerton , CA ) . 
( 1 3 )  Sorval l  RC-5 8  refrigerated superspeed centri fuge 
( DuPont Co . Instrument Products , Newtown , CN ) . 4 . 2  
( 1 4 )  Accumet model 6 3 0  pH meter with a penc i l  thin gel 
f i l l ed polymer body comb ination el ectrode ( F isher S c ien­
trific Co . , Pittsburgh , PA ) . 
4 . 2  Reproduction o f  Edste in ' s  IPC-HPLC method 
Because thi s  exact method ( 3 9 )  was not used for 
the analys i s  of  samples except in the initial search for 
an extract ion solvent , the s l ightly modi f ied assay 
procedure will  be presented in an abbrevi ated form . 
A 3 0  X 3 . 9  mm I . D . 1 0  �m part i c l e  s i z e , �BondapakN 
C 1 8  ( Waters Assoc . )  reverse-phase column was used . I t 
had about 2 0 , 0 0 0  pl ates/meter and had been stored for at 
least 5 years in 50% methanol a fter an unknown h i story 
o f  use . The mob i l e  phase con s i sted o f  methano l ­
acetonitril e-water ( 2 5 : 1 5 : 6 0 v/v )  containing 0 . 0 0 1  M 
sodium pentane sul fonate ( S PS )  adj usted to pH 3 . 0  with 
6 - 8 drops of phosphoric acid . The mob i l e  phase was 
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f i ltered prior to u s e  with a n  Alpha-4 5 0  metricel mem­
brane ( 4 7  mID, 0 . 4 5 �m , Gelman S c iences , Ann Arbor , MI ) 
and then ultrasonicated under vacuum for an additional 
10  min . The flow rate was 1 . 7  ml/min at amb ient temper­
atures . The volume inj ected was 1 0 0  �l . The internal 
standard was quinine . 
Extraction procedure for I PC-HPLC : 
( 1 )  1 0 0  �l each o f  PYR standards ( 1 - 5 0  �g/ml ) was 
added to 16 X 1 2 5  mm glass culture tubes with 
PTFE l ined screw caps ( Kimb l e , Corning , NY ) . 
( 2 )  Bl ank RBCs , plasma , or buffer 0 . 5  ml was added . 
( 3 )  1 0 0  �l o f  Q 4 . 0  �g/ml was added . 
( 4 )  For RBCs only , 1 . 0  ml o f  water was added , briefly 
vortexed . 
( 5 )  1 5 0  �l o f  4 M sod ium hydroxide was added . 
( 6 )  15 ml o f  hexane/methyl ene chloride ( 2 : 1 ) was 
added . 
( 7 )  Tubes were shaken 3 0  min at 2 2 0  cyc l e s/min . 
( 8 )  S amples were centri fuged for 2 0  min in IEC UV 
centri fuge at 2 1 0 0  rpm . 
( 9 )  Tubes were pl aced in acetone bath in - 7 0 ·  
free z er for 1 5  min o r  unt i l  fro z en . 
( 1 0 )  Organic phase was decanted into another tube and 
evaporated to dryness in 3 8 ·  water bath under a 
gentle stream o f  nitrogen . 
( 1 1 )  The res idue was reconstituted with 5 0 0  �l o f  
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methanol and 1 0 0  �l  was inj ected . 
The concentration o f  the counter- ion S PS was 
varied to see its e f fect on retention t imes and cap a c i ty 
factors for PYR and Q .  The pH o f  the mob i l e  phas e  was 
a l s o  varied . The extraction recoveries o f  PYR and Q 
were also  studied . 
4 . 3  Assay o f  PYR us ing prig ina 1 RP-HPLC method 
4 . 3 . 1  Selection of interna l standard 
Internal standards used in the pub l i shed a s says 
could not be obta ined . Prospect ive compounds with 
structures s imilar to PYR and other antimalarials  were 
rev iewed for the ir uv absorbance and other propert i e s . 
chlorpheniramine , ranitidine , quinine , proca inamide , 
N-acetylprocainamide ( NAPA) , dapsone , phenytoin , and 
trimethoprim were some of the compounds examined . A l l  
but one o f  them were ruled out f o r  o n e  o f  thes e  reasons : 
( 1 )  b i nding to glass , ( 2 )  be ing commonly found in 
exp ired bl ood bank p l asma , ( 3 )  known chromatographi c  
d i f f iculties , or ( 4 )  d i f ferent extraction propert i e s . 
NAPA was chosen because of its appropriate UV 
absorbance , bas ic functional group , known stab i l ity , and 
most importantly , because a test inj ect ion on the pre l i ­
minary system used to analyze PYR revealed a retent ion 
t ime very s imilar to PYR ' s .  
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F i gure 3 .  structure o f  N-acetylproca inamide ( NAPA ) 
4 . 3 . 2  S e l ection o f  extraction s o lvent 
A rev iew of the l iterature revea l ed that PYR wa s 
extractab l e  into nonp o l a r  s olvents such a s  ethylene 
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chl o r ide at an a l ka l ine pH . However ,  they did not have 
the same interna l standard . Experiments were performed 
to determine the extraction recovery of 11 �g/ml PYR and 
NAPA HCL from hexane , 2-propano l ,  ether , ethyl acetat e , 
ethyl ene chloride , and methy l ene chloride us ing exp i red 
b l ood bank p l a sma that had been a l ka l i n i z ed with 0 .2 ml 
of 4 M  KOH. Note : Later , the mol a rity of the KOH was 
decreased to 0 . 8 M and the s ame volume was used . Th i s  
w a s  because the strong alkal in ity o f  the 4 M  KOH removed 
the s i l anes from s i l a n i z ed g l a s s  and a l l owed PYR to b i nd 
to the g l a s s . The O . 8 M KOH produced l e s s  s i l ane remov a l  
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but adequately alka l i n i z ed p l a sma samp l e s  for extraction 
purposes . 
4 . 3 . 3  Separat ion o f  PYR and NAPA 
The chromatographi c  separat ion o f  PYR and NAPA was 
eva luated us ing phosphate buffer with acetonitri l e  and 
methanol as the organic mod i f iers . The percentage o f  
each constituent was varied , the p H  o f  the aqueous phas e  
w a s  varied , and the best chromatography determined by 
eva luat ing peak symmetry , retention t imes , peak resolu­
tion , and peak heights . D i f ferent mo larities and s a l t s  
o f  phosphate buffer were evaluated . 
4 . 3 . 4  Preparation o f  the mob i l e  pha s e  
The mob i l e  phase cons i sted o f  aceton itrile and 
methanol as organ ic mod i f iers and a phosphate bu ffer 
adj usted to a pH o f  6 . 9 5 .  The phosphate buffer was 
prepared by making 0 . 0 3 M so lut ions of KH2 P04 ( 4 . 0 8 gi L )  
and K2 HP04 ( 5 . 2 2 gi L)  in water . The pH o f  the buffer 
was adj usted to 6 . 9 5 by the addition of KH2 P04 to the 
K2 HP04 solution whi l e  stirring with a PTFE stir bar and 
monitoring the pH of the solution with a F i sher Accumet 
model 6 3 0  pH meter . Volumes o f  4 0 0  ml o f  potass ium 
phosphate buffer , 4 5 0  ml of methanol ( F i sher HPLC 
grade ) , and 1 5 0  ml of acetonitr i l e  ( F i sher HPLC grade ) 
were mixed together . They were f i ltered through an 
Alpha- 4 5 0  0 . 4 5 �m metr icel membrane f i l ter ( Ge lman 
s c i ences , Inc . , Ann Arbor , MI ) and then ultrasonicated 
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for 7 additional minutes . The phosphate buffer was near 
its l imit o f  solub i l ity in the organi c -aqueous mixture 
because o ften the f i lter membrane would have to be 
changed before f i l tration was comp l ete due to prec ipita­
tion cl ogging up the f i lter before 1 0 0 0  ml could be 
f i l tered . 
4 . 3 . 5  Column , detector and recorder characteristics 
Separat ion was conducted on a 150  mm X 4 . 6  mm I . D . 
Econosphere� column packed with 5 micron RP- 1 8  spherical 
particles (All  tech As sociates , Inc . jAppl ied S c ience 
Labs , Deerf ield , I L ) . There was an addit ional pre­
column between the pump and the inj ector . It was a 
saturator co lumn , a 2 5  cm X 3 . 9  rom I . D . column packed 
with 50 micron high capac ity s i l ica (Al ltechjAppl ied 
s c i ence Labs , Deerfield , I L ) . Th i s  saturator column 
protects the analytical column from the neutral pH o f  
the mob i l e  phase b y  s aturating the mob i l e  phase with 
dissolved s i l ica ( 5 ,  12 2 ) . The mob i l e  phase cons i s ted 
of 4 5 : 1 5 : 4 0 methanol : acetonitr i l e : pH 6 , 9 5 ,  0 . 0 3 M potas­
s ium phosphate buffer at a f l ow rate o f  1 . 6  mljmin with 
a column inlet pres sure o f  1 5 0 0 - 2 5 0 0  p s i . The separa­
t ions were performed at amb ient temperature at a detec­
tion wavel ength o f  2 5 4  nm and a nonstandard 2 8 0  nm s l it 
in the detector . The sens itivity sett ing was 0 . 0 0 5  
a . u . f . s .  ( absorbance units ful l  sca l e )  for the l ower 
concentrat ions and 0 . 0 1 a . u . f . s .  for above 5 0 0  ng/ml 
for the plasma and RBC curves .  The sens itivity was 
0 . 0 0 5  a . u . f . s .  for the buffer curve inj ectons . The 
recorder speed was 0 . 2 5 cm/min . Peak he ights were 
measured by hand with a s ingl e  ruler to the nearest 
1 mm . 
4 . 3 . 6  Quant i f ication o f  PYR in matrices 
4 . 3 . 6 . 1  Extraction procedures 
Plasma Extract ion Procedure 
( 1 )  Add 1 0 0  �l each of PYR standards ( 0 . 1  to 5 . 0  
�g PYR/ml in methano l )  to s i l ani z ed 1 6  X 1 2 5 mm 
glass culture tubes with PTFE l ined screw caps 
for standard curve . For unknown samples and 
contro l s , methanol was added instead . 
( 2 )  Add 1 0 0  �l o f  NAPA HCI ( 0 . 8  �g/ml in methano l ) . 
( 3 )  Add 0 . 5  ml plasma ( contro l , samp l e , or b l ank) . 
( 4 )  Add 2 0 0  �l o f  0 . 8  M potas s ium hydroxide . 
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( 5 )  Add 7 m l  o f  methyl ene chloride , briefly vortex . 
( 6 )  Shake 1 0  min in Eberbach shaker ( 2 2 0  shakes/min ) .  
( 7 )  Centri fuge 1 0  min in model UV centri fuge at 2 1 0 0  
rpm . 
( 8 )  Asp irate to waste the aqueous l ayer . 
( 9 )  Decant organic phase into another tube and eva­
porate to dryness in 3 8 °  water bath under a 
gentle stream o f  nitrogen . 
( 1 0 )  Reconst itute residue with 2 0 0  �l o f  pH 6 . 9 5 
potass ium phosphate buf fer and inj ect 1 0 0  �l . 
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RBCS Extraction Procedure 
( 1 )  Add 1 0 0  �l each of PYR standards ( 0 . 1 2 to 5 . 0  
�g PYR/ml methanol )  to 1 6  X 1 2 5  mm glass culture 
tube s  with PTFE l ined screw cap s . For samp l e s  
methanol was added instead . 
( 2 )  Add 0 . 5  ml o f  RBCs ( unknown s amp l e s  or bl ank 
RBCs for standard curv e )  with a 1 ml syringe . 
( 3 )  Add 0 . 5  ml o f  0 . 5  M Na2 C0 3 s olution , vortex 1 5  
sec . 
( 4 )  Add 1 2  ml o f  1 : 3  mixture o f  methyl ene chloride 
and n-butyl chloride , vortex 2 0  sec . 
( 5 )  Rotate on wheel whi l e  process ing others . 
( 6 )  Shake on Eberbach shaker 2 0  min . 
( 7) centri fuge at 2 1 0 0  rpm for 1 5  min . 
( 8 )  Quant itatively remove us ing a graduated cyl inder 
1 2  ml o f  the organic l ayer and place it in 
another tube . 
( 9 )  Evaporate the organic phas e  in each tube to 
dryness , vortex each tube every 5 min as evapora­
tion proceeds . 
( 1 0 )  Reconstitute res idue with 2 0 0  �l o f  potas s ium 
phosphate buf fer and inj ect 1 0 0  �l . 
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Bu ffer S ampl e s  
Buf fer samples and controls were inj ected 
directly . Buf fer standards were prepared by evaporating 
1 0 0  �l o f  each standard in plastic tubes and reconst i ­
tuting with 5 0 0  �l o f  phosphate buf fer . 
4 . 3 . 6 . 2  Cal ibrat ion curves 
Cal ibrat ion curves in b l ank p l a sma were prepared 
by pl ott ing peak height rat ios of PYR to internal stan­
dard as a funct ion of tneoret ical PYR concentrat ion . 
Concentrations were then back-calculated from thes e  
curves us ing a l inear regress ion program . One control 
was run for every 1 0  samples . The acceptab l e  l imit o f  
error for control s  was 1 0 %  o f  the sp iked concentrat ion . 
Bl ank plasma on each day was the same as that used in 
the experiment o f  that day . 
Cal ibration curves in bl ank RBCs and bu ffer were 
made by pl ott ing peak he ights ( a fter 1 0 0  �l inj ections ) 
o f  PYR as a function o f  theoretical PYR concentrati ons . 
Concentrat ions were then back-calcul ated from thes e  
curves . A hand-held calculator ( T I - 5 9  I I I , Texas 
Instruments , Inc . , Lubbock , TX ) was used for thes e  
calculations . Buffer control s  were run for every 1 0  
samp l e s . There were no contro l s  for RBCs . 
Concentrations o f  PYR in p l a sma , RBCs or bu ffer 
unknown s amples and control s  were determined by apply ing 
peak he ight rat ios or peak he ights to the appropriate 
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cal ibrat ion curves . 
4 . 3 . 6 . 3  Recovery and prec is ion studies 
Recoveries o f  PYR and the internal standard were 
determined by tripl icate analys i s  of p l a sma and RBC 
standards at many d i f ferent concentrati ons . Peak 
heights obtained from extracted standards were compared 
to peak heights obta ined f o l l owing direct inj ections o f  
unextracted standards ( evaporated sp iked solutions that 
were reconstituted with the same volume of phosphate 
buffer as the extracted samples ) .  
The reproduc ib i l ity o f  the extract ion procedure 
and HPLC analys i s  was determined by extract ing and 
analyz ing 10 rep l i cates of 4 contro l s  in plasma on a 
s ingle day . 
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4 . 4  VacutainerN pH changes 
4 . 4 . 1  Blood drawing and pH measurement procedures 
A normal subj ect ' s  b l ood was drawn from a forearm 
vein using a Vacuta inerN needle and holder ( through the 
stoppers ) into repl icate Vacuta inerN tubes . These 
Becton-Dickinson vacuta inerN Systems ( Rutherford , NJ ) 
were used : 
Tab le 5 .  Vacuta inerN Systems 
Vacuta inerN Addit ive 
B-D No . 6 4 5 1  1 0 . 5  mg Na 2 EDTA 
( l avender top s )  
B - D  No . 6 4 8 0  1 4 3  US P units N a  Heparin 
( green tops ) 
B-D No . 6 4 1 9 18 mg Na citrate and 
( b lue tops ) 2 . 4  mg citric Acid 
Bl ood Vo lume 
7 .  ml 
1 0 . ml 
4 . 5  ml 
The tubes were centri fuged wh i l e  still sealed . The 
z ero time pH was taken as the pH immediately upon remov­
ing the stoppers whi l e  the plasma rested over the RBCs . 
Then the plasma was transferred by pasteur p ipet to 
culture tubes and the rema ining pH values obtained using 
the Accumet pH meter . 
4 . 5  Equi l ibrium dialys i s  (ED)  
4 . 5 . 1  Membrane preparation 
Spectrapor® 1 membrane tub ing ( Spectrum Med i c a l  
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I ndustries Inc . , Los Ange l e s , CAl made o f  cellulose with 
a mol ecular weight cut o f f  6 0 0 0 -8 0 0 0  was used in the 
dialysis experiment s . At no t ime was tub ing touched 
except with metal surgical instruments .  A piece o f  
tub ing was removed from the box and washed i n  runn ing 
lukewarm tap water for at least 2 h to remove glycerol 
( humectant and plastici z e r ) . The tub ing was rinsed 5 
t imes with dist i l led water and then rinsed 3 - 5  t imes 
with isotonic phosphate buf fer ( I PB) . The tub ing was 
cut into sma l l  c ircles that fit the E D  cel l s . The cut 
membranes were stored in the refrigerator and be fore u s e  
were rinsed 5 t imes with fresh IPB . 
4 . 5 . 2  Spectrum equ i l ibrium dialyz er 
The Spectrum equ i l ibrium dialyzer was assemb led 
according to the instructions that came with it . 
Briefly , using tweez ers , membranes were b l otted on 
t i s sues , placed on the PTFE semi-micro cel l  ha l f  with 
the seal ing ridge , and the matching cel l -hal f  was p l aced 
on top , sandwiching the membrane between the two halve s . 
The cel l s , in sets o f  5 cel l s , were p l aced between spac­
ers in the cell  carriers . After plac ing the assemb l ed 
unit in the f i l l ing cl amp on a ring stand , they were 
f i l l ed us ing a Pipetman® ( G i l son Internationa l , Midd l e ­
town , WI ) a n d  a Ra inin C-2 0 0  microl iter p ipette tip 
( Rainin Instrument Co . , Inc . , Brighton , MA ) . Thes e  tips 
snugly fit the holes in the cel l s . The 5 cell  un its 
were p laced in the drive unit which was pl aced in the 
3 7 °  water bath . The speed o f  rotat ion was 12 - 2 0  rpm 
depending on the experiment . 
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Removal o f  cell  contents was performed b y  b l owing 
the contents out with a p ipettor and catching the l i qu id 
in a plastic tube ( 12 X 7 5  rom polystyrene culture tub e s  
with snap caps , Elkay Products , Inc . , Shrewsbury , MA ) . 
When a volume o f  1 ml was p l aced in the cel l -ha l f  at 
the beginning o f  the dialys i s , about 0 . 7  ml was recov­
ered . 
4 . 5 . 3  Protein assay 
In every ED experiment involving albumin , the 
albumin content o f  each of the cel l s  at the end o f  
d i a l y s i s  was measured us ing a n  assay spec i f i c  for 
albumin . S amples « 1 . 0  ml ) from ED were c o l l ected in 
plastic tubes as described above . For the assay o f  
albumin , the f o l l owing standard procedure a s  described 
in the pamphl et that came with the BCG Reagent was f o l ­
l owed : 
( 1 )  Pipet 5 . 0  ml o f  BCG [ bromcres o l  green ] Albumin 
Reagent ( Stanb i o  Laboratory , Inc . , S an Anton i o , TX ) 
into each PET vial ( 2 0  ml polyethylene terephthalate 
scint i l l ation vial , Wheaton S c ient i f i c , M i l lvi l l e , 
NJ ) • 
( 2 )  P ipet 2 0 . 0  �l us ing an SMI micro/pettor ( S c ient i f i c  
Manufacturing Industries , Berke l ey ,  CA l o f  each 
samp l e  into the BCG reagent and rinsed the tip o f  
the s i l icon i z ed glass p ipet i n  the BCG . 
( 3 )  Wa it 5 mins , gently swirl the samp l e  and then pour 
an a l i quot into the polystyrene cuvets ( F i sher 
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S c ient i f i c , Fairlawn , NJ ) and read the UV absorbance 
at 5 5 0  nm . 
( 4 )  The albumin concentrat ion o f  the unknown was not 
calcul ated from the f o l l owing equation given in the 
instruct ions , 
Abs unk X Conc . std g/dl unknown ( 1 6 )  
Abs std 
but from a 3 po int l inear regre s s i on cal ibrat ion 
curve us ing a lbumin standards in norma l sal ine 
( S igma Diagnost icsN , st . Lou i s , MO ) 2 g/dl and 4 
g/dl as wel l  as a z ero po int for albumin determina-
t ion . 
The results were usua l ly ident ical because the 
absorbance for the 2 g/dl standard was the same as hal f 
the absorbance for the 4 g/dl standard . 
4 . 5 . 4  Adjustment o f  pl asma pH 
Plasma pH was adj usted immediately before d i a lys i s  
b y  b l owing 5 %  C02 in oxygen over the plasma in a p l a s t i c  
scint i l l at i on '1ial (Wheaton S c i ent i f i c , Millvil l e , NJ ) . 
Approximately 3 0  min were required to bring the pH from 
7 . 8  to 7 . 3 5 .  Usually pH was adj usted to 7 . 3  because the 
pH rose about 0 . 1  unit during dialys i s ; and thi s  phe-
nomenon varied with the amount o f  buffer added to the 
p l a sma to dilute the proteins ( e . g .  the more buf fer 
added , the less the pH rose during dialys i s )  . 
4 . 5 . 5  General ED procedure 
PYR was added to the buf fer s olut ions in concen­
trations given for the spec i f i c  experiments .  The con­
centrat ion o f  PYR in the buf fer and protein containing 
s olutions a fter ED was measured by HPLC . s eparate 
cal ibration curves were made for each matrix us ing the 
s ame plasma or buf fer s olutions a s  in the ED for the 
b l ank s olution . Changes in volumes o f  each cell -ha l f  
during dialys i s  were determined from the changes in 
protein concentrat ion measured by the BCG dye b inding 
procedure . Plasma and prote in s olutions were di luted 
only 5% by volume shi fts . Buf fer concentrations were 
cons idered the free concentrations of PYR . Plasma o r  
other protein conta ining solutions conta ined the total 
PYR concentrat i ons . Bound PYR was the d i fference o r  
total - free = bound . Fract ion free was calcul ated a s  
free PYR d ivided b y  the total PYR . 
4 . 5 . 6  S ources o f  dilution o f  protein 
4 . 5 . 6 . 1  water content o f  membranes 
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Two membranes that had been prepared i n  the usual 
manner were we ighed , a l l owed to dry , and we ighed aga i n . 
The d i f ference in the we ight was taken as the water 
content . 
7 1  
4 . 5 . 6 . 2  Vo lume shi fts 
During dialys i s , free water from the buffer s ide 
o f  the membrane o ften passes through the membrane t o  the 
protein conta ining s ide . Thi s  d ilut ion is cal l ed a 
volume shift . To measure volume shi fts , the albumi n  
concentration f o r  each cell  w a s  measured a fter d i a l ys i s . 
The original solution o f  prote in ( p l asma or albumi n  i n  
buffer ) was measured and taken a s  the original albumin 
l evel . 
4 . 5 . 7  Evaluation o f  b inding to ED c e l l s  and membranes 
Binding to the ED apparatus was evaluated by 
adding 1 ml o f  pH 7 . 4  IPB to one cel l -hal f in the car­
rier and 1 ml o f  85 ng/ml PYR in I PB to the other c e l l ­
ha l f .  This was done with 5 cel l s . The cel l s  were 
dialyzed for 4 h at 1 5  rpm in the 3 7 °  water bath . At 
the end o f  4 h ,  samples were removed from each of the 
cel l s  and analyzed for PYR . The amount o f  PYR p l aced in 
the cel l s  at the beginning o f  dialys i s  was compared t o  
the amount removed a fter dialys i s  to determine the 
recovery of PYR from the system . 
4 . 5 . 8  Determination o f  time to equ i l ibr ium for d i a lys i s  
The fol l owing 2 paragraphs describe the 2 exper­
iments done to determine the time to equ i l ibrium for 
dialys i s . 
I sotonic solutions o f  PYR 4 0 0  ng/ml ( pH 7 . 4 )  were 
d i a ly z ed aga inst equal volumes ( 1  ml ) of exp i red b l ood 
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bank p l asma ( pH 8 . 0 1 )  a t  1 2  rpm i n  a 3 7 '  water bath . 
S amples o f  cel l s  were taken from 2 min to 2 4 0  min . 
Albumin concentration measured at the end o f  dialys i s  
was 2 5 . 9  gi L .  Us ing the buffer s ide data , noncompart­
mental analy s i s  was performed to find the t ime t o  
equ i l ibrium . The area under the curve ( AUC ) and area 
under the moment curve ( AUMC ) were calculated us ing the 
trap e z o idal rul e  ( 5 7 )  and a hand calcul ator . 
The pH o f  some o f  the above exp ired b lood bank 
p l a sma was adj usted by gass ing with 5% C02 in oxygen . 
It was dialyzed aga inst an equal volume ( 1  ml ) o f  I P B  
sp iked with 4 0 0  nglml o f  PYR . The cel l s  were rotated at 
1 2  rpm in a 3 7 '  water bath . The cel l s  were emptied from 
3 to 2 8 0  min . The AUC and AUMC for the buffer PYR were 
cal cul ated as described above . Due to column f a i lure 
the plasma cell concentrations were lost . The a lbum i n  
concentration at t h e  end o f  dialys i s  w a s  3 0 . 4  gi L .  
4 . 5 . 9  Influence o f  pl asma pH on protein binding 
4 . 5 . 9 . 1  Comparison o f  pH 7 . 3 5 and pH 8 . 0  pl asma 
A drug free mal e  ( DR)  volunteer ' s  bl ood was c o l ­
lected into Vacutainers� conta ining heparin . After 
separat ing the plasma from the cel l s , the plasma pH was 
adj usted by gass ing with 5 %  C02 in oxygen immediately 
prior to ED . Cel l s  were rotated in the Spectrum appara­
tus at 1 7  rpm in a 3 7 '  water bath for 5 h .  The average 
total PYR in plasma ( n=6 ) at the end of dialys i s  was 3 6 2  
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ng/ml ( 4 . 7 % CV , range 3 3 6 . 0 5 - 3 7 9 . 6 7 ng/ml ) .  At the end 
of dialysis the average albumin l evel ( n= 6 ) in p l a sma 
was 5 1 . 3  g/L or 7 . 4  X 1 0 - 4 M ( 6 . 4 % CV) . The unbound 
fraction in pl asma was determined by divid ing the PYR 
concentrat ion in the buffer compartment ( free drug ) by 
the PYR concentration in the plasma compartment ( total 
drug ) . Thi s  assumed that no protein was found in the 
buffer compartment . Each dialys i s  c e l l  was treated 
indiv idually . 
4 . 5 . 9 . 2 .  E f fects o f  pH on protein binding 
Solutions o f  isotonic phosphate buf fer at various 
pHs were made by mixing isotonic ( NaCI added ) solutions 
o f  Na2 HP04 and KH2 P04 to make pH 6 . 7  7 . 0 ,  7 . 4 ,  7 . 7 ,  and 
8 . 0 .  These solutions were used to reconstitute evapor­
ated PYR in volumetric fl asks to make s olutions o f  PYR 
at 4 0 0  ng/ml . A drug-free individua l ' s  ( E C )  heparini z ed 
p l a sma was used . It was adj usted to the pH as near as 
p o s s ib l e  (minimum 7 . 3 ) to the buffer pH be fore dialys i s . 
The pH values reported are for the p l a sma at the end o f  
the 5 h dialys i s . These PYR-conta ining buffer solutions 
were dialyzed against plasma in tripl icate . Cel l s  were 
rotated at 17  rpm in 3 7 °  water bath . Albumin concentra­
tion o f  the plasma s ide at the end o f  dialys i s  was 4 3 . 7  
g/ L ( 3 . 9 2 %  CV ) . 
A second experiment was performed in trip l i cate as  
above except that due to equipment fai lure the Spectrum 
7 4  
c el l s  had t o  b e  rotated b y  hand and dia lys i s  t ime was 
increased to 6 h 2 0  min . S o lut ions o f  PYR were made at 
pH 6 . 3 ,  6 . 5 ,  6 . 7 ,  6 . 9 ,  and 7 . 1  at 4 0 0  ngjml . Albumin 
concentration at the end o f  dialys i s  was 4 5 . 6  gj L ( 6 . 4 9 %  
CV ) . 
4 . 5 . 1 0 Influence o f  ant icoagul ants on protein binding 
The day be fore the ED , bl ood from a drug- free 
volunteer (AR) was c o l l ected into 3 kinds of Vacutain­
ers� : vacutainersN conta ining EDTA or heparin for p l a sma 
and red-top Vacuta inersN conta ining no ant i -coagul ant 
for serum . IPB s olutions o f  PYR at 1 2 0 0  ngjml were made 
by reconstitut ing evaporated PYR in volumetric fl asks . 
sp iked IPB solutions were dialyzed aga inst p l asma o r  
serum in trip l icate . Albumin in the samp l e s  measured at 
the end time averaged 4 1 . 8  gj L ( 6 . 0 6 X 1 0 - 4 M )  and the 
ending pH was 7 . 4 .  ANOVA was performed us ing SAS PROC 
Glli . 
4 . 5 . 1 1 Concentration dependence of protein binding 
Two solutions o f  PYR were made by reconstitut ing 
evaporated P Y R  in vOlumetric fl asks . A drug- free volun­
teer ' s  ( DR )  heparin i z ed plasma was dialyzed aga inst 
sp iked solut ions o f  PYR at 118 ngjml and 3 6 3  ngjml I P B . 
Before dialysis the plasma pH was adj usted to pH 7 . 4  
with 5 %  C0 2 in oxygen . S amples were removed a fter 5 h 
in a 3 7 °  water bath rotating at 1 8  rpm . At the end o f  
the dialysis the albumin was 4 5 . 5 6  gj L ( 6 . 6  X 1 0 - 4  M )  
and the pH o f  the plasma was 7 . 5 .  A t test was per­
formed on the data us ing SAS PROC T TEST . 
4 . 5 . 1 2 Binding to pur i f ied human serum albumin 
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T o  4 7  mg o f  puri f ied human serum albumin ( HSA)  
( Pi erce no . 3 0 4 4 5  a f f inity puri f ied HSA , Pierce Chemical  
Co . ,  Rockford , I L )  was  added approximately 2 ml o f  pH 
7 . 3 5 I PB .  One mil l i l iter o f  thi s  protein solution was 
dialyzed aga inst an equal volume ( 1  ml ) o f  IPB sp iked 
with PYR 3 5 0  ngjml in  dupl icate . Cel l s  were rotated in 
the Spectrum dialyzer apparatus at 1 8  rpm for 5 h in  a 
3 7 ·  water bath . Albumin was 1 4 . 1 8 gj l or 2 . 0 6 X 1 0 - 4 M 
at the end o f  dialys i s . 
4 . 5 . 1 3 Binding to a I-acid glycoprotein (AAG) 
About 2 ml o f  IPB pH 7 . 3 5 was added to approxi­
mately 7 . 4  mg o f  AAG ( Prod . No . G-9 8 8 5 , human a I -acid 
glycoprote in , S igma Chemical Co . , st . Lou i s , MO ) . Thi s  
AA G  s olution was dialyzed i n  dup l icate against a n  equal 
volume ( 0 . 9  ml ) o f  IPB spiked with PYR 3 5 0  ngjml a s  
described in section 4 . 5 . 12 .  The AAG concentrat ion was 
c a l cul ated to be 3 . 7  giL at the beginning o f  the exper­
iment without correct ions for water content . PYR con­
tent was assayed us ing 0 . 5  ml o f  each samp l e . The 
solutions recovered from th i s  experiment that were not 
used in the assay of the drug were comb ined with what 
was l e ft of the original AAG s olution to make about 0 . 7 3 
ml . Added to thi s  volume was 4 ml o f  pH 7 . 3 5 IPB . Thus , 
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the AAG was cal culated t o  b e  l e s s  than 0 . 5 7 1  gj L a t  the 
beginning o f  the second AAG experiment . Thi s  AAG s o l u ­
t ion w a s  dialyzed against 0 . 9  ml o f  pH 7 . 3 5 I PB contain­
ing 3 5 0  ng PYRjml for 5 . 5  h .  At the end o f  dialys i s , 
the pH was 7 . 4 .  
4 . 5 . 1 4 Binding to pl asma proteins 
Three studies ( Studies 1 ,  2 ,  and 3 )  were performed 
to determine a f f inity constants for PYR to a lbumin in 
plasma . 
This paragraph is a description o f  S tudy 1 .  
Pl asma was obtained from a drug- free volunteer ( E C ) . 
I s otonic pH 7 . 4  phosphate buf fer ( I PB ) sp iked with PYR 
concentrat ions 1 4 0 ,  2 8 0 , 4 8 0 , 7 2 0 ,  1 4 4 0 ,  4 1 0 0  ngjml 
( maximum 1 . 6  X 1 0 - 5 M )  was dialyzed aga inst plasma that 
was adj usted to pH 7 . 2 3 with 5 %  C02 in oxygen prior to 
dialys i s . The c e l l s  were f i l l ed in dupl icate with 
regards to PYR concentrat ion . The cel l s  were rotated in 
the Spectrum dialyzer at 20  rpm for 5 h in a 3 7 °  water 
bath . The albumin concentrat ion at the end o f  the 
dialysis was 2 3 . 5  gj L or 3 . 4 1 X 1 0 - 4 M ( 3 . 9 % CV ) . 
Thi s  paragraph is a descript ion o f  Study 2 .  The 
pooled drug- free heparin i z ed plasma that was used came 
from three volunteers ( E C ,  DR , AR ) and it was di luted to 
one - f i fth plasma with pH 7 . 3 5 IPB . The p l a sma- I PB 
mixture was dialyzed against IPB containing PYR at 1 4 0 ,  
2 5 0 , 4 0 0 , 6 0 0 , 7 8 0 ,  1 2 0 0 ,  2 2 0 0 , 4 1 0 0  ngjml in dupl icate . 
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The cel l s  were rotated i n  the Spectrum dialyzer a t  l S  
rpm for 5 h i n  a 3 7 °  water bath . The albumin concentra­
t ion o f  the plasma at the end was S . l 3 gj L or l . l S X 
l O - 4 M ( 4 . l % CV) . 
This paragraph is a description S tudy 3 .  Heparin­
i z ed plasma from a drug- free femal e  ( AR )  was d i l uted 
with IPB pH 7 . 3  and dialyzed aga inst s o lut ions of PYR at 
concentrations o f  7 2 0 ,  3 7 0 0 , 9 l 0 0 , l S O O O , and 4 5 0 0 0  
ngjml IPB . The cel l s  were rotated in the Spectrum 
dialyzer at lS rpm for 6 h in a 3 7 °  water bath . The pH 
at the end o f  the dialys i s  was 7 . 3  and the albumi n  
concentrat ion o f  the plasma s ide w a s  0 . 6 6 gj L or 9 . 5 9 X 
l O - 6 M ( 7 . 2 % CV ) . 
The data coll ected in studies l ,  2 ,  and 3 were f it 
to the Klot z , Scatchard , Bl anchard , and Larsen equations 
as suming one or two b inding s ites and us ing ljbuffer 
concentrat ion , lj s quared buffer concentration , ljplasma 
concentration and lj squared plasma concentration a s  the 
weighting functions . The fits were evaluated on the 
b a s i s  o f  correl ation coeffic ients , R2 values , sums o f  
s quares , weighted sums o f  squares , res idua l s , corr e l a ­
tion matrix o f  t h e  parameters , p l ots o f  t h e  data , p l ots 
o f  the res idua l s ,  and reasonab i l ity o f  the parameter 
est imates . 
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4 . 5 . 1 5 Binding t o  hemogl obin (Hbl 
4 . 5 . 1 5 . 1  stroma- free hemogl ob in preparation 
Bl ood was obtained from a human subj ect ( AR )  and 
trans ferred by syringe into 4 heparin Vacuta inersN . 
These were centri fuged for 1 5  min in a desk-top lEC 
centri fuge . The plasma and buffy coat were removed . 
Approximately 2 volumes o f  IPB pH 7 . 4  were added a s  a 
washing solution . The mixture was rocked for 5 min , a 
sufficient t ime to redistribute the RBCs . Then the c e l l  
mixture was spun f o r  5 min . The washing procedure was 
repeated 3 t imes with care to remove any rema ining buf fy 
coat . After remov ing the res idual lPB , an equal volume 
of d i s t i l l ed deion i z ed water was added to the packed 
cel l s . The tubes were vortexed 1 - 2 min and comp l ete 
hemolysis was as sumed . The hemolysate was trans ferred 
t o  2 plastic centri fuge tubes and the tubes were centri­
fuged in a Sorval l  RC- 5 8  Superspeed centri fuge at 2 7 , 0 0 0  
X G for 3 0  min a t  room temperature . The Hb-contain ing 
hemo lysate was decanted for further analys i s  and the 
p e l l et ( RBe stroma ) was d i scarded . 
4 . 5 . 1 5 . 2  Measurement o f  Hb 
The fol l owing is the procedure used to measure Hb 
in who l e  bl ood and in plasma to check for hemolys i s . 
Hb was measured us ing the s igma D i agnosticsN Total 
HB kit ( Proc . No . 5 2 5 , S igma Chemical Co . ,  s t . Lou i s , 
MO ) . Drabkin ' s  solution was prepared by reconstituting 
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Drabki n ' s  reagent with 1 0 0 0  m 1  o f  water and adding 0 . 5  
ml o f  3 0 % Brij - 3 5  solution ( 3 0  g/dl ) . The Hb standard 
containing lyoph i l i z ed human methemog l ob im was reconst i ­
tuted with 5 0 . 0  m l  o f  Drabkin ' s  solution to make a 
cyanmethemoglobin standard solution . Hb has a MW 
6 4 , 4 5 8 . The m i l l imo lar absorptivity o f  cyanmethemog l o ­
b i n  i s  4 4 . 0  at 5 4 0  nm . Diluted working standards equi­
val ent to b l ood Hb l evel s  o f  0 . 0 ,  6 . 0 ,  1 2 . 0 ,  and 1 8 . 0  
g/dl were prepared . The absorbance o f  these di luted 
standards read at 5 4 0  nm on the Beckman DB-GT spectro­
photometer were used to make a cal ibration curve o f  
absorbance values versus bl ood Hb . The curve was l inear 
and passed through the origin . 
Procedure to measure bl ood Hb : 
( 1 )  Add 5 . 0  ml o f  Drabkin ' s  solution to each tube . 
( 2 )  To each tube add 2 0 . 0  �l ( with an SM! p ipettor)  o f  
whole bl ood and rinse the p ipet with reagent . Mix 
wel l . 
( 3 )  Al l ow to stand at least 1 5  min at room temperature . 
( 4 )  Read abs orbance of each tube versus b l ank ( 0 . 0  g/d1 
standard ) as reference . 
( 5 )  Determine total Hb concentration o f  each samp l e  from 
c a l ibrat ion curve . 
4 . 5 . 1 5 . 3  Binding to Hb 
The b inding of 4 l eve l s  of PYR ( 6 5 ,  3 0 0 ,  4 0 0 , and 
9 4 0  ng/ml ) to hemoglobin was investigated by dialys i s  
against pH 7 . 4  IPB at 3 7 °  for 5 h .  
4 . 6  Part itioning o f  PYR into RBCs 
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A few experiments were done to determine the 
partitioning of PYR into RBCs . Prel iminary studies 
showed that equ i l ibrium between medium and RBCs i n  RBC 
suspens ions in buffer was reached very quickly . The 
s ame l evels were achieved by l e s s  than 5 min a s  in  2 0  or 
3 0  min rocking t ime . The 2 0  min rocking t imes were 
chosen to as sure good mixture of PYR and cel l s . 
4 . 6 . 1  RBC/bu ffer rat io a s  a funct ion o f  buffer pH 
The volume o f  3 0  ml o f  bl ood was drawn from a ma l e  
volunteer ( DR )  through a Butterfly® infusion set ( 2 1G X 
3 / 4  X 12 " ,  Abbott Hosp ital s ,  Inc . , North Chicago , I L )  
into a syringe and transferred into 5 heparin cont a i ning 
tubes ( No . 6 4 8 3 , Becton Dickinson , Rutherford , NJ ) . The 
bl ood was centri fuged , the plasma was removed and the 
cel l s  were washed 3 t imes with pH 7 . 3 3 I PB .  The washing 
cons i sted o f  adding 2 or 3 volumes o f  IPB , rocking 5 
min , spinning 1 0  min at 2 1 0 0  rpm , removing the buffer a s  
we l l  a s  the buffy c oa t , and repe a t i ng t h i s  procedure . 
The cel l s  were washed in KimaX® culture tubes ( 1 6 X 1 2 5 
mm , Kimb l e , Corning , NY ) rather than in the original 
Vacuta inersN . PYR (2  �g in methanol ) was evaporated in 
s ix 50  ml volumetric flasks . The methanol was evapor­
ated and the res idue was reconstituted with pH 6 . 7 ,  7 . 1 , 
7 . 4 ,  7 . 7 ,  7 . 9 ,  or 8 . 0  IPB to make 6 4 0 0  ng/ml solutions . 
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The volumes o f  1 . 5  ml o f  packed cel l s  and 2 . 5  ml 
of I PB containing PYR were pl aced in plastic v i a l s . They 
were rocked for 2 0  min . The HCT was taken in microca-
p i l l ary tubes . The tubes containing the cel l s  suspended 
in buffer were centri fuged . Nearly a l l  o f  the buffer 
was removed , and the cel l s  gently resuspended in the 
rema ining buffer before a second HCT was taken on the 
packed cell s .  PYR was assayed in the packed cel l s  and 
in the buffer . 
The RBC concentrat ion was corrected by this equ a-
t i on us ing the HCT for the cel l suspension : 
WB - P ( l -HCT ) 
RBCcorrected = ( 1 7 )  
HCT 
wh ich can be derived from : 
WB = RBC*HCT + P* ( l-HCT ) ( 1 8 )  
where WB i s  the who l e  b lood PYR concentration ( in this 
case the RBC suspens ion concentrat ion ) ;  P i s  the p l a sma , 
buffer , or buffer-pl asma mixture concentrat ion ; and HCT 
i s  the hematocrit o f  the cell suspens ion . The true WB 
concentra t i on , a fter measuring the RBC and p l a sma con-
centrat ions and making correct ions , was calcul ated from 
E q . ( 1 8 ) . 
Regression analyses o f  thi s  data and theoret ical 
data calcul ated from equations in Chapter 2 were per-
formed us ing SAS PROC REG . 
4 . 6 . 2  Influence o f  pl asma albumin l evel s  on RBC PYR 
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Thi s  paragraph i s  a description o f  s tudy R 1 . The 
volume o f  3 0  ml of bl ood was drawn from a male volunteer 
( DR )  through a Butterfly® infus ion set ( Abbott Hosp i ­
tal s , Inc . , North Chicago , I L )  into a syringe and trans­
ferred into 5 heparin contain ing tubes ( No .  6 4 8 3  Vacu­
ta inersN , Becton Dickinson , Rutherford , NJ ) . The who l e  
blood hematocrit ( HCT ) was measured . The b l ood was 
centri fuged , the plasma was removed and the cel l s  were 
washed with pH 7 . 4  IPB . PYR ( 1  �g ) was evaporated in 4 
tubes . 
To these s i l a n i z ed culture tubes were added pH 
7 . 3 3 I PB , plasma , and RBCs in the fol l owing manner :  
( 1 )  To each tube was added buffer f i rst , then 1 . 7 5 ml 
RBCs with a syringe , then plasma . 
( 2 )  To the f irst tube was added RBCs then 4 X 0 . 8  ml 
plasma . 
( 3 )  To the second tube was added 1 X 0 . 8  ml IPB , RBCs , 
and 3 X 0 . 8  ml plasma . 
( 4 )  To the third tube was added 2 X 0 . 8  ml I PB ,  RBC s , 
and 2 X 0 . 8  ml plasma . 
( 5 )  To the fourth tube was added 3 X 0 . 8  ml I PB , RBCs , 
and 1 X 0 . 8  ml plasma . 
study R1 was performed to determine the dependence 
of the partitioning of PYR into RBCs upon albumin l eve l s  
in p l a sma in a manner originated b y  Garrett ( 5 4 ) . The 
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a l bumin was measured i n  2 0  � l  o f  the p l a sma o r  p l a sma­
buffer mixture . Hb was measured in the plasma a fter its 
s eparation from the cel l s  to detect s igni f i cant hemoly­
s i s . An Hb l evel greater than 0 . 0  was determined to be 
unacceptabl e  hemolysis and the s amp l e  was d i scarded . 
These 4 tubes were gently rocked 2 0  min . The HCT 
was taken on each tube . They were spun 2 0  mins . Nearly 
all o f . the plasma-buffer was removed , and the packed 
cel l s  were gently resuspended in the p l a sma rema in ing in 
the tube . A HCT was taken on the RBC suspension ( packed 
c e l l s ) . The cel l suspen s i on was used to determine the 
RBC l evel . The RBC l evel was corrected for trapped 
plasma us ing Eg . ( 1 7 ) . 
4 . 6 . 3  Determination o f  RBC/pl asma rat io 
Thi s  paragraph i s  a description o f  study R2 . 
Bl ood was coll ected as described in s ection 4 . 6 . 2 .  
Approximately 2 or 3 �g o f  PYR was evaporated in 5 
tubes . Three ml o f  who l e  b l ood was added to each tube 
and they were rocked for 2 0  min . The HCT was taken on 
the who l e  bl ood ; the tubes were spun 2 0  m i n ; the p l a sma 
was removed ; and the cel l s  were mixed gently be fore a 
HCT was taken on the packed cel l s . Albumin was measured 
in the p l a sma . PYR concentrat ions were determined in 
the packed cel l s  and in the plasma . RBC l eve l s  were 
corrected for trapped plasma a s  described above . 
Chapter 5 
Result s  
5 . 1  Reproduct ion of Edsteins ' s  IPC-HPLC assay 
Fig . 4 shows chromatograms o f  the resolution o f  
PYR and Q .  Due to the age and previous use o f  the �Bon­
dapakN column and the del eterious e ffects o f  the coun­
ter-ion sodium pentane sul fonate ( S PS ) on the column , 
the column ' s  performance decl ined rap idly from 1 9 , 0 0 0  t o  
l e s s  than 6 0 0 0  plates/meter . In fact , spl it peaks and 
inadequate resolution devel oped in the chromatograms 
a fter only 12  l iters of mob i l e  phase . Examples o f  a 
peak with a shoulder ( PYR peak) and lack o f  resolution 
o f  PYR and Q can be seen in the last inj ection in Fig . 
4 .  At its best , this I PC-HPLC procedure had a l imit o f  
detection for PYR o f  2 0 0  ng/ml o f  plasma or RBCs . 
Only minor a l terat i ons o f  Edstein ' s  ( 3 9 )  assay 
were necessary for peak resolut i on . The column was 
identi ca l . The mob i l e  phase used by Edstein created too 
much back pres sure and l ong retent ion t imes in th i s  
author ' s  system . There fore , it was changed from 0 . 0 0 5  M 
S PS pH 3 . 4  to 0 . 0 0 1  M SPS pH 3 . 0 . The f l ow rate was 
decreased from 1 . 7  to 1 . 5  ml/min . 
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Blank Q 320 ng/ml 
0 . 0 1 AUFS Plasma P 1000 ng/ml 
Extract at 4 and 6 . 6  
min , respect1 vely 
Unextracted Extraction 
Standard from 0 . 5  ml 
1000 ng PYR/ml RBCs spiked Q p Retention time s :  with 1000 ng/ml 
Q 4 . 4  min 
� Q P 7 . 0  min Q I I  
I' 
i' 
� : i ' !�� t 1 /  � J. J � �  
t 0 0 .. t l' I I 
F igure 4 .  Chromatograms o f  PYR and Q in I PC-HPLC a s say . 
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5 . 1 . 1  E f fects o f  ion pa ir agent and pH 
The e f fects o f  varying the concentration o f  the 
ion pair agent and pH were eva luated whi l e  optim i z ing 
Edstein ' s  as say on my system . 
The e f fects o f  the concentration o f  the ion p a i r  
agent SPS c a n  be seen in the p l o t  o f  capacity factor 
versus concentrat ion o f  S PS ( F ig .  5 ) . As the counter­
ion concentrat ion increased , peaks became asymmetr i c , 
split , and were not resolved . The retent ion t imes a l s o  
increased with S P S  concentrat ion . Chromatographi c  con­
ditions for Figure 5 were mob i l e  phase 2 5 : 1 5 : 6 0 v/v 
methano l : acetonitrile : 0 . 0 0 1  M S PS pH 3 . 14 at a f l ow rate 
o f  1 . 6  ml/min us ing a waters �BondapakN 1 0  �m part i c l e  
s i z e  3 0  c m  X 3 . 9  mm T D  column . 
The e ffects o f  pH on retention t imes ( Rt )  o f  PYR 
and Q are shown in p l ots of Rt versus pH of the mob i l e  
phase a t  5 . 0  roM SPS and a flow rate o f  1 . 5  ml/min ( F ig .  
6 ) • 
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5.4 
5 .2  
4 . 8  
4 . 6  
4 . 4  
4 . 2  
" 3 .8  
3 .6  
3 . 4  
3 . 2  
2 . 8  
2 . 6  
2 . 4  
2 . 2  
� 
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Fig . 5 .  E f fect of S PS concentrat ion on capacity factors .  
3 . 2  3 . 4  3 . 6  
o 
3 . 8  
pH  
PYR  
4 . 2  4 . 4  4 . 6  4 . 8  
Q 
F i g . 6 .  P l ot of the retention times of PYR and Q versus 
pH of the mobile phase . 
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5 . 2  RP-HPLC assay results 
More than 15% vjv acetonitri l e  caused decreas ing 
peak he ight and ta i l ing . More than 6 0 %  vjv total 
organic caused PYR and NAPA to have the same retent ion 
t imes or to run into the plasma unwanted constituent s . 
Retention t imes were 4 . 5  and 5 . 3 5 min for NAPA and PYR 
respectively . 
By far the most d i f ficult obstacle to overcome in 
the devel opment o f  th is assay was the del eterious 
e ffects o f  the neutral pH of the mob i l e  phase on the 
analyt ical column . The pH o f  the mob i l e  phase was 
respons ible for the dissolution o f  the column packing 
material that l ed to column failure . When column f a i l ­
u r e  developed , the samples run that day had t o  be d i s ­
carded . Typically , the standards , contro l s , and s amp l e s  
would b e  prepared f o r  inj ection ( extracted , etc . ) .  
Then , at some t ime during the ir inj ection , the column 
would deteriorate to the po int that it was not icab l e . 
S ometimes , column failure would not be noticed unt i l  the 
regress ion of  the cal ibrat ion curves at the end of the 
day , and all o f  the samples would be lost for that day . 
The rap id dis solution and devel opment o f  voids in 
the column packing led to the fai lure o f  the Econo­
sphereN columns . The l i fet ime in l iters o f  mob i l e  phase 
i s  presented in Tab l e  6 for be fore and a fter the use of 
the s aturator column . When new , the columns tested by 
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the Al ltech procedure had 6 0 - 9 0 , 0 0 0  p l ates/meter . When 
they failed they had less than 4 0 , 0 0 0  p l ates/meter . 
After 2 columns had failed , the saturator column devel ­
oped high back pressure . A 6 . 5  cm ( 2 2 %  o f  the column 
l ength ) void had devel oped in the saturator column . 
Thi s  particle s i z e  reduction had caused the pressure 
prob l em . At that time , the saturator column was 
repacked . 
Tested by the Al ltech procedure , the new Econo­
sphereN columns typ ically had 6 0 , 0 0 0 - 1 0 0 , 0 0 0  
p l ates/meter a t  the retent ion t ime o f  PYR . After f a i l ­
ure , the same columns would have around 4 0 , 0 0 0  
p l ates/meter . 
Tab l e  6 .  Summary o f  All tech EconosphereN l i fe 
Mob i l e  phase Liters unt i l  l ost 
4 7 : 1 5 : 3 8 v/v MeOH : ACN : 0 . 0 1 5  M NaPB , KPB pH 6 . 9  8 . 5  
4 5 : 1 5 : 4 0 MeOH : ACN : 0 . 0 3 M KPB , pH 6 . 9 5 1 5 . 5  
same mob i l e  phase as above , with saturator column 3 2 . 
same mob i l e  phase as above , with saturator column 2 0 .  
KPB=potass ium phosphate buffer , NaPB=sodium phosphate 
b u f f e r ,  MeOH-methancl , ACN=aceton itr i l e ,  v-volume 
The s aturator column increased the l i fet ime of the 
EconosphereN columns . It would have been better to use 
a column with a higher carbon load because they are 
known to res ist the e f fects o f  pH better ( 1 2 4 ) . 
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Changing from the sodium salt to the potas s ium 
salt o f  phosphate a l s o  improved the l i fetime o f  the c o l ­
umns and reduced the back pressure o f  t h e  system . The 
sodium salt was not as  solub l e  in the mob i l e  phase and 
precip itates cl ogged the column as  wel l  a s  the mob i l e  
phase filtering apparatus . Use o f  the potass ium s a l t  
a l l owed the increas ing o f  the mo l arity o f  the phosphate 
buf fer and achievement o f  better peak shape . 
Some o f  the symptoms o f  column fai lure observed 
were peak changes and standard curve changes . Peak 
changes included irregular peak height and area ; peak 
broadening , tail ing , and fronting ; spl it peaks ; base o f  
peaks higher o n  one s ide ; and disappearance o f  peaks . 
The most common peak change was spl itting o f  peaks . 
Thes e  spl it peaks could not be used to make a cal ibra­
tion curve . Standard curve changes included variab i l ity 
in s l ope and peak height from day to day and loss o f  
s ens itivity . Overa l l , column fai lure led to basel ine 
dri ft and decreases in column e f f i c iency . 
Another prob l em was the b inding o f  the PYR and 
internal standard to glass . Even though a l l  o f  the 
glassware was s i l an i z ed , the bu ffer used for reconstitu­
tion dissolved the s i l anes off the glass when a l l owed 
enough t ime . Because the reconst itut ion volume was 
sma l l , only one inj ection ( somet imes two for the higher 
concentrat ions ) was possible for each samp l e  for the 
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p l a sma and RBC extracts . storage o f  the samples which 
were in glass tubes was also not possible because the 
buffer stripped the s i l anes off the glass and a l l owed 
the drug to b ind to it . storage was p o s s ib l e  in p l a s t i c  
tubes . 
The time involved in the extraction o f  the p l a sma 
and RBC samples was also critical . For the plasma 
extraction procedure , more than a 10 min shake resulted 
in great variabil ity in the NAPA recovery due to its 
b inding to glass stripped by the potas s ium hydroxide 
added to alka l i n i z e  the samp l e . The reason that the 
molarity of the potass ium hydroxide was decreased from 4 
to 0 . 8  M was that there was less stripping o f  the 
s i l anes at the l ower buffer concentrat ion . Variab i l ity 
in the peak heights of the NAPA made cal ibration curves 
very d i f f icult . 
When exposed to organ ic solvents , RBCs become hard 
clumps from which drug is impos s ib l e  to extract , even 
a fter vortexing . Tubes had to be rotated between addi ­
t i o n  o f  the organ ic solvent and the 2 0  m i n  shaking t ime 
to prevent settl ing of the RBCs into a hard mas s . For 
the RBC extract ion procedure , shaking had to be 
increased to 20 minutes because PYR extraction was poor 
at less shaking time due to the clump ing o f  the RBCs . 
However , that gave the NAPA t ime to b ind to glass  and 
get trapped in the RBC clumps which introduced too much 
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variab i l ity in i t s  recovery . For thi s  reason , an inter-
nal standard wa s not used and quantitative remova l  o f  
the organ i c  pha s e  wa s i ntroduced . 
5 . 2 . 1  E f fect o f  pH on retent ion times 
The e f fect of the changes in pH of the phosphate 
b u f fer in the mob i l e  pha s e  can be seen in F igure 7 .  The 
chromatograph i c  cond i t i ons for th is were : 3 5 % 0 . 0 2 M Na 
and K phosphate bu f f e r , 1 5 %  acetonitri l e ,  and 5 0 %  metha -
nol at f l ow rate 1 . 6  ml/min . 
E F F E C T  O F  pH ON R ETENTIO N  TIMES 
5 . 5  -,----- -----------------------, 
.� 
5 . 5  
. : � 
4 j  �,� 3 5 - "G-�B-------
5 . 2  5 . 4  5 . 5  
:J PYR 
5 . 8  7 . 2  
p H  
NAPA 
F i g . 7 .  E f fects of pH on retent i on t imes for PYR and 
NAPA.. 
• �j 
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5 . 2 . 2  Cal ibrat ion curves 
A chromatogram for the plasma s amples appears in 
F igure 8 ,  for the RBCs in Figure 9 ,  for the buf fer in 
F igure 1 0 . Examples o f  cal ibration curves appear in 
F igures 1 1  and 1 2 . 
Two cal ibration curves were necessary for each 
matrix for 2 4 - 1 4 0  ng/ml and 1 4 0 - 1 0 0 0  ng/ml . A c l o se-up 
of the lower end of the high cal ibrat ion curve ( Figure 
1 2 ) shows the change in s l ope at 1 4 0  ng/ml . 
Although the s l opes do not appear to be that d i f­
ferent for the two cal ibrat ion curves for each matrix , 
the concentrat ion predicted for the 1 0 0  ng/ml samp l e  
us ing the high curve ( range 1 4 0  - 1 0 0 0  ng/ml ) w a s  o f f  
b y  2 0  - 2 5 % . 
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F i gure 8 .  Chroma togram o f  PYR and NAPA in p l a sma s ampl e .  
R BC s  b l a n k  
0.005 
A U F S  
I l . 
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3 0  
py r 
" 
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F igure 9 .  Chromatogram o f  PYR in RBC samp l e . 
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F igure 1 0 . Chromatogram of PYR in buffer sample .  
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B I P H A S I C  C A L I B R A T I O N  C U R V ES 
0 . 2  0 . 4  0 . 6  
( T h o u s a n d s )  
?YR C o n c e n tr"o t i o n  ( n g / 111 1 )  
S L O P :: S  . 2 9  .. V S  . 3 6  0 
0 . 8  
F i gure 1 1 . Typ ical p l a sma cal ibration curves . 
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F igure 1 2 .  C l o s e -up o f  the l ower end o f  the p l a sma c a l i -
brat i o n  curves . 
5 . 2 . 3  Recovery. prec i s ion and accuracy stud ies 
Results o f  the prec i s ion , accuracy and recovery 
studies for the RP-HPLC method are in Tables 7 - 1 1  for 
the plasma , Tables 1 2 - 1 5  for the RBCs and Tables 1 6 - 1 9  
for the buffer . 
At least one control was run for every 1 0  samp l e s  
a n d  it was n o t  acceptable to have greater than 1 0 %  error 
from the sp iked concentration o f  the control . Contro l s  
were varied from day to day because the cho ice o f  the 
contro l s  was dependent on the expected concentrat ions in 
the samples . In other words , in an ED exper iment where 
the expected plasma concentrat ion at the end o f  d i a l ys i s  
w a s  3 6 0  ngjml , the control used in that day ' s  run was 
around 3 5 0  ngjml . 
The percent recovery values in Tab l e  7 were deter­
mined by comparing the peak he ights from extracted 
s amples to the peak he ights o f  unextracted samp l e s  ( eva­
porated standard solutions that had been reconst ituted 
the s ame way ) . 
In Table 8 ,  on Day 1 ,  the cal ibrat i on curv e  
included a 20 ngjml standard . On later days , the l im i t  
o f  detect ion was found to be higher , a n d  t h e  2 0  ngjml 
standard was repl aced with a 3 0  ngjml standard in order 
to retain a 6 po int cal ibrat ion curve . 
In Tables 1 6  and 17 , 7 standards are miss ing 
because they were lost or went off scal e . 
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Tab l e  7 .  Percent recovery from extracted spiked pl a sma 
cal ibration standards 
Low Cal ibrat ion Curve 
PYR Concentration 
(ngiml l N Mean Recovery 
2 4  4 7 8 . 6  
4 0  4 8 5 . 1  
1 4 0  4 8 6 . 6  
Overal l  12  8 1 . 9  
( Range 7 1 . 4 - 9 5 . 2  
NAPA 3 2  8 2 . 6  
( Range 6 9 . 7  - 1 0 6 % ) 
H igh Cal ibrat ion Curve 
PYR Concentration 
% )  
(ngiml l N Mean Recovery 
1 4 0  3 9 0 . 4  
2 0 0  3 7 8 . 2  
4 0 0  3 8 1 . 4  
6 0 0  3 7 9 . 7  
1 0 0 0  3 9 1 .  7 
Overa l l  15  8 5 . 4  
( Range 7 5 . 4  - 9 9 . 3 ) 
NAPA 1 5  8 0 . 9  
% CV 
1 0 . 5  
1 0 . 8  
5 . 2  
8 . 7  
1 0 . 2  
% CV 
3 . 7  
3 . 8  
1 . 2  
5 . 7  
7 . 6  
7 . 9  
7 . 7  
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TABLE 8. BACK-CALCULATE D  CONCENTRATIONS OF PYR PLASMA S TANDARDS 
U S I NG A LINEAR F I T  FOR '£HE LOW CONCENTRATIONS 
C a l i b r a t i o n  Standards ( ngLml )  
D£y-- 2 0  2 4  30 4 0  60 1 0 0  1 4 0  
1 1 9 . 9 5 2 4 . 2 0 37 . 8 1 60 . 9 4 1 06 . 7 9  1 4 2 . 1 4 
1 8 . 97 2 5 . 1 0  4 2 . 7 6 57 . 8 2 9 3 . 1 2 1 3 6 . 64 
1 9 . 7 5 2 3 . 51 36 . 4 1  60 . 1 5 1 0 5 . 0 8  138 . 60 
1 8 . 2 3 
5 2 3 . 06 31 . 7 7  4 2 . 4 0 57 . 2 5 9 6 . 9 4 1 4 2 . 3 7 
7 2 4 . 7 2 l o s t  38 . 7 4 60 . 53 l o s t  1 4 0 . 0 1 
1 0  2 3 . 9 5 2 9 . 6 5 4 1 .  9 2  60 . 4 1 9 5 . 50 1 4 2 . 57 
N 4 6 2 6 6 5 6 
Mean 1 9 . 2  2 4 . 1  30 . 8  4 0 . 0  59 . 5  9 9 . 5  1 4 0 . 
% CV 4 . 0 9 3 . 13 4 . 87 6 . 7 4 2 . 63 6 . 1 0  1 . 7 2 
. %  E r r o r  - 3 . 9  0 . 38 2 . 57 0 . 0 2 - 0 . 8 0 - 0 . 5 1 0 . 2 8 
.... 
0 0 
TABLE 9 .  BACK-CALCULATED CONCENTRATIONS OF PYR PLASMA STANDARDS 
USI NG A LINEAR FIT FOR THE HIGH CONCENTRATIONS 
C a l ibrat ion S t andards (ngLml) --------------- --
. Day- 14 0  2 0 0  4 0 0  6 0 0  1 0 0 0  
1 146.3 9 1 9 4 .4 6  4 0 5.2 2 616.4 6 1 0 66.0 2  
1 4 3 .4 7  2 1 0.7 8  3 62 .2 1 567.2 4 9 3 9.9 9 
1 4 3 .2 7 19 8.7 4 4 3 5 . 4 6 5 7 5.7 4 1 0 1 4 .5 2  
2 1 5 0.0 0 2 1 4 . 5 0  3 61.76 566.4 6 1 0 2 8 .4 9  
3 1 4 9 .61 1 8 3 .60 4 0 8 .0 0 612.14  9 9 4 .65 
4 1 4 9 .8 0  1 9 5.5 0 3 9 6.9 2 5 9 2.56 1 0 0 5.2 3 
6 1 5 1 . 3 5  2 0 8 .9 4  3 65.8 7 5 9 0.3 2 1 0 1 4 .8 7  
7 1 4 8.26 2 0 2 .2 1  3 9 1.7 2 5 9 0.2 4 1 0 0 7.57 
8 1 4 2 .3 9 1 8 8 .2 3  4 0 2 .8 0 614.18 9 9 2 .3 9 
9 1 4 0.0 0 2 0 0.2 3 4 0 8.2 1 5 9 6.69 9 9 9 .60 
11 1 4 3.12 2 0 1 . 3 8 3 9 8 . 1 5 5 9 3 . 3 1 1 0 0 4 .0 4  
N 1 1  1 1  1 1  1 1  1 1  
Mean 1 4 6. 2 0 0. 3 9 4 .  5 9 3 . 1 0 1 0. 
% CV 2 .63 4 .67 5.7 8 2 .9 5  2 .9 8  
. % Error 4 . 3 9 0.06 - 1.4 5 -1. 2 4  0.61 
'-" 
0 '-" 
1 0 2  
Tab l e  1 0 . PYR concentrat ions in sI;1iked control I;1l a sma 
s amI;1l es 
Control Concentrat ions (ngLmll 
Day 3 5  6 8  1 5 0  3 3 0  4 2 0  7 2 0  
1 3 7 . 6 5 6 7 . 5 6 1 4 9 . 7 3 3 2 0 . 8 0 7 2 7 . 1 0 
4 0 . 1 7 6 8 . 4 6 1 4 5 . 8 7 3 5 5 . 6 7 6 8 4 . 1 4 
3 3 . 1 0 6 5 . 3 8 1 4 3 . 5 7 3 1 9 . 2  6 9 2 . 4 2 
3 5 . 3 5 6 8 . 7 0 1 5 3 . 8 6 3 3 5 . 6 6 7 3 7 . 1 6 
3 8 . 3 4 6 5 . 5 5  1 5 1 . 7 4  3 4 5 . 3 0 7 3 4 . 6 8 
3 7 . 4 7 6 3 . 7 3 1 3 8 . 8 8 3 2 7 . 8 8 7 3 5 . 5 8 
3 7 . 5 0 7 3 . 9 9 1 5 2 . 4 9 3 6 6 . 8 4 7 0 7 . 5 2 
3 4 . 8 4 7 0 . 0 4 1 5 3 . 4 0 3 2 0 . 18 7 3 0 . 6 1 
3 8 . 5 3 68 . 7 0 1 4 8 . 2 0 3 2 5 . 5 2 6 8 2 . 0 2 
3 5 . 4 1 6 7 . 9 3 1 5 1 . 5 0 3 2 1 .  7 5  7 7 2 . 9 9 
3 2 . 1 6 1 5 1 . 5 8  
2 1 4 9 . 7 1 3 3 3 . 1 2 6 9 8 . 4 2 
1 4 6 . 3 9 
1 4 4 . 4 2 
1 5 3 . 2 6 
1 5 1 . 4 4  
1 4 0 . 3 8 
1 5 2 . 0 8 
1 5 2 . 8 7 
1 4 8 . 4 0 
1 5 1 . 2 3 
( continued on next page ) 
1 0 3  
Tab l e  1 0  cont inued : 
1 5 1 .  3 0  
3 3 2 6 . 7 6 
4 7 1 7 . 2 9 
5 3 4 . 9 7 
6 1 6 0 . 0 0 
7 3 2 . 7 1 3 1 7 . 3 6 
8 1 3 5 . 5 3 
9 4 1 2 . 2 7 7 0 0 . 0 7  
1 0  4 1 .  5 1  1 3 3 . 9 5 
1 1  4 3 7 . 1 0  7 3 7 . 7 4 
N 1 4  1 0  2 5  1 3  2 1 4  
Mean 3 6 . 4  6 8 . 0  1 4 8 . 3 3 2 . 4 2 4 . 7 1 8 . 
% CV 7 . 6 8 4 . 1 7 4 . 1 3 4 . 6 0 4 . 1 3 3 . 5 6 
%Error 1 . 1 4 2 . 8 4 - 1 . 0 2 0 . 6 1 1 . 1 6 - 0 . 2 2 
TABLE 1 l . LINEAR REGRE S S ION ON PEAK HEIGHT RATI O  ( PYR/NAPA ) 
VERSUS CONCENTRATION OF PYR FOR PLASMA CURVES 
Low Curve H igh Curve 
Day S l ope R Y - i ntercept S l ope R Y - I ntercept 
1 0 . 00306 0 . 9 97 0 . 0 5 3  0 . 003 5 6  0 . 9 9 6  - 0 . 0 2 2  
2 0 . 0 0 4 2 9  0 . 9 9 6  - 0 . 1 8 8  
3 0 . 002 8 4  0 . 9 9 9  - 0 . 0 3 9  
4 0 . 0 0 2 50 0 . 9 9 9  0 . 0 0 9  
5 0 . 002 6 2  0 . 9 9 8  - 0 . 00 9  
6 0 . 00 3 6 4  0 . 9 9 8  - 0 . 1 4 2  
7 0 . 002 5 5  0 . 9 9 9  - 0 . 005 0 . 00274 0 . 9 9 9  - 0 . 0 5 5  
8 0 . 00 3 1 0  0 . 9 9 9  - 0 . 0 0 4  
9 0 . 0 0 0 6 4  0 . 9 9 9  - 0 . 0 1 6  
1 0  0 . 00273 0 . 9 9 9  - 0 . 01 0  
1 1  0 . 0 0 2 9 8  0 . 9 9 9  - 0 . 0 3 4  
I-' 0 ..,. 
Tab l e  1 2 .  Percent recovery from extracted spiked RBC 
cal ibrat ion standards 
Low Cal ibrat ion Curve 
PYR Concentration 
(ngLml ) N Mean Recovery 
2 4  3 8 2 . 0  
3 0  3 8 2 . 4  
4 0  3 8 7 . 9  
6 0  3 8 6 . 7  
1 0 0  3 8 0 . 6  
1 4 0  3 8 7 . 1  
Overal l  1 8  8 4 . 4  
( Range 7 6 . 9  - 9 0 . 9  % )  
H igh Cal ibration Curve 
PYR Concentrat ion 
(ngLml) N Mean Recovery 
1 4 0  3 7 1 . 7  
2 0 0  3 8 2 . 6  
4 0 0  3 9 3 . 8  
6 0 0  3 8 5 . 9  
1 0 0 0  3 8 8 . 0  
Overa l l  1 5  8 4 . 4  
( Range 6 2 . 5  - 9 8 . 1 ) 
% CV 
5 . 4 2 
0 . 0 0 
5 . 9 7 
1 . 9 1 
0 . 0 0 
1 .  5 1  
4 . 5 3 
% CV 
1 1 . 6 
1 .  6 3  
5 . 0 1 
1 .  6 8  
7 . 2 8 
1 0 . 4  
1 0 5  
Tab l e  1 3 . Back-calcul ated concentrat ions o f  PYR RBC 
standards using a l inear fit o f  peak he ight versus con­
centration for the l ow concentrations 
Cal ibrat ion standards ( ng/ml ) 
Day 2 4  3 0  4 0  
1 
2 
3 
N 
2 4 . 5 4 
2 4 . 5 4 
2 4 . 5 4 
2 5 . 0 9 
2 6 . 8 7 
2 5 . 0 9 
2 5 . 3 3  
2 5 . 3 3 
2 3 . 5 4 
9 
!-lean 2 5 . 0  
% CV 3 . 6 1 
%Error4 . 1 2 
2 8 . 6 5 
2 8 . 6 5 
3 2 . 2 2 
3 0 . 7 1 
3 0 . 7 1 
3 0 . 7 1 
6 
3 0 . 3  
4 . 5 8 
0 . 9 3 
4 1 . 9 9 
3 6 . 7 5 
3 8 . 5 0 
3 5 . 7 8 
3 9 . 3 4 
3 9 . 3 4 
4 1 . 4 7 
4 1 . 4 7 
3 7 . 8 8 
9 
3 9 . 2  
5 . 5 7 
- 2 . 0 8 
6 0  
6 2 . 9 2 
6 2 . 9 2 
6 2 . 9 2 
6 0 . 7 2 
6 4 . 2 8 
6 0 . 7 2 
5 9 . 3 9 
5 9 . 3 9 
6 1 . 1 9  
9 
6 1 . 6 
2 . 8 1 
2 . 6 8 
1 0 0  
9 4 . 3 1 
9 4 . 3 1 
9 6 . 0 6  
9 6 . 3 5 
9 6 . 3 5 
9 6 . 3 5 
9 5 . 2 4 
9 5 . 2 4 
9 5 . 2 4  
9 
9 5 . 5  
0 . 8 7 
- 4 . 5 1 
Percent CV = ( standard deviation/mean)  X 1 0 0  
1 4 0 
1 3 9 . 6 6 
1 4 6 . 6 4 
1 4 1 .  4 1  
1 4 2 . 6 6 
1 4 4 . 4 4 
1 3 9 . 1 0 
1 4 1 . 8 5 
1 4 5 . 4 3 
1 4 1 . 8 5 
9 
1 4 3 . 
3 . 9 1 
2 . 3 4 
1 0 6  
1 0 7  
Tab l e  14 . Back-calcul ated concentrat ions of PYR RBC 
standards us ing a l inear fit o f  �eak he ight versus con-
centrat ion for the high concentrat ions 
Cal ibrat ion Standards ( ng/ml ) 
Day: 1 4 0  2 0 0  4 0 0  6 0 0  1 0 0 0  
4 1 5 5 . 4 3 2 0 8 . 2 5 4 0 0 . 1 6  5 6 5 . 6 5 1 0 0 9 . 3 3 
1 3 2 . 5 5 2 1 1 .  7 7  4 1 4 . 2 4 5 8 3 . 2 6 9 4 5 . 9 4 
1 4 8 . 3 9 2 0 6 . 4 9 3 7 9 . 0 3 5 7 2 . 7 0 1 0 8 6 . 7 9 
5 1 3 1 . 2 9 1 8 7 . 4 9 4 1 2 . 2 7 6 2 5 . 3 5 9 8 3 . 6 0 
N 4 4 4 4 4 
Mean 14 1 .  2 0 3 . 4 0 1 .  5 8 6 . 1 0 1 0 . 
% CV 8 . 3 9 5 . 3 5 4 . 0 3 4 . 5 6 5 . 9 2 
% Error 1 .  3 7  1 .  7 5  0 . 3 6 - 2 . 2 1 0 . 6 4 
Percent cv ( standard deviation/mean ) X 1 0 0  
Tab l e  1 5 . Linear regres s ion o f  cal ibrat ion curves for 
RBCs peak he ight versus concentrations 
Low Concentrat ions 
Day 
1 
2 
3 
S l ope 
0 . 0 0 2 8 7  
0 . 0 0 2 8 1  
0 . 0 0 2 7 9  
H igh Concentrations 
4 
5 
0 . 0 0 2 8 4  
0 . 4 2 7  
R 
0 . 9 9 7  
0 . 9 9 8  
0 . 9 9 8  
0 . 9 9 5  
0 . 9 9 9  
Y- intercept 
- 0 . 0 2 0  
- 0 . 0 2 0  
- 0 . 0 1 6  
-0 . 12 6  
-7 . 0 7 
1 0 8  
'fABLE 16 .  BACK- CALCULATED CONCENTRATONS OF PYR BUFFER STANDARDS US I NG A 
LINEAR FIT OF PEAK HEIGHT VERSUS CONCENTRATI ON FOR THE LOW CONCENTRAT IONS 
C a l ibrat ion Standards ( ngjm l ) 
Day 2 4  3 0  4 0  6 0  1 0 0  1 4 0  
1 2 3 . 9 0 2 7 . 9 1 6 1 .  9 8  1 0 2 . 0 7 1 3 8 . 1 4  
4 2 6 . 2 0  2 9 . 3 6 3 7 . 2 5 6 0 . 9 3 1 0 0 . 4 0 1 3 9 . 9 8 
5 2 5 . 2 4 3 7 . 2 8  5 8 . 3 5 1 0 6 . 5 2 1 3 6 . 6 2  
6 2 1 .  4 2  2 9 . 0 1  4 4 . 1 8 5 9 . 3 5 1 0 1 .  0 6  1 3 9 . 9 8 
7 2 6 . 1 0 3 2 . 1 9 3 3 . 2 7 5 6 . 5 4 9 9 . 1 5 14 1 .  7 6  
8 2 2 . 8 6 2 8 . 7 3 4 3 . 4 1 5 8 . 0 8 1 0 2 . 1 1 1 3 8 . 8 1 
9 2 4 . 8 8 3 1 .  0 4  3 3 . 7 4 5 8 . 7 4 1 0 0 . 3 0 1 4 0 . 3 2 
1 3  2 3 . 7 4 4 1 .  5 1  5 9 . 2 9 9 8 . 4 0 1 4 1 . 0 6 
1 4  2 4 . 8 2 2 9 . 4 4 3 :3 . 6 9 6 1 .  8 1  9 8 . 8 1 1 4 0 . 4 3  
1 5  2 1 .  6 6  2 9 . 1 0 4 0 . 2 6  5 8 . 8 5 1 1 0 . 9 1 1 3 3 . 2 2 
1 6  3 0 . 2 2  5 8 . 4 0 9 9 . 3 9 1 4 0 . 3 9 
N 1 0 9 9 1 1  1 1  1 1  
Mean 2 4 . 1  2 9 . 7  4 0 . 0  5 9 . 3  1 0 2 . 1 3 9 .  
% CV 7 . 1 3 4 . 3 7 6 . 4 2 2 . 7 9 3 . 7 2  1 .  7 5  
% Error 0 . 4 3 - 1 . 1  -0 . 1 1 - 1 . 1 6 1 .  7 4  - 0 . 6 0 
..... 
0 '"' 
TABLE 1 7 . BACK-CALCULATED CONCENTRATI ONS OF PYR BUFFER STANDARDS U S I NG A 
LI NEAR F I T  OF PEAK HEIGHT VERSUS CONCENTRATION FOR THE H I GH CONCENTRAT IONS 
C a l ibrat ion S t andards ( ng/ml ) 
Day 1 4 0  2 0 0  4 0 0  6 0 0  1 0 0 0  
2 1 4 4 . 0 5 1 9 6 . 7 2 3 8 7 . 5 5 6 1 6 . 5 4 9 9 5 . 1 5  
3 1 5 1 . 6 2  2 2 1 . 4 1 3 6 9 . 7 1 5 7 7 . 6 3 1 0 1 9 . 6 3 
4 1 3 9 . 6 0 2 0 5 . 8 7 3 9 6 . 2 4 5 9 3 . 9 4 1 0 0 3 . 9 7 
8 1 3 8 . 3 4 2 0 6 . 8 7  4 1 2 . 4 6 5 7 1 . 1 5 1 0 1 1 . 1 8 
1 0  1 3 8 . 8 1 2 0 0 . 7 9 4 0 0 . 5 1 6 0 0 . 2 3 9 9 9 . 6 7 
1 1  1 3 2 . 6 5 3 9 0 . 9 5 6 2 9 . 3 8 9 8 7 . 0 2 
1 2  1 9 6 . 5 7 3 8 8 . 4 9 5 7 1 . 2 7 1 0 1 9 . 0 9 
1 6  1 4 0 . 3 9 2 1 8 . 6 8 3 8 3 . 2 3 5 8 7 . 8 0 1 0 1 0 . 2 9 
N 7 7 8 8 8 
Mean 1 4 1 . 2 0 7 . 3 9 1 .  5 9 3 . 1 0 1 0 . 
% CV 4 . 1 6 4 . 8 3 3 . 2 2 3 . 5 7 1 . 1 4 
% Error 0 . 5 6 3 . 4  -2 . 2 2 - 1 . 0 9  0 . 5 8 
...... ...... 
0 
TABLE 1 8 . BUFFEH CONTROLS 
Day 4 0  1 0 0  1 4 0  2 8 0  4 8 0  7 0 0  
1 4 1 . 9 4  
2 4 3 . 2 7 
3 7 . 8 2 
4 1 3 9 . 9 8 2 8 9 . 8 4 4 7 6 . 7 9 6 7 4 . 4 8 
1 3 9 . 8 6 2 7 9 . 0 9 4 8 7 . 1 7 7 1 6 . 0 7  
1 4 3 . 8 1 4 6 2 . 14 
5 0 2 . 9 5 
6 4 0 . 3 9 9 3 . 4 8 
8 3 9 . 7 4 4 69 . 0 3 
1 0  4 4 8 . 7 2 
1 1  5 0 0 . 2 3 
12  4 7 9 . 8 8 7 12 . 9 3 
4 8 9 . 0 2 
1 3  4 1 . 5 1 1 3 3 . 9 5 
1 4  1 0 0 . 0 4 4 9 8 . 9 4 
9 3 . 3 9 4 8 5 . 6 5 
1 0 0 . 0 4 5 1 2 . 2 4 
1 0 0 . 0 4 5 1 2 . 2 4 
9 6 . 7 2 5 3 2 . 1 9 
9 6 . 7 2 
1 5  1 5 0 . 8 0 
1 6  1 0 9 . 6 4 4 8 1 .  0 7  
4 8 5 . 5 1 
4 8 5 . 5 1 
N 6 8 5 2 1 7  3 
Mean 4 1 .  9 9 . 1 4 2 . 2 8 4 . 4 8 9 . 7 0 1 . 
% CV 4 . 6 6 5 . 2 5 4 . 3 7 2 . 6 7 4 . 1 0 3 . 3 0 
?c; Error 1.  9 5  - 1 . 2 4  1 . 2 0 1 .  5 9  1 .  8 3  0 . 1 7 .  
Percent cv ( S tandard Deviation/Mean)  X 1 0 0  
..... 
..... 
..... 
Tab l e  1 9 . Linear regress ion on cal ibrat ion curves for 
buffer peak he ight versus PYR concentration 
Low Concentrat ions 
Day S l ope R Y - intercept 
1 *  0 . 2 4 9  0 . 9 9 9  - 1 . 4 6 
4 0 . 1 2 7  0 . 9 9 9  0 . 2 8 1  
5 *  0 . 3 3 2  0 . 9 9 6  - 1 . 3 8  
6 0 . 1 3 2  0 . 9 9 9  - 0 . 3 2 5  
7 *  0 . 3 2 9  0 . 9 9 9  - 2 . 5 8 
8 0 . 1 3 6  0 . 9 9 9  - 0 . 9 2 
9 *  0 . 3 2 5  0 . 9 9 9  - 1 . 5 8 
13  0 . 1 4 1  0 . 9 9 9  0 . 1 6 2  
1 4  0 . 1 0 8  0 . 9 9 9  0 . 8 1 7 
15  0 . 1 3 5  0 . 9 9 2  1 .  0 9  
1 6  0 . 1 9 5  0 . 9 9 9  - 0 . 4 0 0  
H igh Concentrat ions 
2 * 0 . 6 5 5  0 . 9 9 9  - 3 5 . 8 6 
3 *  0 . 6 8 8  0 . 9 9 8  - 3 3 . 2 8 
1 0  0 . 1 4 5  1 . 0 0 0  - 0 . 1 5 5  
1 1  0 . 1 0 1  0 . 9 9 9  - 1 . 3 5  
1 2  0 . 2 1 9 0 . 9 9 8  - 1 2 . 0  
1 6  0 . 2 2 5  0 . 9 9 9  - 1 2 . 2  
* d i f ferent reconstitution volume than others 
1 1 2  
1 1 3  
5 . 3  Vacuta inerN pH as a function o f  add it ive and t ime 
There i s  a rap id and s ign i f icant increase in 
p l asma pH in unseal ed conta iners a s  the C02 escapes . I n  
contrast , there i s  a lmost no change in RBC p H  because o f  
the i r  greater buffer capac ity . 
Seal ing the tubes results in a more constant pH a s  
o n e  c a n  s e e  in Tables 2 0  a n d  2 1  b y  comparing the p H  
values f o r  the sealed and unsealed tubes . 
The results o f  ANOVA us ing SAS are in Tab l e  22 
below .  There is a s igni f icant d i f ference in the z ero­
t ime pH for heparin tubes compared to Vacuta inersN con­
ta ining EDTA and c itrate anticoagulants . citrate is the 
only one of  the 3 additives with buf fering power in 
these sma l l  quantities . In fact , the tubes are l abeled 
" 0 . 1 0 5M buf fered sodium c itrate . "  
Graphs o f  the rap id rise in pl asma pH are a l s o  
shown in F igures 1 3 a  and 1 3 b  wh ich fol l ow Tab l e  2 1 .  
1 1 4  
Tab l e  2 0 .  Measured 12H values at various t imes 
Unsealed Tubes 
T ime Add it ive Plasma 12H % c . v .  RBCs 12H % c . v .  
0 EDTA ( n=5 ) 7 . 3 0 6  0 . 3 2 7 . 3 3 0 . 3 0 
Heparin 7 . 4 9 6  0 . 5 8 7 . 5 4 0 . 0 8 
Buffered c itrate 7 . 2 9 0 . 0 1 7 . 2 8 0 . 0 9  
1 5  EDTA ( n=4 ) 7 . 4 0 0 . 4 6 7 . 3 2 0 . 5 1 
Heparin 7 . 5 7 2  0 . 0 7 7 . 5 2 0 . 4 1 
Bu f fered citrate 7 . 3 7 8  0 . 0 7 7 . 3 0 0 . 0  
3 0  EDTA ( n=4 ) 7 . 4 6 5  0 . 3 2 7 . 3 5 0 . 2 8 
Heparin 7 . 5 7 5  0 . 0 8 7 . 5 2 0 . 1 7 
Buf fered citrate 7 . 4 2 8  0 . 2 8 7 . 3 4 0 . 0 8 
6 0  EDTA ( n=4 ) 7 . 5 7 0 . 4 2 7 . 3 5 
Heparin 7 . 6 0 2  0 . 0 0 7 . 5 0 0 . 0 0 
Buffered c itrate 7 . 4 9 5  0 . 0 8 7 . 3 5 0 . 0  
1 2 0  EDTA ( n=4 ) 7 . 6 8 0 . 5 5 7 . 3 6 0 . 3 9 
Heparin 7 . 7 0 5  0 . 0 0 7 . 5 4 0 . 0 0 
( continued on next page ) 
Tab l e  2 0  continues : 
S e a l ed Tubes N= l 
6 0  EDTA 7 . 3 2 
Buf fered c itrate 7 . 2 9 7 . 2 9 
1 2 0  EDTA 7 . 3 8 7 . 2 2 
Heparin 7 . 5 2 7 . 2 2 
1 8 0  EDTA 7 . 3 9 7 . 4 0 
Heparin 7 . 5 1 7 . 4 0 
N=4 except for z ero time when N=5 for each set o f  
unsealed tubes . 
Percent CV = ( standard deviation/mean) X 1 0 0 %  
Tab l e  2 1 .  Change in pH o f  med ium for the first hour 
1 1 5  
Unsealed pH units/hr pH at z ero t ime 
Plasma in vacuta iners� conta ining : 
0 . 1 0 5  M buf fered Na c itrate 
1 4 3 USP units Na heparin 
0 . 2  
0 . 3  
7 . 2 9 
7 . 5 5 
Who l e  b l ood in Vacuta inersN conta ining 0 . 1 0 5  M buf fered 
Na c itrate 
RBCs in VacutainersN containing 
1 4 3  USP units Na heparin 
Sealed 
0 . 0 7 
0 . 0  
Whol e  b l ood in a vacuta inerN contain ing 
0 . 1 0 5  M buffered Na c itrate 0 . 0  
7 . 2 8 
7 . 4 8 
7 . 2 9 
1 1 6  
A .  CHANGE I N  pH O F  UNSEALED PLASMA 
N O N - B UF F ER ED YAC UTA I N E R S"( HEPARI N )  
8 . 2  -,--------------------'-----------, 
8 . 1  
7 . 9  
� 
7 . 8  
7 . 7  
7 . 6  
7 . 5  
0 1 00 200 300  400 
T ime (min)  
B.  CHANGE IN pH OF UNSEALED P L A S M A  
NON- BUFFERED VACUTA INERSCEDTA) 
7.7 '1-------------------------------,
7 . 65 jl 
7 . 6  
7 . 55 
� 
7 . 5  l' 7 AS 
7 . 4 
] � , ,, V 
7 . 3  , 
o 20  40 60 60  1 00 
Time ( m i n )  
F i gures 1 3 a , 1 3 b . T ime dependent r i s e  in pH o f  p l a sma 
in 2 Vacuta inersN . 
1 2 0 
1 1 7  
5 . 3 . 1  D i f ferences in zero time pH in Vacutainers� 
Results o f  ANOVA are in Tab l e  22 below .  The fact 
that F = 8 0 . 0 7 exceeds the F tab l e  value by a l arge 
margin indicates that there i s  a s igni f icant d i f ference 
in the zero t ime pH produced by the ant i coagul ant add i ­
t ives in the tubes . The Tukey group ing shows that the 
z ero t ime pH values in tubes contain ing heparin are 
s igni f icantly d i fferent from the pH values in tubes 
containing EDTA or buf fered c itrate . 
EDTA and c itrate produced the same pH at zero 
t ime according to the ANOVA . 
Tab l e  2 2 . ANOVA for z ero time 2H in d i fferent 
vacutainers"' . 
Analys i s  o f  variance Procedure 
Dependent variab l e : zero time pH 
S ource 
Model 
Error 
Cor . total 
R- square 
pH mean 
DF S S  
2 0 . 1 3 1 3 2 0 0 0  
1 2  0 . 0 0 9 8 4 0 0 0  
1 4  0 . 1 4 1 1 6 0 0 0  
0 . 9 3 0 2 9 2  
7 . 3 6 4 0 0 0  
MS F-value 
0 . 0 6 5 6 6  8 0 . 0 7 
0 . 0 0 0 8 2  
cv 0 . 3 8 8 9 %  
Tukey ' s student i z ed range test for variabl e :  2H 
Alpha = 0 . 0 0 1  DF 1 2  M S E  = 0 . 0 0 0 8 2  
Critical value o f  studenti z ed range = 6 . 9 1 7 
Minimum s ign i f icant d i f ference = 0 . 0 8 8 5 8  
Means with the same l etter are not s igni f i cantly 
d i f ferent . 
Tukey Group ing Mean 
A 7 . 4 9 6 0 0  
B 7 . 3 0 6 0 0  
B 7 . 2 9 0 0 0  
N 
5 
5 
5 
Ant icoagulant 
Heparin 
EDTA 
c itrate 
1 1 8  
PR>F 
0 . 0 0 0 1  
5 . 4  E f fect o f  pH on cell/med ium rat i o s  
1 1 9  
Tab l e  2 3  contains calcul ated cel l/medium rat i o s  
for theoretical pairs o f  p H  values m o s t  l ikely to be 
encountered i n  the body and l aboratory . These pH values 
were introduced in Section 2 . 9 . 1  in Chapter 2 .  Musc l e  
t i s sue cel l s  are p H  7 . 0 2 .  Phys iological plasma i s  7 . 4 .  
Unsealed pl asma is pH 8 . 0 .  I n  buffer , c e l l -medium pH 
pa irs are 6 . 6 7 ,  6 . 7 ;  7 . 2 6 ,  7 . 4 ;  and 7 . 6 9 ,  8 . 0 .  
Overa l l , Tab l e  2 3  shows the e ffects o f  medium pH 
on partition ing o f  severa l drugs into cel l s . I n  thi s  
tab l e , the medium i s  e ither p l a sma or buffer . The 
purpose of thi s  tab l e  i s  three- fold . F irst , it shows 
that the pKa of each weak acid or weak base determines 
the magn itude o f  the e f fect on the cel l/medium rat i o  
a s  changes occur in the medium pH . The weaker the a c i d  
or base , the less e f fect p H  h a s  on t h e  rat io . S econdly , 
in the s ituation where RBC pH i s  7 . 2 6 and unsealed 
p l asma pH is  8 . 0 ,  the rat ios do not a lways re fl ect the 
in v ivo s ituation o f  RBC pH 7 . 2 6 and p l a sma pH 7 . 4 .  
Thirdly , the last column ( muscle pH 7 . 0 2 a n d  pl asma pH 
7 . 4 ) shows that weak bases have higher cel l/med ium 
rat ios that weak acids in every case . 
The cel l/medium rati o s  for the hydrogen ion are 
included to show that bases wh ich have a high pKa have 
the s ame cel l/med ium rat io a s  the hydrogen i on . 
1 2 0 
Tab l e  2 3 . CellLmedium rat ios for weak acids and weak 
bases 
CELLS pH 6 . 6 7 7 . 2 6 7 . 6 9 7 . 2 6 7 . 0 2 
MEDIUM pH 6 . 7  7 . 4  8 . 0  8 . 0  7 . 4  
Drug 12Ka 
WA 3 . 4 9 0 . 9 3 0 . 7 2 0 . 4 9 0 . 1 8 0 . 4 2 
WA 7 . 1 3 0 . 9 8 0 . 8 2 0 . 5 5 0 . 2 8 0 . 6 2 
WA 8 . 3 1 0 . 9 7 0 . 9 2 0 . 6 5 0 . 9 7 0 . 9 4 
WA 1 0 . 0  1 . 0  1 . 0  1 . 0  1 . 0  1 . 0  
PYR 7 . 1 3 1 .  0 5  1 . 1 3 1 . 1 2 1 . 5 3 1 .  4 9  
WB 8 . 1  1 .  0 7  1 .  3 2  1 .  5 8  3 . 5  2 . 17 
WB 9 . 1  1 .  0 7  1 .  3 7  1 . 9 7 5 . 1 6 2 . 3 7 
WB 1 0 . 0  1 .  0 7  1 .  3 8  2 . 0 4 5 . 5  2 . 4  
Hydrogen ion 1 .  0 7  1 .  3 8  2 . 0 4 5 . 5  2 . 4  
WA weak acid 
WB weak base 
1 2 1  
5 . 5  Equi l ibrium dialys i s  
5 . 5 . 1  water content o f  dialys i s  membranes 
The d i f ferences in wet and dry membranes were 
taken a s  their water content . The d i fferences in weight 
( b e fore and a fter dry ing ) for 2 cut membranes were 
0 . 0 3 9 9  and 0 . 0 4 2 9 . Assuming 1 ml of water we ighs 1 g ,  
there i s  about 4 1 . 4  � 1  o f  water held by each membrane .  
To  make a correct ion for volume o f  ED cel l s  to whi ch 1 
ml has been added to each cell -hal f ,  one could add about 
4 1  �l  for a total volume of 2 . 0 4 1  mI . Thi s  i s  not a 
l arge d i lution o f  cell  contents . 
5 . 5 . 2  Volume shi fts 
For each experiment involving a lbumin , it was 
mea sured in each cell at the end o f  dialys i s . To study 
volume shi fts , the a lbumin concentrat ion at the end o f  
d i a l y s i s  was compared t o  the albumin concentrat ion i n  
the o r iginal plasma . Disregarding di lut i on from the 
water content of the membranes ,  the results in Tab l e  2 4  
show that there were l e s s  than 1 0 %  shi fts o f  water 
volume in the cel l s . 
Tab l e  2 4 . Albumin (giL) changes 
O r iginal Ending !:! Percent 
4 5 . 8  4 3 . 7  1 5  -4 . 5 6 
2 5 . 9  2 3 . 5  1 5  -9 . 1 9 
4 7 . 5  4 5 . 6  1 5  - 3 . 9 8 
8 . 0  8 . 1 3 1 5  + 1 . 6 2  
4 4 . 2  4 3 . 6  3 - 1 .  3 4  
4 4 . 2  4 0 . 6 6 3 -7 . 9 7 
4 5 . 1  4 2 . 1 3 3 - 6 . 5 0 
5 . 5 . 3  B inding to ED apparatus 
1 2 2  
during dialys i s  
change 
B inding to the Spectrum cel l s  and membrane did not 
occur . The original solut i on o f  PYR in pH 7 . 4  IPB was 
assayed to be 8 5 . 1  ng/ml . At the end o f  a 4 h dialys i s , 
the PYR content o f  each cell -hal f was assayed and 
reported below .  The mean concentration recovered i n  
each cell -hal f  was 4 2 . 7  ng/ml ( 2 . 9 % CV ) . Comb ined 
recovery in each hal f  was 8 5 . 4  ng/ml . 
Tab l e  2 5 .  PYR (ngiml)  at end o f  dialys i s  
C e l l  Hal f 1 Hal f 2 
1 4 2 . 8  4 4 . 3  
2 4 1 . 6  4 3 . 3  
3 4 2 . 8  4 4 . 3  
4 4 1 . 6  4 0 . 9  
5 . 5 . 4  Determination o f  t ime to equ i l ibrium 
1 2 3  
Two E D  experiments were run a t  1 2  rpm t o  determine 
t ime to equ i l ibrium for PYR b inding to p l a sma prote ins . 
The graphs o f  the changes in the free and total PYR 
concentrations , PYR in the two cell -halves , are shown i n  
F igure 1 4 . The results o f  the moment analys i s  o f  the 
areas under the curves ( AUCs ) and areas under the moment 
curves ( AUMCs )  for only the free PYR ( measured in the 
buffer cell -hal f )  are below . The determination o f  t ime 
to equ i l ibrium as described here i s  a new app l i cation o f  
noncompartmental analys i s  based o n  stat i s t ical moment 
theory . 
For the f irst experiment us ing exp ired b l ood bank 
p l a sma pH 8 . 0  with albumin 2 5 . 9  gi L ,  the AUC i s  1 5 0 0 0  ng 
ml - l min- I , AUMC is  1 0 7 0 0 0 0  ng ml - l , mean res idence t ime 
( MRT ) calcul ated as AUMC/AUC i s  7 1 . 5  min , and the hal f­
l i fe i s  0 . 6 9 3  X MRT or 4 9 . 5  min . 
For the second experiment us ing the s ame l ot o f  
p l a sma adj usted t o  p H  7 . 4  with albumin 3 0 . 4  a t  the end 
of d i a lys i s , the AUC i s  2 2 0 0 0  ng ml - lmin- l , AUMC i s  
1 5 8 0 0 0 0  n g  ml - l , MRT i s  7 2 . 6  min , and hal f l i fe i s  5 0 . 3  
min . 
These experiments were done at the s l owest rpm o f  
any E D  experiment , thus it is  s a f e  to as sume that the 
t ime to equ i l ibrium would also  be the s l owest in compar­
ison with experiments run at higher rpms . 
1 2 4  
The results for these two experiments were remark­
ably s imilar . The hal f- l ives to equ i l ibrium are neces -
sary for the des ign o f  the other experiments . It was 
a s sumed that in 6 hal f-l ives , equ i l ibrium was reached . 
APPROACH TO EQUILIBRIUM DURING DIALYSIS 
ALBUMIN 30.4 GIL, pH 7.4 
5 0 0  
T I ME ( M I  N )  
APPROACH T O  EQUILIBRIUM DURING 
DIALYSIS, ALBUMIN 25.9 GIL 
1 0 0 2 0 0  
T I ME ( M I  N )  
D FREE £:. TOTAL PLASMA 
J O O  
Fig 14. App roaches to equ i l ib rium in d i a l ys i s  exp e r -
iments . 
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5 . 5 . 5  I n fluence o f  pH on protein b inding 
5 . 5 . 5 . 1  Binding at pH 7 . 4  versus pH 8 . 0  
1 2 6 
The plasma protein b inding at pH 7 . 4  was not 
s i gn i ficantly d i fferent than at pH 8 . 0 .  The results o f  
a S tudent ' s  t test are in Tab l e  2 6 .  
Tab l e  2 6 . Binding at pH 7 . 4  vs . pH 8 . 0  
T Test Procedure 
Var i ab l e : Percent free PYR 
pH N Mean SD 
8 3 14 . 4 6 6 6 7  0 . 3 4 6 7 4 6 7 9  
7 . 4  3 1 5 . 1 6 3 3 3  0 . 3 7 7 5 3 5 8 7  
Variances T DF 
Unequal -2 . 3 5 4 0  4 . 0  
Equal -2 . 3 5 4 0  4 . 0  
For Ho : VARIANCES ARE EQUAL , 
PROB>F ' = 0 . 9 1 5 1  
S E  Standard Error 
S D  Standard Deviation 
DF Degrees o f  Freedom 
SE  Min Max 
0 . 2 0 0 1 9 4 3 5  1 4 . 0 8 1 4 . 7 5 
0 . 2 17 9 7 0 4 4  1 4 . 7 5 1 5 . 4 9 
PR>T 
0 . 0 7 8 8  
0 . 0 7 8 2  
F '  = 1 . 1 9 with 2 and 2 DF 
S . S . S . 2  Influence o f  a range o f  pH values on binding 
1 2 7  
Plasma protein b inding was de£initely in£luenced 
by p l a sma pH even though as described above , the 
influence did not reach stat i st i c a l  s ign i f i cance in that 
experiment . 
The pH values reported in F igure I S are for the 
cel l s  at the end o f  the dialys i s . Albumin concentra-
t ions were 4 3 . 7  gi L ( n= l S ,  3 . 9 % CV) for the h igher pH 
values and 4 S . 6  gi L ( n=l S ,  6 . S % CV) for the l ower pH 
values . 
In F igure I S ,  each po int represents the mean o f  3 .  
INFLUENCE O F  pH O N  PROTEIN BIND ING 
pH AT END OF DIALYSIS 
C EACH PT=MEAN OF .3 
Figure I S .  Influence o f  pH on p l a sma prote i n  b inding . 
5 . 5 . 6  Concentrat ion dependence of protein b inding i n  
t h e  therapeut i c  range 
1 2 8  
The binding a t  two l eve l s  o f  PYR was studied . The 
� test shows that there i s  a s i gn i f i cant d i fference 
between percent free at 1 1 8  nglm1 versus 3 6 3  ng/m1 . 
These 2 l evels o f  PYR were chosen because they are both 
within the therapeut ic range , and due to assay l imits , 
l ower concentrations o f  PYR could not be examined . The 
albumin concentrat ion was 4 5 . 6  gi L ( 1 . 5 2 %  CV ) . 
Tab l e  2 7 . Binding at 2 PYR concentrations 
T TEST PROCEDURE 
var i ab l e : Percent free PYR 
Cone N Mean S D  SE 
1 1 8  5 3 . 5 3 2 0 0  0 . 4 9 5 2 9 7 8 9  0 . 2 2 1 5 0 3 9 5  
3 6 3  5 4 . 9 1 2 0 0  0 . 9 8 1 3 3 5 8 2  0 . 4 3 8 8 6 6 7 2  
Variances T DF P>T 
Unequal -2 . 8 0 7 2  5 . 9  . 0 3 15 
E qual -2 . 8 0 7 2  8 . 0  . 0 2 2 9  
MIN MAX 
3 . 0 8 0  4 . 0 8 0  
3 . 5 5 0  5 . 8 9 0  
For Ho : VARIANCES ARE EQUAL , F ' =  3 . 9 3 with 4 and 4 DF 
PROB > F '  - 0 . 2 1 3 8  
1 2 9  
5 . 5 . 7  Summary o f  influence o f  albumin on PYR b ind ing 
I n  F igure 1 6  below , the relationship between 
p l a sma albumin and percent free PYR can be seen . These 
were the comb ined data for 7 d i fferent days involving 
experiments where the ending pH was 7 . 3  to 7 . 5 .  The 
results show that there is a s igni f i cant correlation 
( R= O . 8 9 3 )  between percent free PYR and albumin yielding 
the equation % free = - O . 4 6 7 ( albumin gj L )  + 2 3 . 5 .  
Z FREE PYR VS. ALBUMIN CONCENTRATION 
1 0  
1 0  2 0  3 0  4 0  50  
A L  BUM ! N ( giL ) 
LINE THROUGH PREDICTED POINTS 
6. OBSERVED X PREDICTED 
F i g  1 6 . Influence of albumin on percent free PYR . 
Tab l e  2 8 . Linear regres s ion o f  percent free PYR on 
album in concentrat ion 
Dependent variab l e : Percent free PYR 
S OURCE OF S S  MS F VALUE P>F 
1 3 0  
Model 1 4 3 9 . 2 6 1 9 0  4 3 9 . 2 6 19 0  3 9 . 3 0 5  0 . 0 0 0 1  
Error 10 1 1 1 . 7 5 8 2 9  1 1 . 1 7 5 8 3  
C Total 11 5 5 1 . 0 2 0 2 0  
Root MSE 3 . 3 4 3 0 2 7  R-Square 0 . 7 9 7 2  
oep Mean 1 4 . 2 9 0 5 8  Adj R-square 0 . 7 7 6 9  
CV 2 3 . 3 9 3 2 2  R 0 . 8 9 3  
Parameter estimates 
T for Ho : 
Variab l e  OF Estimate SE  Parameter 
Intercept 1 2 3 . 4 8 7 5 0 8  1 . 7 5 5 9 3 7  1 3 . 3 7 6  
Albumin 1 - 0 . 4 6 7 1 6 5  0 . 0 7 4 5 1 6  - 6 . 2 6 9  
Cook ' s  D o n  observat ions range 0 . 0 0 3  t o  0 . 4 0 0  
o P > T 
0 . 0 0 0 1  
0 . 0 0 0 1  
1 3 1  
5 . 5 . 8  Percent free PYR i n  d i f ferent tubes 
There was no d i f ference in percent free PYR ( 1 0 0 0  
ng/ml ) i n  plasma o r  serum c o l l ected i n  three d i f ferent 
typ e s  of Vacuta inersN conta ining 2 d i fferent ant icoagu­
l ant add itive s . The results o f  PRoe GLM in SAS are i n  
Tab l e  2 9  below .  
1 3 2  
Tab l e  2 9 . Percent free PYR in d i f ferent tube s  
General Linear Model s  Procedure 
Dependent variab l e : Percent free PYR 
S ource DF S S  MS F-value PR>F 
Model 2 2 0 . 6 9 7 6 6 7 8 6  1 0 . 3 4 8 8 3 3 9 3  
Error 7 4 7 . 2 4 8 6 6 5 17 
C total 9 6 7 . 9 4 6 3 3 3 0 2  
R-square 0 . 3 0 4 6 1 8  
Free mean 6 . 9 1 8 1 5 0 0 0  
CV 
S ource DF 
Ant i coagul ant 2 
Type I S S  or 
Type III S S  
2 0 . 6 9 7 6 6 7 8 6  
DF Degrees of Freedom 
S S  Sum o f  S quares 
HS Mean S quare 
6 . 7 4 9 8 0 9 3 1  
3 7 . 5 5 4 0 %  
F-va lue 
1 .  5 3  
1 .  5 3  0 . 2 8 0 4  
PR>F 
0 . 2 8 0 4  
PR> F S ign i f i cance probab i l ity for the F value . 
C total Corrected Total 
5 . 5 . 9  B inding to pure human serum albumin 
1 3 3  
The binding o f  3 5 0  ng/ml PYR t o  pure human serum 
albumin in I PB ( 1 4 . 2  g/ L ,  2 . 0 6 X 1 0 -4 Ml resulted i n  
bound PYR values s l ightly higher than thos e  predicted 
for who l e  plasma by the equation in Tab l e  2 8 . 
The " Free " column i s  the buffer cel l -ha l f  and the 
"Albumin" column i s  the a lbumin-conta ining cell -hal f  PYR 
concentrat ion ( ng/ml l . The average a lbumin was 
1 4 . 2  g/ L .  
Tab l e  3 0 .  Binding to puri f ied human albumin 
PYR ng/ml 
Free Albumin % Free % Bound 
3 8 . 9 5 2 8 3 . 5 8 1 3 . 7 4 8 6 . 2 6  
4 2 . 3 9 3 1 9 . 2 6 13 . 2 8 8 6 . 7 2 
Mean 1 3 . 5  8 6 . 5  
5 . 5 . 1 0 Binding to AAG 
PYR binding at 2 l evel s  o f  AAG was determined , at 
stress l evel AAG 3 . 7  g/ L and at normal l evel 0 . 5 7 1  g/ L .  
The b i nding was about 1 0 %  at the high l evel o f  AAG . 
Tab l e  3 1  shows the results . 
Tab l e  3 1 - Bind ing to 3 . 7  g,(L AAG 
PYR ( ng/ml ) 
Free AAG % Bound � Free 
1 7 3 . 2 4 1 9 9 . 6 6 1 3 . 2 3 8 6 . 7 7 
1 7 3 . 2 4 1 8 4 . 0 8 5 . 8 9 9 4 . 1 1 
}lean 9 . 5 6 9 0 . 4  
No binding was apparent in the d i luted AAG . I n  
fact , there was more drug on the free s ide in every 
cel l . Pos sible expl anat ions are that equ i l ibrium had 
not been estab l i shed or the AAG was damaged . The AAG 
had been used in the previous experiment . 
1 3 4  
5 . 5 . 1 1 Analys is o f  protein b inding data from S tud i e s  1 ,  
2 ,  and 3 
Data from S tudies 1 ,  2 ,  and 3 were fit to the 
Bl anchard , Larsen , Scatchard , and doub l e  rec iprocal 
equations described in Chapter 2 .  After f itt ing the 
three sets of data to the Scatchard model , it was obv i ­
o u s  that a l l  o f  the assumptions o f  drug-protein interac­
tions had not been met . 
In the p l ot o f  percent free PYR versus p l a sma 
concentrat ion ( F ig .  17 ) , one can see that the drug i s  
not obeying the l aw o f  mas s  action , the most b a s i c  
as sumpt ion o f  drug-protein b inding interact ions . This 
f igure more l ikely shows a concentrat ion dependent 
d istr ibut ion between the aqueous phas e  and p l a sma pro­
teins ( a lbumin as wel l  as l ipoproteins ) .  In other 
1 3 5  
words , the F igure 1 7  shows a part i t i on i ng that i s  a 
funct ion o f  the solub i l ity o f  PYR , not the l aw o f  mass 
action . The l ow water solub i l ity o f  the PYR makes it 
avo id the pl asma water in favor o f  adsorption on the 
proteins . The proteins act as a s ink at l ow drug con­
centrations . 
Tab l e  3 2  summarizes  the PYR and albumin concentra­
t i ons in studies 1 ,  2 ,  and 3 .  Data from s tudy 1 were 
c o l l ected in the system with the highest protein l evel 
( albumin 3 . 4  X 1 0 - 4M or 2 3 . 5  g/ L )  , yielding opportun ity 
for the s impl e  prec ipitation or adsorption of drug 
on the proteins . The data from S tudies 2 and 3 did not 
display a trend of increas ing b inding with increas ing 
p l a sma concentrat ion , the opposite of what should happen 
in  protein b inding . 
Tab l e  3 2 . Summary o f  prote i n  b ind ing Studies 1 , 2  and 3 
1 
2 
3 
PYR Conc . Range 
(ng/ml l 
14 0 - 4 1 0 0  
1 4 0 - 4 1 0 0  
7 2 0 - 4 5 0 0 0  
Albumin concentration 
l£L..hl 
2 3 . 5  
8 . 1 3 
0 . 6 6 
Initial est imates for the first sto ich i ometric 
b inding constant from the relat i onship ( b ound/ free ) / 
albumi n  in mo lar un its ( 6 3 )  as l i sted below ( Tab l e  3 3 )  
were i n  excell ent agreement with the K1 values from the 
1 3 6 
nonl i near f its o f  data from Studies 1 and 2 .  However , 
for data from Study 3 ,  because o f  its h igher PYR concen­
trations and l ower a lbumin concentrat ion , the i n i t i a l  
est imates for K1 were more variab l e  a n d  l e s s  l ikel y  t o  
refl ect t h e  true K1 values f o r  t h e  interaction o f  PYR 
with a lbumin at phys iologic concentrat ions . 
1 3 7  
Tab l e  3 3 .  Estimates o f  the f i rst stoichiometric b inding 
constant K1 
. study 1 2 3 
2 8 8 9 5 . 8  2 5 3 8 1 .  0 8 1 2 3 5 . 7  
2 0 2 3 2 . 4  2 4 1 9 6 . 4  7 9 5 8 7 . 6  
2 1 9 8 3 . 0  3 0 0 8 0 . 3  5 0 7 1 1 . 8 
2 7 7 4 8 . 5  2 5 3 1 3 . 3  3 0 8 3 5 . 5  
2 8 2 3 4 . 1  3 1 2 6 1 . 9  6 4 2 0 4 . 6  
2 9 9 1 8 . 6  3 3 4 9 1 . 4  7 4 5 1 7 . 0  
3 2 7 1 4 . 5  2 9 5 9 5 . 1  4 7 8 9 3 . 5  
2 9 2 8 4 . 1  2 7 8 8 4 . 4  4 0 1 8 9 . 4  
2 9 3 7 8 . 5  3 0 3 4 5 . 2  4 7 7 3 9 . 3  
3 6 5 4 0 . 5  2 7 7 1 8 . 3  4 6 0 6 3 . 9  
3 4 2 5 3 . 4  2 8 2 6 7 . 4  4 3 6 6 7 . 9  
3 0 3 3 5 . 4  2 9 3 2 3 . 8  5 6 9 8 0 . 3  
2 6 7 1 4 . 7  4 8 3 2 8 . 2  
2 6 7 7 0 . 7  3 7 4 2 1 . 9 
2 9 5 6 8 . 7  2 6 7 0 9 . 5  
N 1 2  1 5  1 5  
Mean 2 9 0 0 0  2 8 0 0 0  5 2 0 0 0  
% CV 1 5 . 7  8 . 7 8 3 2 . 2  
Z FREE VS PLASMA PYR CONCENTRATION 
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F igure 1 7 a  and b .  Percent free PYR versus total p l a sma 
concentration for data from Studies 1 and 2 .  
1 3 9  
A l inear relationship was not obta ined a fter 
pl otting accord ing t o  the S catchard equation a s  one can 
see in Figures 1 8 -2 0 .  The parameter est imates from PRoe 
REG in SAS us ing the S catchard E q . ( 9 )  for one or two 
s ites were a l s o  nonsens ical . Due to the previous ly 
described probl ems associated with the doub l e  reciprocal 
p l ot , what l ooked l ike a stra ight l ine was obtained but 
the parameter estimates were meaningl ess . 
SCA TCHARD PLOT OF DATA FROM STUDY 1 
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F i g . 1 8 . S catchard plot o f  data from study 1 .  
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Fig . 1 9 . Scatchard plot o f  data from s tudy 2 .  
SCA TCHARD PLOT OF DATA FROM STUDY 3 
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Fig . 2 0 .  Scatchard plot o f  data from s tudy 3 .  
1 4 0  
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The most success was obta ined with the stoichiom­
etric approach . Data from Studies 1 , 2 ,  and 3 were f i t  
us ing one and two s ite unwe ighted model s  o f  the Klotz 
equation (Eq.  ( 1 0 )  in Chapter 2 ) . They were compared 
us ing an F-rat io test ( 1 3 )  and then we ight ing functions 
were added . The reason that the one and two s ite model s  
were compared us ing the unwe ighted fits was that the 
res iduals were too sma l l  to have s igni f icance us ing 
we ighted res idua l s . Thus , a more correct model could 
not be chosen . We ighting was used for fits  o f  both 
mode l s , but only the unwe ighted model s  were used in 
cal culat ing F values . 
Data from Study 1 had the l owest range o f  PYR 
concentrat ions ( summar i z ed in Tab l e  3 2 )  and the highest 
albumin concentration ( 3 . 4  X 1 0 -4 M ) . The highest 
p l a sma concentrat ion was 3 6 6 0  ng/ml or 1 . 4 7 X 1 0 - 5 M .  
The two s ite fit for thi s  set o f  data did not show 
s ign i f icant improvement over the one s ite model where F 
was 1 . 3 2 7  ( F . 0 1 = 9 . 6 5 ; 1 ,  1 1 ) . The we ighting factor o f  
l/bu f fer concentration improved the f i t  only a t  the high 
concentrat ions . The results o f  the fit to the Klotz 
equ a t i o n  are in Tab l e  3 4 . 
The p l ots o f  the observed and predicted values are 
in Figure 2 1  and the res idua l s  are in F igure 2 2 . The 
res iduals show that the model may be inappropriate . 
1 4 2  
Tab l e  3 4 . Nonl inear f i t  o f  data from s tudy 1 using the 
Klotz equation 
SAS NLIN statistics us ing method DUD 
Dependent variab l e : r 
S ource DF Weighted S S  Weighted MS 
Regress ion 1 . 0 0 0 0 1 8 1 5 9 5 4 9  . 0 0 0 0 1 8 1 5 9 4 9  
Res idua l 1 1  2 . 5 1 5 0 0 1E - 0 7  2 . 2 8 6 3 6 4 E - 0 8  
Uncorr . Total 12 . 0 0 0 0 1 0 7 6 8 1 6 7  
Asymptot ic 9 5 %  
Parameter Est imate Asymptot i c  SE  Confidence interval 
K1 3 2 0 1 8 . 4 7 0 2 8  1 1 6 6 . 6 6 3 8 9 2 7  2 9 4 5 0 . 6 5 1  - 3 4 5 8 6 . 2 9 
Correlation matrix o f  the parameters 
K1 
1 .  0 0 0 0  
We ighted Res idual Sums o f  Squares ( WRS S ) 2 . 5 1 5 0 0  X 1 0 - 7 
KLOTZ FIT OF PYR DATA FROM STUDY 1 
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Figure 2 1 .  Klotz p l ot of data from s tudy 1 showing 
observat ions and predicted po ints from the fit . Line 
through f itted po ints . 
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Figure 2 2 . Res idual s  for Kl otz f i t  of above data . 
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Data from study 2 had a l ow range o f  concentra­
t i ons ( maximum on plasma s ide 3 6 5 0  nglml , 1 . 5  X 1 0 - 5  M ) , 
but had s l ightly more in the h igher range compared t o  
d a t a  from study 1 .  The albumin concentration was 8 . 1 3 
gi L ( 1 . 1 7 9  X 10 - 4  M ) . The h ighest PYR concentration was 
3 6 4 6  ng/m1 ( 1 . 4 6 X 1 0 - 5  M ) . 
The two s ite mode l  was s ign i f i cantly better than 
the one s ite model in the Klotz fit . F = 2 1 . 2 exceeds 
the table FO . 0 1 = 9 . 0 7 ( 1 ,  1 3 ) . Weight ing improved the 
f i t . The parameter est imates for the a f f inity constants 
K1 and K2 were more l ikely correct in that K1 was larger 
than K2 . The results o f  the fit to the Klotz equat ion 
are in Table 34  and the p l ots are in Figures 23  and 2 4 . 
The p l ot o f  the res idua l s  shows , even though these were 
improved by weight ing , that thi s  may be an inappropriate 
model to describe the data . The fit appears to very 
good , however . The standard error o f  the est imate for 
K1 was only 3% o f  the est imate . The standard error for 
the est imate o f  K2 , however , was 4 7 %  o f  the estimate , 
indicative of a prob l em with the model or poor data . 
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Tab l e  3 5 . Nonl inear fit o f  data from study 2 u s i ng the 
Klotz eguation 
SAS NLIN statistics us ing method DUD 
Dependent variab l e : r 
We ight ing 1/bu f fer PYR concentrat ion 
S ource DF We ighted SS 
Regress ion 2 0 . 0 0 0 0 3 8 5 6 1 9 1  
Res idual 1 3  1 . 3 0 6 5 4 2 E - 0 7  
Uncorr . Total 15 0 . 0 0 0 0 3 8 6 9 2 5 6 3  
Corr Total 14 0 . 0 0 0 0 2 3 9 1 1 2 4 5  
We ighted MS 
0 . 0 0 0 0 1 9 2 8 0 9 6  
1 .  0 0 5 0 3 2 E - 0 8  
Asymptot i c  9 5 %  
Parameter Est imate Asymptoti c  S E  Conf idence interv a l  
K1 2 8 2 2 8 . 0 8 4 3 6  8 7 3 . 4 5 8 0 2 6 1  2 6 3 4 1 . 0 9 4  - 3 0 1 1 5 . 0 7 
K2 1 7 3 6 7 . 9 1 9 9 7  8 2 4 9 . 3 1 8 2 4 1 3 - 4 5 3 . 6 3 8  - 3 5 1 8 9 . 4 8 
Corre l at ion matrix o f  the parameters 
K1 
1 .  0 0 0 0  
- 0 . 8 3 7 2  
K2 
- 0 . 8 3 7 2  
1 .  0 0 0 0  
We ighted Res i dual Sums o f  Squares ( WRS S )  1 . 3 0 6 5 4  X 1 0 - 7 
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F i gure 2 3 . Klotz plot o f  data from s tudy 2 showing 
observat ions and predicted po ints from the fit . Line 
through fitted po ints . 
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Figure 2 4 .  Res iduals for Klotz fit of above data . 
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study 3 had b y  far the largest range o f  p l a sma PYR 
concentrat ions , go ing up to 3 3 , 0 0 0  nglml ( 1 . 3 3  X 1 0 - 4 M )  
whi ch i s  ten t imes the h ighest concentrat ions ( 1 . 5  X 
1 0 - 5  M )  for the other two sets o f  data . According t o  
Klotz , it i s  very important to go past the inflection 
po int in h i s  p l ot to f ind accurate parameter est imate s . 
Data from study 3 a l s o  had the l owest a l bumin concentra­
t i on ( 0 . 6 6 gi L ,  9 . 5 6 X 1 0 - 6  M ) . For this reason , it  may 
have the least chance of the three data sets to have the 
s o lub i l ity phenomenon be the ma in interact ion between 
the drug and proteins . In other words , the albumi n  
l evel and the high PYR l evel s  may a l l ow one to observe a 
drug-protein interaction as a funct ion o f  the l aw o f  
mas s  action . 
On the other hand , such a l ow protein concentra­
t i on may have produced unusual b inding results . 
Fits o f  data 4 7  to the Kl otz equation were s im i l a r  
whether or n o t  we ighting w a s  used and between fits f o r  
d i f ferent weighting funct i ons . The one s ite model 
y i elded l arge standard errors for est imates , 2 4 % of the 
estimate , and the F value for the comparison with the 
two s i te mode l was 4 3 . 2 3 4 , highly s igni f i cant at the Q 
0 . 0 1 l evel ( F . 0 1 = 9 . 0 7 ; 1 , 1 3 ) . The fit us ing 11p l a sma 
we ight i ng was a l ittle better than the others . The 
results for the Kl otz fit are in Tab l e  3 6 .  The pattern 
in the res idual s  ( increas ing with increas ing free PYR ) 
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cl early indicates a n  i l l -conditi oned model . The stan­
dard errors for the est imates K1 and K2 are 1 3 . 5  % and 
33 % o f  the estimates , respect ive ly . The plasma and 
buf fer concentrat ions in thi s  experiment were beyond the 
range o f  the a s say and had been d i luted to with i n  the 
range . There i s  ev idence o f  greater variab i l ity in the 
assay in the plot o f  the observed po ints . There i s  
greater spread in the dupl icate po ints . The increas ing 
res idua l s  with increas ing concentration most l ikel y  
refl ect the assay variab i l ity at h igh concentrat ions . 
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Tab l e  3 6 .  Nonl inear fit o f  data from study 3 u s ing the 
Klotz equation 
SAS NLIN stat i stics  using method DUD 
Dependent variab l e : r 
Weighting l/plasma PYR concentration 
S ource DF We ighted SS Weighted MS 
Regres s ion 2 0 . 0 0 0 17 4 3 4 9 2 1  . 0 0 0 0 8 7 1 7 4 6 0  
Res i dual 1 3  0 . 0 0 0 0 0 6 0 7 1 4 8  4 . 6 7 0 4 E - 0 7  
Uncorr . Total 1 5  0 . 0 0 0 1 0 2 9 6 6 1 5  
Asymptotic 9 5 %  
Parameter Estimate Asymptotic S E  Confidence interval 
K1 5 3 2 3 4 . 9 9 8 5 2  7 2 1 1 . 3 8 9 7 6 8 5  3 7 6 5 5 . 7 4 7  - 6 8 8 1 4 . 2 5 
K2 2 4 8 7 0 . 1 1 0 1 0  8 1 2 7 . 3 9 5 2 0 6 6  7 3 1 1 . 9 5 1  - 4 2 4 2 8 . 2 7 
Correl ation matrix o f  the parameters 
K1 
1 . 0 0 0 0  
- 0 . 7 4 1 0  
K2 
- 0 . 7 4 1 0  
1 . 0 0 0 0  
Weighted Res idual Sums o f  Squares ( WRS S )  6 . 0 7 1 4 8  X 1 0 - 6  
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F i gure 2 5 .  Kl otz plot of data from study 3 showing 
observations and predi cted points from the fit . Line 
through fitted p o i nt s . 
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F igure 2 6 .  Res idua l s  for Klotz f i t  of above data . 
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5 . 6  RBC part ition ing and b inding 
5 . 6 . 1  Binding to hemolysate 
1 5 1  
There was a n  unusual amount o f  variab i l ity i n  the 
b inding o f  PYR to hemolysate . There was variab i l i ty i n  
t h e  H b  concentrations at t h e  end o f  t h e  5 h dialys i s  
even though each cell -hal f  w a s  f i l l ed in the same man­
ner . There was a l s o  variab i l ity in the percent PYR 
bound . The results are given below . The free PYR 
concentrat ion was that PYR in the buffer cel l -ha l f ,  and 
the total PYR was that in the hemo lysate cel l -hal f .  The 
average hemogl obin concentrat ion at the end o f  dialys i s  
was 1 . 6  X 1 0 - 3  M .  
There are a t  least two sources o f  thi s  variation . 
within 1 5  min after f i l l ing the Spectrum cel l s , 3 o f  
them appeared t o  b e  leaking ( ce l l s  5 ,  6 and 7 ) . A l s o , 
the as say variab i l ity ' s  role is great when the buf fe r  
concentrat ions have almost no error ( di rect inj ect i o n )  
a n d  the hemolysate l eve l s  have error due t o  t h e  extrac­
tion procedure . In the same way , because the percent 
free and percent bound were s imilar , the calcul ation o f  
them has a lot o f  error from the hemolysate PYR concen­
trat ion but not from the buf fer PYR concentrat ion . 
The average percent bound from Tab l e  3 7  i s  4 2 . 5 % 
to the hemo lysate . The hemolysate in thi s  exper iment 
conta ins more dilute Hb than that found ins ide a RBC 
because in making the hemolysate , the RBC contents were 
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d i luted t o  about one-hal f the normal concentration . 
However , higher b inding than about 4 3 %  would not be 
expected because there does not appear to be a trend f o r  
greater b inding with h igher H b  concentrat ion . There i s  
a l s o  no apparent PYR concentrat ion dependency 
in b inding . Mean bound PYR was 4 2 . 5  ( 1 9 %  CV ) . 
Tab l e  3 7 . Binding to hemolysate 
Free PYR Total Free Hb Bound 
( ng/ml l  
1 7 7 . 7 7 
1 2 9 . 0 3 
1 7 7 . 7 7 
2 1 .  6 6  
2 1 .  6 6  
1 0 3 . 6 7 
8 5 . 3 8 
1 1 4 . 6 3 
3 5 5 . 7 9 
3 5 0 . 4 0 
N 
Mean 
% c v  
(ng/mll  
2 7 0 . 5 1 
2 2 9 . 5 9 
2 4 7 . 9 7 
3 9 . 9 3 
4 7 . 1 0 
1 8 9 . 9 1 
1 8 8 . 1 5 
1 8 7 . 8 1 
5 9 7 . 7 5 
5 7 9 . 6 0 
% 
6 5 . 7 2 
5 6 . 2 0 
7 1 .  6 9  
5 4 . 2 4 
4 5 . 9 9 
5 4 . 5 9  
4 5 . 3 8 
6 1 .  0 4  
5 9 . 5 2  
6 0 . 4 6 
1 0  
5 7 . 5  
14 . 1  
(g/dl l  
1 0 . 9 9 8  
1 0 . 7 2 3  
9 . 3 4 5  
9 . 4 3 6  
9 . 0 6 9  
1 3 . 4 7 9  
1 0 . 5 3 9  
9 . 8 0 4  
9 . 0 6 9  
8 . 8 8 5  
1 0  
1 0 . 1  
1 3 . 6  
% 
3 4 . 2 8 
4 3 . 8  
2 8 . 3 1 
4 5 . 7 6 
5 4 . 0 1 
4 5 . 4 1 
5 4 . 6 2 
3 8 . 9 6 
4 0 . 4 8 
3 9 . 5 4 
1 0  
4 2 . 5  
1 9 . 1  
1 5 3  
5 . 6 . 2  RBC/bu ffer concentrat ion ratio as a funct ion of pH 
The observed RBCjbu f fer rat i o  was compared to the 
theoret ical ratio predicted by Equat ion ( 1 5 )  in Chap­
ter 2 .  The results are in the f igures below and in 
Tables  38  and 3 9 . F igure 2 7 , the plot o f  RBCjbuf fe r  PYR 
rat io versus buf fer pH , compares the observed data with 
theoret ical po ints which have been fit to a l ine . A 
graph o f  the res idua l s  from the fits to l inear equations 
has also  been inc luded to show that th i s  relationship is 
not l inear , but approximates one because the pKa and pH 
o f  the medium are so close . 
The figure shows that there is a pro found e f fect 
o f  pH on the partitioning o f  PYR into RBCs . Thi s  
stresses the importance o f  the ma intenance o f  phys i o ­
l ogic p H  or a t  l east the reporting o f  p H  in part it i on­
ing studies . This e f fect would l ikely be dimini shed in 
a system containing albumin . 
Note that the s l opes o f  the f itted l ines are not 
equal for the observed versus the theoretical rat io s . 
The overa l l  observed mean rat io was 5 . 2 7 ( 2 1 . 3 % CV , 
n=7 ) . At pH 7 . 4 ,  the mean rat io was 5 . 1 6 ( 1 1 . 8 %  CV , 
n=2 ) . The mean d i f ference between the observed and 
theoret ical rat ios was 4 . 1 5 ( 1 9 . 7 % CV) . There is 4 t imes 
as much PYR in the cel l s  as predicted by the theoret ical 
ratio . Thi s  indicates b inding to the cell  membrane or 
Hb ins ide the cel l . 
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Figure 2 7 . Graph o f  RBe/bu f fe r  rati o  vs . buffer pH for 
observed � and theoretical 0 data . 
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Tab l e  3 8 . RBC/bu ffer rat io a s  a funct ion o f  buffer pH 
Anal y s i s  o f  variance 
Dependent Variable : observed rat i o  
S ource 
Model 
Error 
DF S S  MS F-value PR>F 
1 5 . 9 4 5 3 4 4 4 3  5 . 9 4 5 3 4 4 4 3  1 8 . 1 1 2  0 . 0 0 8 0  
5 1 . 6 4 1 2 5 5 9 9  0 . 3 2 8 2 5 1 2 0  
C Total 6 7 . 5 8 6 6 0 0 4 2  
1 5 5  
R- square 0 . 7 8 3 7  Adj R-square 0 . 7 4 0 4  cv 1 0 . 8 6 2 9  
Parameter Estimates 
T for H O : Parameter 
vari ab l e  DF Est imate 
SE 
SE Parameter= O PR>T 
Intercept 1 - 1 0 . 9 4 2 7  3 . 8 1 6 6 5 9 9 2  - 2 . 8 6 7  
pH 1 2 . 1 7 4 6 8 4  0 . 5 1 0 9 8 8 1 7 4 . 2 5 6  
Sum o f  residua l s  1 . 8 3 1 8 7 E - 1 5  
Sum o f  squared res idua l s  1 . 6 4 1 2 5 6  
Predicted Res id S S  3 . 8 9 4 4 9 1  
0 . 0 3 5 1  
0 . 0 0 8 0  
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Tab l e  3 9 . Theoret ical RBC/bu f fer rat i o  a s  a function o f  
buffer pH 
Dependent Variabl e :  Theoret ical rat i o  
S ource DF S S  MS F-value PR> F  
Model 
Error 
1 0 . 8 5 7 8 2 6 9 6  0 . 8 5 7 8 2 6 9 6  4 6 2 . 1 5 9  0 . 0 0 0 1  
5 0 . 0 0 9 2 8 0 6 4  0 . 0 0 1 8 5 6 1 2 9  
C Total 6 0 . 8 6 7 1 0 7 6 1  
R-square 0 . 9 8 9 3  Adj R-square 0 . 9 8 7 2  CV 3 . 7 8 2 5 6  
T for HO : 
Parameter Estimates 
Parameter 
variable DF Est imate SE Parameter=O PR>T 
I ntercept 1 - 5 . 0 2 1  0 . 2 8 7 0 0 1 6 4  - 1 7 . 4 9 5  
pH 1 0 . 8 2 6 0 5 2 3  0 . 0 3 8 4 2 4 8 1  
Sum o f  res idual s  2 . 0 8 1 6 7 E - 1 7  
Sum o f  squared res idual s  0 . 0 0 9 2 8 0 6 4 5  
Pred i cted Res id S S  0 . 0 2 4 9 4 7 7 5  
2 1 . 4 9 8  
0 . 0 0 0 1  
0 . 0 0 0 1  
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5 . 6 . 3  RBC/plasma PYR rat io 
In study Rl , the experiment to determine 
RBC/plasma rat i o  a s  a funct ion o f  albumin , a h igh l evel 
o f  PYR was chosen to avoid the solub i l ity phenomenon 
observed at l ow l eve l s  of PYR . There was a probl em with 
the column fa i l ing that day , and the column had been 
turned around 3 - 4 times by then . Assay o f  drug in 
RBCs is d i f f i cult because o f  the tendency o f  them to 
form bubbles . Due to the lack o f  contro l s , it is d i f f i ­
cult t o  estimate the accuracy o f  assaying PYR in RBCs . 
Attempts to make RBC control s  were unsucce s s ful 
because o f  the ir viscous nature , tendency to form 
bubbles , and clot format ion . To measure volumes o f  
RBCs , syringes were chosen . Packed RBCs cannot be 
pipetted by a ir-displ acement p ipettors because o f  the 
v i scous nature o f  RBCs . Contro l s  in pre-measured 0 . 5  ml  
volumes in tubes cl otted in the refrigerator , and when 
vortexed , the c l ots did not comp l etely break up . I n  
addit ion , the RBCs coat the wal l s  o f  the tube and the 
add ition o f  organic extracting so lvents cements RBCs to 
the wal l s  of  the tubes . Even adding water to the cel l s  
and vortexing does not comp l etely break up the clots 
enough to get go cd recovery o f  drug . Thus , the storage 
o f  contro l s  was imposs ib l e . 
However , even though there is an unknown factor o f  
error i n  these RBC experiments , trends and relationships 
can s t i l l  be discerned . 
There are two p l ots o f  the RBC/plasma PYR rat i o  
versus p l a sma a lbumin concentrat ion on t h e  f o l l owing 
page . F igure 2 9  shows data from study Rl , the exper­
iment that was des igned to show the relationship 
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between the rat io and the albumin concentrat ion . The 
other p l ot ( Fig . 3 0 )  shows the comb ined data of s tudy Rl 
and s tudy R2 , the study to determine the RBC/plasma 
rat i o . The data from study R2 was not corrected for 
hematocrit or albumin concentration be fore plottiong in 
F i g . 3 0 .  
There appears to be a negative relat ionship 
between the rat io and the albumin concentrat ion . Part i ­
t ioning into RBCs decreases a s  plasma albumin increa s e s . 
Albumin is changing in F igure 2 9  for the f irst exper­
iment . However ,  albumin i s  fairly constant in Figure 3 0  
at 4 5 . 5  gi L ( 3 . 3 4 %  CV ) and HCT i s  constant at 0 . 4 4 for 
the points not included in Figure 2 9 , and there i s  s t i l l  
a negat ive relationship apparent . s t i l l , there i s  a 
l a rge amount o f  scatter in the data . 
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Figure 2 9 . RBC/plasma ratio vs . plasma albumin concen­
trat ion for data from s tudy Rl . 
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Figure 3 1 .  RBC/plasma ratio vs . p l a sma PYR concentrat i o n  
for data from study R1 . 
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f igure 3 2. . RBC/plasma. ratio vs . plasma PYR concentra­
tion for data from Studi es R1 and R2 . 
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The data showing the relat ionship between RBC o r  
p l a sma and who l e  bl ood PYR l eve l s  are p l otted i n  F igures 
3 3 - 3 6 .  It is obvious that there i s  a strong positive 
relationship between plasma and whol e  bl ood PYR l evel s .  
As plasma l eve l s  increase , who l e  bl ood l evel s increa s e . 
Thi s  relationship is not as strong for the RBC 
versus whole bl ood PYR p l ots . On the contrary , there 
appears to be a random distribut ion between RBC and 
who l e  bl ood PYR l evels in Figures 3 5  and 3 6 .  The range 
of PYR concentrations in RBCs is narrower for data from 
study R2 compared to Study R1 , but for S tudy R1 that 
involved varying a lbumin l eve l s , there i s  a negative 
relationship between RBC and who l e  blood concentrations 
o f  PYR . 
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Figure 3 3 . Plasma vs . who l e  b l ood PYR concentrati on s  
f o r  data from s tudy R1 . 
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F i gure 3 4 . Plasma vs . who l e  b l ood PYR concentration for 
data from Studies R1 and R2 . 
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Figure 3 5 .  RBC vs . whol e  b lood PYR concentrat ions for 
the data from study R1 . 
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F igure 3 6 .  RBC vs . whol e  blood PYR concentrat ions for 
the data from studies R1 and R2 . 
Chapter 6 
D i scus s ion 
6 . 1  Analytical methodology 
Initial studies with Edstein ' s  assay ( 3 9 )  ind i ­
cated that it w a s  not adequate f o r  the proposed stud i e s . 
Edste in ' s  assay may have worked i f  a new �Bondapak� 
column had been used , but the one used was in poor 
condit ion init i a l ly with only a maximum o f  1 9 , 0 0 0  
p l ates/meter . Deteriorat ion o f  thi s  column was rap i d . 
The peaks were broad and t a i l ed ( F ig . 4 ) . 
S everal facts support the idea that decreas ing the 
solub i l ity o f  PYR in the mob i l e  pha s e  improves the 
chromatography of PYR . S olub i l ity was decreased by 
increas ing the ionic strength o f  the reconst itut ing 
s o lvent or the mob i l e  phase . 
After evaporation o f  the organ ic so lvent used to 
extract PYR from b i o l ogical fluids , Edste in used mob i l e  
phase t o  reconstitute the res idue . Very poor chromatog­
raphy resulted from us ing mob i l e  phase to reconst itute 
the residue . Peaks displ ayed tail ing , fronting and were 
much shorter . The use o f  1 0 0 %  methano l  to reconst itute 
the residue resulted in tail ing , front ing , and decreased 
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peak height a l s o . On the other hand , potass ium phos ­
phate buffer l ike that used in the mob i l e  phase gave 
excel l ent narrow peaks and s o  it was used . The results 
with 50%  methanol in water were ident ical to the results 
with phosphate buf fer as a reconst itut ion s o lvent . Th i s  
suggests that the solub i l ity o f  PYR in the reconstitu­
t ion so lvent and its interact ion with the mob i l e  phas e  
were factors determining the peak shape and resolut i o n . 
The compos ition o f  �he mob i l e  pha s e  a l s o  influ­
enced the chromatography . As discussed in Chapter 5 ,  
the use o f  both monobas i c  and diba s i c  potass ium s a l t s  o f  
phosphate , s o  that the ionic strength o f  the mob i l e  
phase could b e  increased , w a s  necessary f o r  better peak 
height and resolut i on . The addition o f  more than 1 5 %  o f  
acetonitrile t o  the mob i l e  phas e  ( wh i l e  holding the 
rat i o  o f  organic to aqueous components in the mob i l e  
phase constant ) resulted in peak fronting and t a i l ing . 
The solub i l ity o f  PYR in acetonitr i l e  i s  probably 
greater than that in water . Improving the solub i l ity o f  
PYR in the mob i l e  phase was advantageous t o  a l imited 
degree . 
Th i s  " sa l t ing out " ef fect in the mob i l e  phase 
resulted in improved e f f i c iency for the interaction of 
the PYR with the stationary phase . 
Previous assays have used other ant ima l arial s a s  
internal standards . However , it wa s preferred not to use 
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another compound that binds t o  glass  and antima l a r i a l s  
are b a s e s  that o ften b ind to glass . After it was found 
that NAPA had appropriate chromatograph ic and extract i o n  
characteri stics , it w a s  chosen as t h e  internal standard 
even though it has an unrel ated chemical structure and 
hydrophi l i c  properties . 
Spectral data for PYR ( 9 0 )  has shown good absor­
bance at 2 5 4  or 2 8 0 . 
By far the b iggest problem with this assay was the 
rap id deterioration of the Econosphere� co lumns . I n  
addition , s ince 1 0 0 0  m l  batches o f  mob i l e  phase were 
made , for 1 0 - 1 5  samples there was a relatively l ong 
equ i l ibrat ion t ime for the system each day . Each new 
batch o f  mob i l e  pha se had to be run through the system 
for an hour be fore cons i stent responses were observed . 
The saturator column helped prol ong the l i fet ime 
of the columns cons iderably ( Table 6 ) . However , eventu­
a l l y  the economy of the columns was revealed in the i r  
rap id fai lure . I n  the future , it would be prudent to 
use columns with h igher carbon l oad and not the car­
tridge type o f  column . Cartridges cannot be opened for 
the purpose o f  f i l l ing voids that form . It was the 
formation of voids that caused the f a i lure of the c o l -
umns . 
These studies used four Econosphere� columns . The 
first one was d i f ferent from the others in that the NAPA 
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had a l onger retent ion t ime than the PYR . Confound ing 
th i s  observat ion was the fact that at that t ime a l ower 
mo lar ity and the sodium salt o f  phosphate bu ffer was 
used in the mob i l e  phase . It was with the first column 
that the prel iminary work was done , and so the graphs o f  
the e f fect o f  p H  o n  retent ion t imes are odd . The l atter 
. three columns demonstrated consi stent results , and a 
s ingl e mob i l e  phase compos ition was used . 
Composit ion o f  the mob i l e  phas e  was determined by 
trial and error . Us ing the potas s ium salt o f  the phos ­
phate buffer i n  the mob i l e  phase was very important . The 
increased solub i l ity o f  potas s ium in organ ics compared 
to sodium a l l owed the mo larity o f  the buffer to be 
increased in order to get better chromatography ( better 
reso lution and peak height ) and it also lengthened the 
l i fet ime of  the column . Two p i ston s e a l s  had to be 
repl aced during a week ' s  time when the sodium salt was 
used due to the salt precipitation on the seal s . The 
column was also damaged by the sodium s a l t . 
The l onger the tubes sat whi l e  process ing other 
tubes ,  the l ower the recovery o f  PYR and NAPA . The 
reduced recovery o f  NAPA with t ime indicates that it 
also b inds to glass . The t ime involved in the extrac­
tion o f  the plasma and RBC samples was critica l . Thi s  
was due to the alka l i n i z ati on step i n  the extract ion 
procedures . 
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The water-solub l e  s i l aniz ing agent Aqua S i l N  was 
much easier to work with than SurfaS i l N , a hydrocarbon­
s o lubl e  agent . Aqua S i l N  was e a s i ly removed , however , by 
neutral or basic pH buffers . Thus , glas sware had to b e  
re- s i lan i z ed with every use , a n d  t h e  removal o f  the 
s i l anes from the glass during any procedures resulted in 
PYR b inding to the glass . 
Recovery was consi stent and Tab l e  7 showed no 
concentration dependency . Overal l  recovery o f  PYR was 
8 1 . 9 % ( 8 . 7 % CV ) in the l ow concentration range curve and 
8 5 . 4 % ( 7 . 9 % CV ) in the h igh curve . NAPA recovery was 
a l s o  consi stent with averages o f  8 2 . 6 % ( 1 0 . 2 % CV) and 
8 0 . 9 % ( 7 . 7 % CV ) for the plasma curves .  
Recovery from RBCs was s imilar to recovery from 
p l a sma with overa l l  recovery 8 4 . 4 5 %  ( 4 . 5 3 %  CV) for the 
l ow curve and 8 4 . 3 8 %  ( 1 0 . 3 9 %  CV ) for the h igh curve . A 
quantitat ive method was used in the RBCs extraction 
procedure . Thus , the variation was produced when sp ik­
ing the RBCs with the methanol solutions of PYR . 
The problems with recovery due to b inding to g l a s s  
could have been solved b y  two actions . First , the use 
o f  a comb inat ion o f  a nonpolar extract ion so lvent ( for 
good recovery o f  the nonpolar PYR ) and a sma l l  amount of  
a p o l a r  so lvent l ike isopropanol has been used to keep 
drugs from binding to glass . Second , the use o f  5 0 %  
methanol for reconst itut ion o f  the res idue from the 
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organic extract ion solvent might have helped . The 
methanol would not have removed the s i l anes from g l a s s  
a n d  thus , would n o t  have contributed to t h e  l o s s  o f  PYR . 
However ,  the addition o f  only 5 %  v/v o f  polar 
s olvents to the extraction solvents resulted in the 
extract ion of unwanted plasma const ituents that inter­
fered with the NAPA and PYR peaks . 
Two standard curves were necessary for the entire 
concentrat ion range 2 4 - 1 0 0 0  ng/ml , a lthough both curves 
were not always run on each day . The curves went from 
24 to 1 4 0  ng/ml for the l ow curve and from 1 4 0  to 1 0 0 0  
ng/ml for the high curve . Below 1 4 0 ng/ml , errors near 
2 0 %  were found us ing the high curve for the 100 ng/ml 
standard . Because the concentration range was great , it 
was better to have two curves for more confidence in the 
l ower concentration range . 
Linearities o f  the b ipha s i c  curves for PYR in 
p l a sma were good with correl at ion coe f f i c i ents o f  0 . 9 9 5  
o r  better . Rep l icate analys i s  o f  the same p l a sma con­
trol ind icated that the variation was less than 1 0 % . 
Intra-day variation was not reported . Due to the ava i l -
ab i l ity o f  only 15 dia lys i s  cel l s , a maximum of 1 5  
samp l e s  were run each day . On each day , there woul d  be 
a standard curve o f  5 or 6 samples , 1 or 2 control s  and 
5 to 1 5  samples . O ften , there were more standards and 
contro l s  than samples . 
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Cal ibrat ion curves for PYR in RBCs were exc e l l ent 
with an overal l  CV less than 9% for standards and over­
all error less than 5 % . Linear regre s s ion on the RBC 
c a l ibration curves produced con s i stent s l opes and R 
greater than 0 . 9 9 5  a lthough on the last day , the h igh 
curve for the RBCs was o f f  due to co lumn f a i lure . 
Cal ibrat ion curves for PYR in buffer were a l s o  
exce l l ent . Overal l  CV for standards was less  than 7 . 5 % ,  
and error was less  than 2 . 3 % .  Buf fer contro l s  were a l s o  
cons istent from day to day with error l e s s  than 2 %  and 
CV less  than 6 % . Peak he ights were nearly identical  
from day to day . 
Control s  were unacceptabl e  i f  more than 1 0 %  d i f -
ferent from the known spiked concentrat ions . I f  con-
troI s were unacceptabl e , the samples run with them were 
also cons idered unacceptab l e . Whenever samples were 
rej ected in this manner ,  experiments were repeated . 
Contro l s  showed no s igns o f  decompostion for the dura ­
t i on o f  the study . 
No pl anned attempt was made to check for interfer­
ences . However , there was an opportunity to rul e  out 
interferences when searching for an internal standard . 
Trimethoprim , qu inine , chlorpheni ramine and procainamide 
do not interfere with the NAPA or PYR peaks . 
6 . 2  Mas s  balance cons iderations 
Proven procedures for study ing prote in b inding are 
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prerequ i s ites for accurate results . One a ssume s , o f  
course ,  that assay error has been minimi z ed .  Error was 
not concentrat ion dependent for the range 24 to 1 0 0 0  
ng/ml i n  the assay presented here . Low concentrations 
have been assayed very accurately as reported in Tab l e s  
1 0  a n d  1 8 . However ,  as say error w i l l  ult imately play a 
role  in studies . The l imit o f  a study i s  o ften the 
a s say l imit of detect ion as it has been in determin ing 
the l owest unbound drug range in my work . 
It is important to cons ider mas s  bal ance . Lo s s e s  
from binding to glass may prevent account ing f o r  mas s  
wh ich makes accurate measurement o f  RBC l eve l s , p l a sma 
l evel s ,  and hematocrit more important , but also more 
dub ious because one can never be sure of the true s ource 
o f  error ( i . e .  random error , analyt ical error , or l o s s  
from b inding to glas s ) . When there i s  b inding to g l a s s , 
sp iked amounts may be greater than the amount recovered , 
and the source o f  error w i l l  never be real i z ed .  
When there i s  b inding t o  glass , one should never 
a s sume that the sp iked amount is the total amount at the 
end or use any form o f  Equat ion 17  without measur ing at 
least t,vo o f  the quanti ties . 
6 . 3  Vacuta iner'" pH and cel l/medium rat ios 
Thes e  studies show that one cannot take the pH of 
p l a sma for granted , espec ially when us ing vacuta iner'" 
tub e s . Ant icoagulant additives to tubes not only have 
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d i f ferent ant icoagul ant properties , but d i fferent chem i ­
c a l  properties that cannot be ignored . 
The initial pH o f  tubes i s  d i f ferent depending on 
the additive . E DTA i s  the best cho ice o f  the ant icoagu­
l ants tested because it has good ant i - c l ott ing proper­
ties and because it tends to l ower the p l a sma pH 
s l ightly whi ch a l l ows for whatever sma l l  r i s e  there 
might be in further immediate process ing . S odium 
heparin produced a s ign i f icantly d i f ferent z ero-t ime pH 
in Vacuta iners� compared to EDTA and sodium c itrate when 
analyz ed us ing ANOVA ( p< . O O l )  and Tukey ' s  student i z ed 
range ( HS D )  test ( a 0 . 0 0 1 ) . Heparin a l s o  a l l owed the 
most rap id rise in pH a s  pl otted in Figure 13 and in 
Tab l e  2 0 .  
Seal ing tubes i s  necessary . Para f i l m  is not a s  
good as tightly fitting caps or stoppers because para­
f i lm tends to loosen with t ime . Also , para f i lm performs 
poorly on s i lani z ed glassware because the glass becomes 
s l ippery , and the contents f l ow out readily when the 
tube i s  ti lted . In addit ion , pH changes so rap idly that 
it was necessary to continue gas s i ng the v i a l s  of p l a sma 
whi l e  l oading the ED ce l l s , a procedure that took about 
1 5 - 3 0  seconds per cel l . Even in the short t ime to f i l l  
1 5  cel l s , p H  changes occur . 
There is a d i f ference in the behavior o f  p l asma 
and RBCs with regards to pH changes when these two 
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components o f  b l ood are open t o  the atmosphere . C0 2 
escapes from plasma and the pH changes rap idly due t o  
its l ow buffer capacity . I n  contrast , there i s  almost 
no change in RBC pH because o f  the ir greater buf fering 
ab i l ity . 
In general , the pH o f  p l a sma r i s e s  rapidly whi l e  
RBCs tend t o  mainta in the ir phys iological pH . The 
result i s  a nonphys iological s ituation . The e f fect o f  
p H  changes o n  the di stribution o f  drugs i n  mediums with 
d i f ferent pH values and d i f ferent t i s sues can be seen in 
Tab l e  2 3 . That tab l e  i l lustrates the critical  nature of  
measuring and reporting pH values in RBC partition i ng 
studies . 
6 . 4  The theoret ical e f fects o f  pH on RBC part ition ing 
The reason for examin ing the changes in pH and 
contribut ion to thos e  changes by d i f ferent anticoagu­
l ants i s  to be abl e  to comment on the e f fects of pH 
change on RBC partit ioning . According to calcul ations 
us ing Eg . ( 1 5 )  the fol l owing trends can be seen : 
( 1 )  For bases , as the pH o f  the medium increases , 
cel l/med ium ratios increase ,  and as the pKa increas e s , 
the e ffect on the rat io increases . There i s  l ittl e  
d i f ference in rat ios f o r  a drug l ike PYR , a weak base 
with a pKa near phy s i o l ogic pH . 
( 2 )  For acids , as the pH o f  the medium increases , 
c e l l/medium rat io decreases , and as the pKa decreases , 
the e f fect on the rat i o  increases . 
( 3 )  Unsealed p l a sma produces falsely high cel l/medium 
rat ios for bases and falsely l ow rat ios for acids . 
( 4 )  Bases are more ion i z ed at l ower pH values and are 
therefore ion-trapped in areas of l ower pH such a s  in 
muscle tissue . 
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( 5 )  Acids are more ion i z ed a t  h igher p H  values and thus 
are ion-trapped in the plasma . 
( 6 )  Trend 4 is responsible for the l arger volume o f  
d i stribution for most basic drugs and i s  why RBC l eve l s  
o f  bases should be examined . 
6 . 5  Prote in b inding and ED in genera l 
Di lutions from the water content o f  membranes o r  
volume shi fts were sma l l . For very h ighly bound drugs 
with concentrat ion dependent protein b inding , thes e  
sma l l  volume shi fts might make a d i f ference . Albumin 
measurement in each cel l -ha l f  at the end o f  dialys i s  is  
a s imp l e  and rap id way o f  detecting volume shifts and 
l e akage o f  protein from the c e l l s . with th is informa­
t ion for each cel l , one can provide a reason for unusual 
results from any one cel l . Thi s  i s  helpful in the 
des i gnat i on of outl iers and a ssurance of ident ical  
conditions in each cel l . The use o f  isotonic buffer in 
dialys i s  did not prevent volume shi fts ent i rely , a s  
reported in Tab l e  2 4 . 
The adj ust ing o f  pH by gass ing with 5% C02 in 
oxygen resulted in concentrating protein in p l a sma . 
Thi s  is due to the loss  o f  water through evaporat ion . 
This could have been o f fset by volume s h i fts from the 
buffer s ide ( 9 2 ) . However , the data for the original 
albumin l eve l s  in Tab l e  24 are for a fter gass ing the 
p l asma , and so , the author can only state that the 
phenomenon happens from experience . 
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There were no losses due to b inding to the Spec­
trum cel l s  or membranes because there was 1 0 0 %  recovery 
from the amount put in the cel l s  as found in Tab l e  2 5 .  
statistical moment theory can be used to eva luate 
equ i l ibrat ion t ime in E D . Virtua l ly ident ical results 
were ach i eved in two experiments . There fore , the 
equ i l ibration hal f- l i fe at 1 2  rpm is 50 min . It was 
a s sumed that in 6 hal f - l ives , or 3 0 0  min , that equ i l i ­
brium was reached , and so dia lys i s  experiments were run 
for 5 hours . 
6 . 5 . 1  Influence o f  oH on protein b inding 
The results o f  the Student ' s  t test in Tab l e  2 6  
for b inding data c o l lected at pH 7 . 4  versus pH 8 . 0  
showed no s igni f icant d i f ference . However ,  there i s  an 
influence o f  pH on protein b inding a s  one can see in  
Figure 1 5 . For th i s  reason , pH should be contro l l ed o r  
at l east reported in a l l  protein b inding stud i e s . 
6 . 5 . 2  Influence o f  PYR concentration on protein b indina 
A Student ' s  t test showed a s ign i f icant d i fference 
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( p< . 0 3 )  i n  binding a t  2 d i f ferent PYR concentrations i n  
the therapeut ic range , 1 2 0  and 3 6 0  nglm1 , and thi s  h a s  
b e e n  reported in Tab l e  2 7 . There is more free drug at a 
higher total plasma concentration . 
However , examination o f  F igure 1 7  shows the oppo­
s ite , that there i s  more percent free drug at l ower 
concentrat ions , in oppos it i on to the l aw o f  mas s  action . 
Thi s  is probably due to the fact that the experiment 
done to show a d i f ference between b inding at 1 2 0  and 3 6 0  
nglml was done at normal a lbumin l eve l s  ( 4 5 . 6  gi L )  whi l e  
the data i n  Figure 17  was c o l lected in p l a sma with a 
l ower than normal albumin level ( 2 3 . 5  gi L ) . Changing 
the protein concentrat ion , if the interaction between 
the drug and prote in is a partit ioning phenomenon , could 
result in d i f ferent percent b inding o f  PYR . 
The phenomenon seen in F igure 1 7  and in the other 
b i nding experiments shows the importance of us ing more 
than one albumin l evel in b inding experiments for the 
purpose o f  determining b inding a f f in ity constants . The 
d i f ference in percent free drug i s  not great enough in 
the therapeut ic range to be s ign i f i cant cl inical ly . Yet , 
whi l e  th i s  d i f ference may not be s ign i f icant c l inica l l y ,  
i t  makes a great deal o f  d i f ference i n  E D  experiments 
involv ing concentrations beyond the therapeut i c  range . 
Thi s  is espec ial ly true for poorly soluble drugs l ike 
PYR that demonstrate a solub i l ity phenomenon in binding 
1 7 7  
experiments a t  l ow a lbumin l eve l s . 
Another conclus ion is that b inding a f f inity con­
stants derived from studies us ing d i fferent a lbumin 
l evel s ,  even in the s ame l aboratory , may not be equal 
and may not refl ect the values in v ivo . 
6 . 5 . 3  Inf luence o f  albumin on protein b inding 
Albumin concentration greatly influences the 
percent free PYR . Even under s l ightly d i f ferent cond i ­
t i ons and o n  7 d i f ferent days , comb ined data shows a 
s ign i f icant correlation ( R2 = 0 . 7 9 7 )  between albumin 
concentrat ion and percent free PYR . The high coe f f i ­
c i ent o f  determination , R2 , indicates that a great deal 
o f  the total variation i s  attributed to the fit rather 
than to res idual error . The equat ion for the relation­
ship i s  percent free = - 0 . 4 6 7  ( albumin ) + 2 3 . 5 .  
6 . 5 . 4  Influence o f  tubes on PYR b inding 
There was no d i f ference in percent free PYR i n  
p l asma coll ected in Vacutainer� tubes conta ining E DTA o r  
heparin or serum col l ected in tubes with no additive at 
the PYR concentration 1 0 0 0  ng/ml ( 4 . 0 2 X 1 0 - 6  M ) . The 
average percent free was 6 . 9 2 ( 3 7 % CV , n=1 0 )  which i s  
equal t o  9 3 . 8 % bound . There was more variation i n  
results i n  that part icular experiment than in other 
exper iments . There was both inter- and intra-tube 
variat i on . 
6 . 5 . 5  Binding to pure human serum a lbum in and AAG 
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The average binding t o  pure human serum album i n  a t  
1 4 . 2  gjL ( 2 . 0 6 X 1 0 - 4 M )  a t  3 0 0  ngjml PYR ( 1 . 2  X 1 0 - 6  M )  
was 8 6 . 5 % bound or 1 3 . 6 % free . Thi s  i s  s l ightly more 
bound than predicted ( 8 3 . 1% )  from the equation i n  Tab l e  
2 8 . 
At a stress l evel o f · AAG , 3 . 7  gj L ( 8 . 4  X 1 0 - 5  M ) , 
PYR ( 2 0 0  ngjml , 8 X 1 0 - 7  M )  was only 9 . 5 6 %  bound . At a 
l ower l evel o f  AAG , there was no b inding detected . 
The sum o f  the b inding to AAG ( 0  at norma l AAG 
l eve l s )  and pure albumin ( 8 6 . 5 % )  does not equal the 
9 3 . 8 % bound found in the p l a sma b i nd ing experiment for 
the comparison o f  d i f ferent Vacuta inersN . These exper­
iments were done at two very d i f ferent PYR l evel s  and 
d i f ferent a lbumin l eve l s , however ,  and s o  corrections 
should be considered . I f  PYR i s  bound more at h igher 
l eve l s  and more at h igher l evel s  o f  albumin , it is 
p o s s ib l e  that the pure a lbumin b inding accounted for a l l  
o f  the p lasma protein b inding . It does not rul e  out the 
presence o f  more b inding proteins in the p l a sma than 
thes e  two prote ins . 
There were two previous reports on the b inding o f  
PYR to p l a sma proteins . Ahmad and Rogers ( 2 )  reported 
the p l a sma protein b inding of PYR a s  8 2 . 3 % in  vitro and 
8 4 . 9 % ex v ivo . Cava l l ito and others ( 1 9 )  reported the 
p l a sma protein b inding of PYR as 8 7 % . The authors o f  
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thos e  reports did not provide albumin concentrat ions , 
but it was a ssumed norma l . The results reported here do 
not disagree with the irs , but the incomp letenes s  o f  
the ir method o f  reporting supports the purpose o f  thi s  
d i s sertation . 
6 . 5 . 6  Plasma protein b inding 
Ahmad ( 1 )  has shown that PYR d i splaces dapsone 
from dapsone ' s  binding s ite which imp l ies that both 
drugs bind to a spec i f i c  s ite on albumin . 
However ,  the extremely poor fits to the S catchard 
( 1 0 6 )  and Bl anchard ( 9 )  model s  and the less than perfect 
fits to the Larsen ( 8 2 )  model show that all o f  the 
as sumptions of the site approach to drug-prote in inter­
actions have not been ful f i l l ed .  Moreover ,  the graph o f  
percent free PYR versus p l a sma PYR concentrat ion ( F ig .  
1 7 a )  shows that the drug does not obey the l aw o f  mas s  
action a t  low concentrat ions . Thi s  suggests that the 
more flexible Klotz analys is i s  more appropriate because 
it does not as sume the presence of s ites and it can be 
app l ied in nonsaturabl e  binding s ituat ions . The d i f fer-
ences between the Klotz ( sto ichiometric ) approach and 
the s ite approach have been discussed in sections 2 . 5 , 
2 . 6  and 2 . 7  o f  Chapter 2 .  
More l ikely , due to the l ow water solub i l ity o f  
PYR , it i s  avoid ing the plasma water in favor o f  
hydrophob ic assoc iation with the p l a sma proteins ( albu-
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min o r  l ipoproteins ) .  Thi s  i s  a solub i l ity phenomenon 
rather than a spec i f ic b inding to albumin and i s  the 
most l ikely reason that PYR does not obey the l aw o f  
mass action i n  study 1 .  
Although binding data for PYR has been l imited i n  
t h e  l iterature , a thorough examinat ion o f  the b inding o f  
metoprine , a structurally rel ated compound , h a s  been 
done and i s  reviewed in Chapter 2 ( Table 3 ) . I f  the 
b inding o f  PYR is l ike the b inding of metoprine , it i s  
p o s s ib l e  that with the conditions o f  s tudy 1 ,  b inding t o  
l ipoproteins di sturbed the interaction o f  PYR with 
albumin at the l ow leve l s  o f  PYR . The a f f inity o f  
metoprine for �-l ipoprotein was much greater than the 
a f f inity for albumin when a f finities were determined in 
pure prote in fractions . However ,  b inding o f  metoprine 
to l ipoproteins was not apparent in who l e  plasma . Meto­
prine i s  more l ipoph i l i c  than PYR ( 1 9 )  and may have a 
stronger attract ion for l ipoprote ins for that reason . 
There are three reasons for attributing the total 
b i nding o f  PYR in whol e  plasma to b inding to albumin : 
( 1 )  the . more l ipoph i l ic compound ( metoprine ) did not 
b ind to l ipoproteins in the presence of a l bumin i n  who l e  
plasma , ( 2 )  PYR d i d  not bind t o  AA G  a t  normal AA G  l ev­
e l s , and ( 3 )  PYR binding in a solution of pure a l bumin 
was a l ittle greater than binding in who l e  p l a sma . 
However , b ind ing to albumin , which was as sumed t o  
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be the maj or b inding protein a fter finding no b inding 
MG , may be st i l l  b e  confounded by b inding to l ipopro-
teins . The l ipoprote in interaction may be con founding 
albumin b inding at a l l  drug l eve l s , but i s  not icab l e  
o n l y  at l ow drug l eve l s . The l ipoproteins p l ay an 
indeterminant role in the solub i l ity phenomenon . 
t o  
T h e  data from S tudies 2 a n d  3 do n o t  show the 
trend of increased binding with increas ing plasma con­
centrat ion . They were col l ected in p l a sma that had been 
d i luted with bu ffer , so that all the proteins would be 
more d i lute . Thi s  could have influenced the b inding o f  
PYR t o  the proteins . 
S olub i l ity phenomena in drug-protein interactions 
have been reported by others ( 9 2 , 9 8 )  and w i l l  be d i s ­
cussed shortly . 
Data from Studies 1 ,  2 ,  and 3 were f i t  with the 
Bl anchard , Larsen , Scatchard , doubl e  reciprocal ,  and 
Klotz equations . Although the doub l e  reciprocal p l ot 
produced what looked l ike a stra ight l ine , the parameter 
est imates from l inear regres s ion o f  the data were mean­
ingl e s s  ( negative val ues for numbers o f  s ites ) , and the 
prob l ems associated with thi s  plot that have been 
rev iewed in Chapter 2 were revealed . The data were 
trans formed in a way that covered up errors and fluctua­
t i ons in  the data so that the true b inding interaction 
was lost . The doub l e  reciprocal plot should not be used 
in protein b inding except for initial estimates when 
only l imited data i s  ava i l ab l e . 
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The Bl anchard fits were extremely poor . The 
Larsen equation i s  robust , but even s o , did not show 
improvements over the fits to the Klotz equation , prob­
ably because it had the same number of parameters ( 8 2 ) . 
Data from Studies 1 and 2 were fit wel l  by the Larsen 
e quation , but data from Study 3 were not . The parameter 
est imates for Kl and K2 were s imilar to the ones from 
the fit to the Klotz equat ion . For the Larsen fits , the 
parameter est imates for fits to data from S tudy 1 had 
standard errors ( S E )  in percent that were 8 . 3  and 8 3 %  of 
the est imates . For data from Study 2 ,  the SE o f  the 
est imates were 3 and 1 6 . 5 % of the est imated parameters . 
For fits to the data from Study 3 ,  the estimates were 
very d i f ferent compared to the estimates for the other 
data sets and the SE  values were 1 5 . 7  and 1 9 . 2 % of the 
est imates of  Kl and K2 . These fits are shown in 
Appendix B .  
The Kl otz o r  stoichiometric approach made the most 
sense for reasons ment ioned above . Fits to the Kl otz  
equation seemed more reasonabl e  that the fits  to the 
other equat ions . 
Comparisons o f  a one s ite and two s ite model for 
each set o f  data revea l ed that only the data from S tudy 
1 were fit better by a one s ite model . As stated 
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before / thi s  data had the l owest concentrations o f  PYR 
( Table 3 2 )  / dem9nstrated a solub i l ity phenomenon / and 
did not obey the l aw of mas s  act ion . Therefore / it i s  
not appropriate to f i t  data from study 1 to any equation 
based on the law o f  mass action . 
Higher concentrat i ons o f  PYR in the other stud i e s  
did n o t  show s igns o f  a solub i l ity phenomenon according 
to the graph in Figure 17b . According t o  Klotz ( 7 6 )  / 
more accurate parameter estimates require higher concen­
trat ions . The results o f  the fits and the we ight ing 
factors that produced the best fits are given in Tab l e s  
3 4 - 3 6 .  
On the other hand / a comparison o f  the b inding 
i sotherms in Figures 2 1 /  2 3 / and 25 reveal that data may 
not have been c o l l ected past the infl ection po int i f  
there i s  one ( 8 2 ) . In other words / the s aturat ion o f  
a lbumin b inding s ites may not have been approached . A 
d i f ferent ial curve / a p l ot o f  the s l op e  versus change in 
free drug / was not entirely succes s ful because o f  the 
i rregularity o f  the data / but did seem to revea l  that 
data from Studies 2 and 3 had gone past inflection 
po ints and that saturat ion had been approached . study 3 
had been des igned to include the highest concentrat ions 
o f  PYR that solub i l ity would permit and the l owest 
albumin concentrat ions that pract ical c i rcumstances 
would a l l ow .  Un fortunately / the l ow a l bumin concentra-
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t ions may have disturbed the true b inding phenomenon and 
resulted in the poorer parameter estimates ( Tabl e s  3 3  
and 3 6 ) . 
I f  the parameter estimates for each set o f  data 
are compared , it appears that there are two stoichiomet­
ric b inding constants K1 at 2 . 8 2 X 1 0 4 M- 1  and K2 at 
1 . 7 4 X 1 0 4 M- 1  from the nonl inear fits of the data f rom 
s tudy 2 .  The estimates from fits to data only from 
s tudy 2 have been reported because data from study 1 did 
not fol l ow the l aw o f  mas s  action and data from s tudy 3 
had other errors . 
The fits agree with the estimates from the e qua­
t i on K1 (bound/ free ) / albumin for sma l l  concentrat ions 
of PYR . The averages were 2 . 9 1 X 1 0 4 and 2 . 8 4 X 1 0 4 M- 1  
for data from study 1 and study 2 ,  respect ively . 
s imilar incons i stenc ies with the l aw o f  mas s  
act i on have been reported e l s ewhere ( 9 2 , 9 8 , 1 0 4 ) . The 
interact ion with tetracycl ine was a s sumed to be a result 
of a dissolut ion o f  tetracycl ine in a l ipoph i l i c  port i o n  
o f  the l ipoprotein mol ecul e ,  rather than an association 
with spec i f i c  b inding s ites . The tetracyc l ine b inding 
to l ipoproteins increased as the concentrat ion o f  tetra­
cycl ine increased , and it was remarkably s imilar to the 
graph o f  the distribution o f  tetracycl ine between chl o­
roform and Krebs phosphate buf fer ( 9 8 ) . 
The quinidine - l ipoprotein interact ion was not the 
1 8 5  
s ame a s  the drug ' s  di stribut ion between buffer and 
chl oro form , in contrast to the tetracycl ine work ( 9 2 ) . 
N i l sen ( 9 2 )  found a decreas ing b inding ratio bound/ free 
with increasing concentrat ion o f  quinidine in accordance 
with the law o f  ma s s  action except for with l ipopro­
teins . 
Th is positive cooperativity seems to dominate in 
the l ow concentrat ions o f  PYR whi l e  the albumin-PYR 
interaction fo l l owing the l aw of mas s  action probab ly 
b lurs thi s  ef fect at higher PYR concentrat ions ( PYR 1 . 6  
X 1 0 - 4 M )  in study 3 .  
S ager et al . ( 1 0 4 ) have shown that proprano l o l  i s  
a l s o  not bound , but distributed to l ipoproteins ( s im i l a r  
to tetracyc l ine )  independent o f  proprano l o l  concentra­
t i on . The binding to plasma proteins for th i s  data 
p l otted according to Scatchard looks very much l i k� 
the ir plot of the binding of proprano l o l  to l ipopro ­
teins . Both have a large amount o f  scatter and a s l op e  
n o t  s ign i f icantly d i f ferent from z ero . 
There is an alternative way o f  portraying the 
b i nding of  PYR to prote in in these studies . I f  one 
cons iders the b inding as a partitioning phenomenon 
between the aqueous plasma water and the hydrophob ic 
protein , it i s  possible that the partit ion c o e f f i c ient , 
Pyr on protein/ PYR in water , changes with the increas ing 
concentration of PYR and results in increased percent 
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b inding with increased PYR concentration ( Fig . 1 7 a ) . I t  
i s  a l s o  possible that the greatest change occurs at the 
l ower l eve l s  of PYR and i s  refl ected by changes in the 
a f f inity for the protein . Changes in a f f inity for the 
protein can be seen in data from s tudy 3 and Tab l e  3 3 , 
where the est imates o f  the a f f i n ity constants are much 
higher than in the other two sets of data ( Studies  1 and 
2 )  where the protein l evels were l ower . S ince the 
a f f in ity is l ow ( K1 values are low) , it is possible that 
nonspec i f i c  b inding rather than spec i f i c  b inding is able 
to predominate at l ow concentrat ions . It is possible 
that nonspec i f i c  b inding to l ipoproteins i s  enough t o  
a l ter the binding to albumin at l ow concentrat ions . 
The pH dependency o f  the protein b inding dep icted 
in F igure 1 5  suggests that there i s  ionic b inding to 
prote in . Th is may not be the case , however ,  because 
both ac ids and bases show pH dependency in prote in 
b inding in the s ame direct ion ( 1 6 ) . More l ikely , there 
i s  a change in the conformat ion of the a lbumin molecu l e  
that i s  respons ible f o r  the pH dependency o f  b inding . 
6 . 6  RBC partition ing and b inding 
6 . 6 . 1  Part i t i on i ng from bu ffer 
Washing packed cel l s  was necessary to remove the 
p l a sma albumin in my some o f  my studies , but not a l l . 
There have been reports that washing c e l l s  may alter the 
phy s i o l ogic binding propert ies of RBCs ( 5 2 , 4 0 ) . 
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Consequently , the b inding o f  PYR t o  RBCs was determined 
in whol e  b l ood assuming RBCs to be the maj ority o f  the 
cellular fract ion o f  bl ood . The observed interaction 
between PYR , proteins , and RBCs should therefore re f l ect 
conditions in bl ood . Thi s  procedure a l l owed p l a sma 
proteins , plasma water , and the presence of other cel l s  
and l ipids t o  contribute t o  the distribut ion between 
p l a sma and cel l s . 
The basic l ipoph i l i c  compound PYR with pKa 7 . 1 3 
would be expected to penetrate the RBC membrane ( 1 0 8 ) . 
Accordingly , the pH-gradient across the membrane shou l d  
influence the di stribut ion between t h e  unbound drug in 
the p l a sma water and the interior cel lular water . 
As suming a pH o f  7 . 2 6 ins ide the RBC ( 1 2 2 )  and 7 . 4  
in the p l asma , a d i stribut ion rat i o  o f  1 . 1 3 can be 
calcul ated from Jacobs ' equat ion . Thi s  type o f  distri­
but ion should produce a stra ight l ine para l l e l  to and at 
a d i stance o f  1 . 1 3 from the abscissa in an RBCjbu f fer 
rat i o  graph s imilar to the one in F igure 27 at pH 7 . 4 .  
The actual rat ios in F igure 2 7  demostrate a 4 - 6  t imes 
h igher rat io than expected . Thi s  strongly suggests than 
addit ional b inding takes place that influences the 
distribut ion of PYR into cel l s . Binding to hemoglobin 
ins ide the cell  and b inding to the cel l membrane are 
possible contributors to thi s  increased rati o . 
Hemoglobin has a hydrophob ic cage around its heme 
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center ( 1 2 7 ) . It i s  not surpris ing that the l ipoph i l i c  
PYR would assoc iate with it . There did not appear to be 
any concentration dependency o f  PYR b i nding to hemogl o ­
b i n  ( Table 3 7 ) . Binding to hemolysate was 4 2 . 5 % which 
would not account for a l l  o f  the uptake by RBCs . The 
mean d i f ference between the theroret ically predicted and 
the observed rat ios was 4 . 1 3 .  On average , there was 4 
t imes as much bound to the c e l l  or bound ins ide the c e l l  
than unbound ins ide the cel l . There fore , the RBC mem­
branes must b ind PYR . 
When plasma was removed and RBCs suspended in 
buffer , there was a pro found e f fect o f  buf fer pH on 
part i tion ing o f  PYR in the RBCs . Using the equat ion by 
Jacob s , the theoretical rat ios at each pair o f  pH values 
were calcul ated and compared to the observed values . 
Linear regression on these values revea l ed d i f ferent 
equations for the l ines . Thi s  analys i s  a s sumed that the 
buffer pH did not a f fect the theoret ical RBC pH . More 
l ikely , however ,  the pH of the RBCs did change s l ight ly 
and for th i s  reason , the observed data does not match 
the theoret ical data . The main reason the observed does 
not match the theoret ical data is  the b inding ins ide and 
to the ce l l s . 
The uptake o f  PYR by RBCs from buffer in whi ch 
b inding was absent showed a relationship to bu ffer pH 
( F i g  2 7 )  and did not show any ev idence of saturab i l ity . 
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The average RBCjbuffer rat i o  was 5 . 1 6 ( 1 1 . 8 % CV , n=2 ) a t  
p H  7 . 4 .  
6 . 6 . 2  I n fluence o f  prot e i n  binding on RBC uptake 
PYR accumu l ated rap idly i n  RBCs which had been 
washed and resuspended i n  bu f f e r  to yield RBCjbuf fe r  
rat i o s  greater than 1 .  However ,  the pres ence o f  p l a sma 
markedl y  reduced RBC uptake . The average RBCj p l a sma 
rat i o  was 0 . 4 2 ( 1 0 %  CV , n=5 ) . Thi s  indicates that the 
p l a sma b i nding o f  PYR diminishes the RBC uptake by 
reduc ing the concentration of unbound drug . Con f i rma­
tion of thi s  hypothes i s  i s  provided by the experiments 
in which p l a sma b i nding was decreased by d i l ut i on o f  
p l a sma with buffer . 
The most common a s sumption i s  that RBC distr ibu­
tion to the b l ood c e l l s  i s  determined s o l e l y  by the 
concentration o f  unbound PYR i n  the p l a sma ( 6 5 ) . Exper­
iments in th i s  report had shown that a l bumi n  was the 
ma i n  b i nding protein i n  the p l a sma , s o  it should b e  the 
ma i n  determinant o f  RBC part i t i o n i ng i n  who l e  b l o od . 
The manner in which the p l asma was d i l uted woul d  have 
d i luted the other proteins equa l l y , and thus , it cannot 
b e  determined from any one experiment that a lbum i n  was 
the sole determinant o f  free fract i on . The good corre­
l at i o n  b etwe en a lbumin l evel and free PYR from s everal 
d i f f erent exper iments us ing d i f ferent p l asma sources 
does support the original hypothe s i s  however .  
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The advantages o f  determining unbound fract ion o f  
drug from the RBC/plasma rat io as outl ined b y  many 
authors ( 1 1 ,  5 3 , 5 4 , 6 5 , 8 1 )  do not provide a great 
advantage over the " tedious " ED methods of measuri ng 
p l a sma b inding in the cl inical s etting . Fremstad ( 5 2 )  
has commented that for the app l i cation o f  thi s  method , 
i f  the di str ibut ion o f  drug to RBCs i s  d irectly and 
l inearly rel ated to the free concentration in the p l a sma 
and if b inding propert ies o f  the RBCs are constant and 
predi ctab l e  in d i f ferent pathol ogical conditions , each 
drug would have to be thoroughly invest igated be fore 
such " s impl e "  methods could be used . To date , there i s  
n o  drug that has been that thoroughly invest igated . 
Garrett has a point however , in cases where the usual 
methods o f  ultra f i l trat ion and E D  do not work , his 
" method o f  variab l e  plasma concentrat ions " in RBC sus­
pens ions to yield percent protein bound may be necess ary 
( 5 4 )  . 
There are more disadvantages than advantages in 
determin ing unbound fraction o f  drug in the plasma from 
the part itioning of the drug into RBCs . The va l idat i o n  
o f  that techn ique f o r  any individual drug would b e  more 
tedious than us ing E D  to determine the fract ion o f  
unbound drug . Working with RBCs and account ing for mass 
bal ance are d i f f icult and add to the reasons why the 
techn i que us ing partitioning into RBCs as a protein 
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b inding screening procedure has not been accepted . I t  
h a s  rema ined obscure in the l iterature s ince i t s  intro­
duction in 19 7 3 . 
Whi l e  on thi s  top i c , it woul d  not be recommended 
that ED with 1 ml Spectrum cel l s  be used for the study 
of RBC uptake . The RBCs are too viscous to manipulate 
and d i f ficult to remove from thes e  type o f  c e l l s . At 
least two authors have used ED for the study o f  RBC 
uptake ( 4 0 ,  8 7 ) . 
Chapter 7 
Conclus ions 
7 . 1  Analytical methodology 
The as say presented in thi s  work i s  adequate for 
pharmacokinet ic studies . It has been app l ied to the 
study of prote in b inding and RBC part i t i oning and b ind­
ing . The as say i s  relatively s impl e  and should e a s i l y  
be reproduced in other labs . I t  requ i re s  a 5 micron C 1 8  
co lumn and a UV detector with a 2 5 4  f i l ter . Due to the 
near-neutral pH o f  the mob i l e  phas e , a s i l ica saturato r  
column i s  recommended . The mob i l e  phas e  cons i sted o f  
methanol -acetonitrile-phosphate bu f fer ( K  salts , 0 . 0 3 M ,  
p H  6 . 9 5 )  i n  4 5 : 1 5 : 4 0 v/v proport i ons . The f l ow rate wa s 
1 . 6  ml/min . 
Extract ion o f  PYR from p l a sma requ i red 7 ml o f  
methylene chloride . Extract ion from RBCs requ i red 1 2  ml 
o f  a 1 : 3  comb ination o f  methyl ene chl oride and n-butyl 
chlor ide . Mean recoveries from p l a sma and RBCs were 
between 8 1 . 9  and 8 5 . 4 % and were not concentrat ion depen­
dent . Extract ion o f  PYR from RBCs was quant itat ive . 
NAPA was used as an internal standard for the 
plasma curves .  NAPA recovery from plasma was 8 2 % . No 
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internal standard was used for the RBC or buffer curve s . 
s olut i ons o f  PYR in buffer could be inj ected directly 
onto the HPLC system without an extraction step . Us ing 
an internal standard for buffer curves introduced more 
error than necessary because it was a d irect inj ection 
techn i que . Al l so lutions o f  PYR were found to stab l e  
for the duration o f  the study . 
Two cal ibrat ion curves were used for each matr i x . 
The range of the cal ibrat ion curves were 2 4 - 1 4 0  ng/ml 
and 1 4 0 - 1 0 0 0  ng/ml . They were l inear with correlation 
coe f f i c ients greater than 0 . 9 9 5 . The l imit o f  detection 
was 24  ng/ml for each matrix . 
Retention t imes were 4 . 5  and 5 . 3 5 minutes for the 
internal standard and PYR respect ively . 
The two b iggest prob l ems with thi s  assay were the 
b i nding of  PYR to glass and the d i s solution o f  the c o l ­
umn packing because o f  the pH o f  the mob i l e  pha s e . I n  
the future , us ing a n  HPLC column with a h igher carbon 
l oad would be recommended . Us ing the cartridge type o f  
column which prevents the re-packing o f  voids i n  the 
column packing would not be recommended . 
7 .2 Medium pH and theoret i c a l  cel l/med ium ratio 
There i s  a rap id and s igni f icant rise in pH of 
p l a sma upon exposure to the atmosphere because o f  the 
loss o f  C0 2 ' The d i f ferent additives in Vacuta iners� 
are partly respons ible for the d i f ferent degree to wh ich 
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pH changes in plasma c o l l ected in Vacuta inersN . Hep a r i n  
causes the fastest rise in pH o f  t h e  add it ives tested . 
It a l s o  produces a s igni fi cantly d i f ferent z ero-t ime p H  
according to ANOVA ( p < O . O O O l )  and Tukey ' s  studenti z ed 
range test ( H S D )  at a=O . O O l . The average z ero-t ime 
p l a sma pH in the three VacutainersN tested was 7 . 3 6 
( 0 . 4 % CV , n=1 5 ) . The tubes conta ining sodium heparin 
had an average pH o f  7 . 5 0 ( 0 . 6 % CV , n=5 ) . 
RBCs tend to mainta in the ir phys iologic pH . Thu s , 
when measuring RBC/plasma concentrat ion rat ios , it i s  
necessary t o  prevent the change i n  pH , t o  adj ust it t o  
norma l pH , o r  t o  report the p H  o f  the medium . other­
w i s e , cel l/med ium rat ios w i l l  be falsely l ow for a c i d i c  
c ompounds and f a l s e l y  high f o r  b a s i c  compounds with the 
magnitude o f  the error depend ing on the pKa o f  the com­
pound . For a l ipoph i l ic drug l ike PYR for wh ich the 
part i t i oning tima i s  short , s i gn i f i cant partit ioning i s  
possible whi l e  process ing blood to yield cel l/med ium 
rat i o s  wh ich would be in error . Rat i o s  could become 
techni c ian dependent if standard i z ed procedures were not 
fol l owed . The most extreme case would be when one tech­
n i c ian who removed the stoppers o f  vacutainersN on rows 
of tubes be fore separat ion o f  the plasma was pa i red with 
another technician who removed the stopper and the 
p l a sma from one tube at a time . 
Rat ios o f  drugs across the RBC membrane are 
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a f fected by the pH o f  the medium because the d i stribu­
t i on o f  drugs across a semi-permeabl e  membrane i s  a pH­
dependent phenomenon . The large volumes o f  d istribut i o n  
for basic drugs supports t h e  i d e a  that b a s i c  drugs tend 
t o  l eave the plasma compartment and d i stribute to 
regions o f  the body with lower pH such a s  the t i s sues 
and b l ood cel l s .  
7 . 3  Protein b ind ing o f  PYR 
PYR was not bound to the dialys i s  c e l l s  nor mem­
branes that were used in thes e  stud i e s . Volume shi fts 
of fluid occurred , but they were not l arge « 1 0 % ) . The 
use o f  isotonic buffer did not prevent volume shifts 
ent i rely . stat istical moment theory was used to deter­
mine that equ i l ibr ium between the two s ides o f  the 
d i a lys is cells was reached in 3 0 0  minute s . 
The pH o f  the p l a sma influenced the protein b ind­
ing o f  PYR as seen in Figure 1 5 , a lthough there was not 
a stat i stically s ign i f i cant d i f ference between b inding 
at pH 7 . 4  and pH 8 . 0 .  
There was a statistically s i gn i f i cant ( p< . 0 3 )  d i f­
ference in prote in b inding at two therapeut ic l eve l s  o f  
PYR , 118 and 3 6 3  ng/ml . There was more percent free PYR 
at the higher total PYR concentration . I n  one prot e i n  
b ind ing experiment in whi ch higher PYR concentrati ons 
and l ower albumin concentrat ions were used , there was a 
concentrat ion dependent protein b inding occurring in 
1 9 5  
oppos it i on to the l aw o f  mas s  action ( Figure 1 7 a )  where 
there was less free drug at higher total drug l eve l s . 
Thi s  arti fact was due to the solub i l ity phenomenon seen 
in data from study 1 and was not seen in the two other 
b inding studies . 
There was a s ign i f i cant e f fect o f  a lbumin concen­
tration on the plasma protein b inding o f  PYR ( p < 0 . 0 0 0 1 ,  
R2 = 0 . 7 9 7 , R = 0 . 8 9 3 ) . For whol e  p l a sma , l inear 
regre s s i on yielded the equat ion percent free PYR = 
- 0 . 4 6 7 ( albumin in gi L )  + 2 3 . 5 .  The high y- intercept 
suggests binding to other const ituents o f  the plasma 
bes ides albumin . However ,  the R2 value shows that most 
o f  the data is  exp l a ined by albumin b inding . 
There was no d i f ference in the percent free PYR i n  
pl asma collected in three d i f ferent types o f  Vacutain­
ers� at 1 0 0 0  ng/ml . The average unbound concentration 
was 6 . 9 % ( 3 7 %  CV , n=1 0 )  at a lbumin 4 1 . 8  gi L .  Thi s  i s  
t h e  same as 9 3 . 1 % bound . 
Binding to pure human albumin in i s otonic phos ­
phate buf fer wa s 8 6 . 5 % .  Thi s  was s l ightly more bound 
that predicted by the equat ion above ( 8 3 . 1 % ) . Th i s  
means that the equation f o r  b inding in p l a sma predicts 
we l l  for pure albumin b inding in buf fer . Thi s  supports 
the conclus ion that b inding to proteins other than a l bu­
min i s  neg l i g ib l e . 
Binding to 8 . 4  X 1 0 - 5 M AAG wa s 9 . 5 6 %  and to 1 . 3  X 
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1 0 - 5  M AAG was z ero . B inding to AAG would not be 
expected in normal plasma or serum according to thes e  
results . 
At l ow concentrat ions , PYR does not fol l ow the l aw 
o f  mass action in its interact ion with p l a sma proteins . 
For this reason , it i s  not pos s ib l e  to ana l y z e  a l l  o f  
the s e  data using standard protein b inding equat ions . 
At higher concentrat ions , PYR fol l ows the l aw o f  
mass action . B inding to albumin i s  presumed to be most 
preval ent and b inding to other prote ins i s  as sumed 
negl igibl e .  Data analys i s  reveal ed better fits to two 
b inding s ites ; however ,  in both cases l arge standard 
e rrors were found for parameter estimates for the s econd 
stoich i ometric binding constant . The res idual s  revealed 
patterns that indicate an i l l -conditioned mode l . S atu­
ration o f  the albumin b inding capac ity was not reached . 
Honore and Brodersen ' s  ( 6 3 )  s imp l i f ication o f  the 
stoichiometric equat ion where ( b ound/ free ) / albumin con­
centrat ions in mo lar units = K1 at l ow concentrations 
gave a s  good estimation o f  K1 as did the nonl inear f i t s  
o f  d a t a  s ets 3 8  and 4 1 .  From th i s  approximat ion , the 
average estimates for K1 are 2 . 9 1 X 1 0 4 M- 1  ( 1 5 %  CV ) for 
data from Study 1 and 2 . 8 4 X 1 0 4 M- 1 ( 8 . 8 % CV ) for data 
from Study 2 .  
From the nonl inear f its o f  data 4 1 ,  the f i rst and 
second class ical stoichiometric b inding constants for 
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PYR are 2 . 8 3 X 1 0 4 M- 1 and 1 . 7 4 X 1 0 4 M- 1 • 
The doub l e-rec iprocal plot should not be used t o  
f ind parameter estimates f o r  drug-prote i n  b inding inter­
act i ons . The Bl anchard and Larsen equat ions do not 
o f fer any advantage over the estab l i shed stoichiometric 
approach o f  Klotz . The Scatchard equat ion and plot 
would be satis factory only for ideal data without coop­
erativity , except that it incorrectly as sumes no error 
i n  the " independent " variab l e  axis and th i s  results in 
under-estimat ion o f  the s l ope o f  the regresson l ine and 
erroneous parameter est imates . The gross man ipulation 
o f  the data makes the S catchard p l ot a poor choice s ince 
methods for nonl inear f itting o f  the data exist . Except 
in ideal cases , the parameter est imates from the Scat­
chard analys is do not re fl ect actual b inding s ite a f f i ­
n ity constants ( 7 7 ) . 
The reason that the S catchard equation and plot 
are st i l l  popular in the l iterature i s  that thi s  l inear 
equation had been firmly estab l i shed a s  " the method o f  
analys i s "  be fore the arrival o f  the computers o n  wh i ch 
non l i near regress ion can easily be done . Unfortunately , 
departure from the use o f  the Scatchard equation has 
been s l ow .  Klotz ' s  sto ichiometric approach i s  c l early 
superior in that it ( 1 )  requ i res less data man ipul ation 
and hence covers up fewer poorly coll ected data , ( 2 )  has 
fewer restrict ive assumpt ions , and ( 3 )  does not ignore 
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the b a s i c  rul e s  o f  stat i stical analys i s . The main 
advantage o f  the Klotz plot i s  that it shows immediately 
whether or not suf f i c i ent data has been c o l l ected (by 
the presence o f  an inflection point ) . Whereas , from 
data on l ineari z ed p l ots , one cannot t e l l  if enough data 
has been coll ected and many errors are covered up . 
In summary , l inear expre s s i ons for protein b inding 
suffer from the prob l ems d iscussed in s ection 2 . 6 .  Two 
important prob l ems di scussed were poor parameter e s t i ­
mates aris ing from ignoring error in t h e  x-axis and 
inab i l ity to tel l if enough data has been col l ected . I n  
the nonl inear Klotz p l ot , one c a n  a ssume that l ittl e  
error exists in the variab l e  o n  the x-ax i s  compared t o  
t h e  variable on t h e  y - a x i s  and o n e  c a n  tell  that enough 
data has been coll ected . Thus , Klotz ' s  approach i s  
recommended with t h e  a s sumption o f  integer values for n .  
7 . 4  RBC part itioning and binding 
The present in vitro study shows that upon 
incubat ion with human bl ood , PYR was preferent i a l l y  
bound to pl asma prote ins . However ,  when plasma ( and 
prote ins ) were rep l aced with buffer , the PYR concentra­
t ion was increased four t imes over the normal concentra­
t i on in RBCs at normal hematocrit . 
The average percent bound to hemo lysate ( Hb 1 . 5 7 X 
1 0 - 3  M )  was 4 2 . 5 % ( 1 9 %  CV , n= l O )  at several l eve l s  o f  
PYR . There was no concentrat ion dependency in PYR b ind-
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ing to hemolysate . At about hal f the normal Hb concen­
tration ins ide the cel l s , Hb b inding does not account 
for a l l  the PYR ins ide the c e l l s . Thi s  would be true 
for the normal Hb concentrat ion a l s o . 
When washed RBCs were suspended in buffer o f  vary­
ing pH values from 6 . 7  to 8 . 0 , there was a pronounced 
e f fect o f  buf fer pH on the part i t i oning of PYR into the 
cel l s  ( F igure 2 7 ) . The RBCjbuf fer concentrat ion rat i o  
a t  p H  7 . 4  was 5 . 1 6 ( 1 2 %  CV , n=2 ) . The average d i f fer­
ence between the observed and theoretical RBC/bu ffer 
rat ios was 4 . 1 4 ( 2 0 % CV , n=7 ) for a l l  the data . Four 
t imes as much PYR was found ins ide the cel l s  or bound to 
the c e l l s  as was predicted to be unbound ins ide the 
ce l l s . Binding to hemoglobin did not ent irely account 
for th i s  h igh rat i o . Therefore , PYR b inds to the RBC 
memb rane . Alterat ion o f  the plasma b ind ing by d i lut ion 
with isotonic phosphate buffer showed that uptake into 
RBCs was proport i onal to the free drug concentrat ion . 
The average RBC/plasma rat i o  was 0 . 4 2 ( 1 0 . 2 % CV , n= 5 ) . 
7 . 5  Final c ommen t s  
These studies con f i rm that final drug concentra­
tion , albumin concentration , and pH make a d i f ference in 
protein b inding and RBC part ition ing . However , albumi n  
concentrat ions , pH , and f i n a l  drug concentration are 
rarely reported in the l iterature . Many other 
researchers have stated that protein b i nd ing as a per-
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centage does not stand a l one . A ful l description o f  the 
condit ions o f  the study i s  a s  important a s  the percent 
bound and a ment ion of the technique ( e . g .  ED or ultra­
f i l tration)  used to f ind the value . The mimicking o f  
phy s i o l ogic conditions cannot be as sumed when a l l  that 
is reported is  percent bound . Albumin concentration and 
pH are two of  the most important experimental cond i t i ons 
in prote in b inding studies , yet they are m i s s ing from 
most reports . 
Data analys is from studies o f  drug-protein b inding 
and measur ing RBC level s  o f  drugs have someth ing i n  com­
mon . In both cases , sources o f  errors are compounded by 
data manipul ation . For instance , the axes in the S cat­
chard p l ot are ( b ound drug concentrat ion/protein concen­
trat ion ) /unbound drug concentration versus bound drug 
concentration/protein concentrat ion . Each concentration 
was measured by an as say that has a sma l l  amount of  
error . Then the concentrat ions are converted to mo l a r  
concentrations . The l atter calcul ation results in 
rounding error . 
Many o f  the analytical art i facts reviewed in Chap­
ter 2 introduce error in measuring drug concentrations 
in RBCs . Experience has shown that hemolys i s  i s  the 
most common prob l em in  determin ing RBC l eve l s  of drugs . 
I f  the RBCs in the original who l e  blood samp l e  hemo l yz e , 
both the plasma and the RBC l evel s  cannot be determined 
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accurately . 
Errors result when RBC drug l evel s  are measured i n  
t h e  w a y  presented here . Error i s  introduced by measur­
ing the hematocrit o f  the who l e  bl ood and the hematocrit 
o f  the packed cells to account for trapped p l a sma . The 
d i f f iculty in measuring the volume of v i scous RBCs 
results in error in assaying for drug concentrat ion in 
RBCs . Error from assaying drug in the p l a sma i s  a l s o  
introduced when correcting the RBC drug l evel f o r  drug 
in the trapped pl asma in the packed RBCs . The fact that 
there are many more sources of error when measuring RBC 
drug l eve l s  compared to pl asma drug l eve l s  i s  evident 
when compar ing F igures 3 3 - 3 6 .  The relat ionship between 
p l a sma and who l e  bl ood PYR l evel s  shows much less error 
than the relationship between RBC and who l e  blood PYR 
l evel s .  
There fore , it i s  recommended that when determin ing 
the RBC l eve l s  o f  drugs , it i s  better to measure the 
p l a sma and whol e  bl ood drug l eve l s , take one hematocr it 
m e a s u r ement and subtract t h e  plasma drug l evel from the 
who l e  bl ood drug l evel to find the RBC drug l eve l . Thi s  
procedure wi l l  estab l i sh mass bal ance . In addition , it  
is  necessary to val i date that the extract ion o f  drug 
from the whol e  blood represents equal extract ion from 
the components o f  bl ood ( ce l l s  as wel l  as p l a sma ) . 
2 0 2  
Chapter 8 
Prospectus 
To extend thi s  work , the author would l ike to 
examine the binding o f  PYR to pur i f ied de fatted album i n , 
to s everal pur i f i ed plasma l ipoprote ins , and several 
concentrations of hemoglobin for the purposes o f  stoich­
i ometric data analys i s . 
In addition , the author would l ike to apply the 
RBC partit ion ing techn iques to examination of the bl ood 
from patients receiving PYR for malaria and toxop l a smo­
s i s . 
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A p p e n d i x  A 
Com p u ter Programs  
COWEN T : PROGRAM FOR RBC/BU F F E R R A T I O  V E R S U S  P H  
GOPT I ON S  HS I Z [-6 . 5 VS I Z E-5 NOD I SP LAY D EV I C E- T EK 4 0 , 4  
G S FMOO E= r e p l a c e  GS FNAME- T E K 4 0 , 4  NOPROVP T ; 
d a t a  p h r o t  i 0 ;  
I NP U T  B U F F ER RBC 
C A R DS ; 
1 3 7 . 8 2 505 . 9 3 
1 40 . 39 5 0 3  . 59 
1 9 8 . 6 7 8 3 6  . 09 
1 1 9 . 89 58 7 89 
1 09 . 6 4 5 5 0 . 4 2 
1 0 1 . 9 6 6 6 5 . 1 6  
, 1 4 . 77 68 1 . 55  
D A T A  C A LC ; 
S E T  p h r o t i o ;  
c o r r b c  
5 6 5  8 5  
53 5 .  , 7 
9 3 9  B 6  
6 7 0  4 8 
6 0 4  9 0  
7 0 4 . 3 1 
7 1 7 .  7 3  
r a t i o  = c o r r b c/b u f f e r :  
PROC P R I NT DATA - C A LC ; 
p h  r t h e o : 
6 4 7 1 7 
7 , 8 40 6 
7 4 1 1 3 2 9  
7 .  4 1 3 29 
7 7 . 3 7 2  
7 .  9 . 48 8 5  
8 . 0  1 . 53 4 3  
T I T L E  " RBC/BU F F ER R A T I O  V E R S U S  p H " ; 
PROC R EG d o t o= c o l c ;  
MOD E L  r o t ; o- p h /R C L I  C LM ;  
O U T P U T  OUT: r o t P R E D I C T ED-PRO R ES I D U A L-R E S ; 
PROC R EG d o t o = c o l c ;  
MOD E L  r t h e O= D h/R e l l  C LM ;  
O U T P U T  OUT= r o t 2  P R E D I C T ED - P R D 2  R E S I D U A L-R E S 2 ; 
d a t a  s um ; s e t  r o t  r o t 2  c o l c ;  
T I T L E  H=2 F=XSW I SS C=WH I T E " RBC/B U F F E R R A T I O  V E R S L'S p H "  
P R OC G P LOT ; 
LAB E L  R A T I D- " RBC/BUF R A T I O " : 
L A B E L  R TH ED- " TH EOR E T I CA L  R A T I O " ; 
L A B E L  PRD2- " PR E D I C T ED " ; 
LAB E L  PRD- " PR E D I C T ED " , 
LAB E L  PH- " p H " , 
LAB E L  R E S- " R ES I DUA L " , L A B E L  R E S 2 - " R ES I D U A L " 
P L O T  r o t i o . p h= l PRO - p h = 2  r t h e o . pH=3 p r d 2 . p H = 4  / OVER LAY , 
P LO T R E S . P H-5 R E S 2 . PH-6/ OV E R L A Y  V R E F =0 ,  
SYMBO L 1  (-WH I T E  V-T R I ANG L E  I =NON E ,  
SYMBO L 2  C=WH I T E  V=X I =J O I N :  
S YMBOU C-WH I T E  V=C I RC L E  I =NON E : 
SYMBO L 4  C-wH I T E V=X I = J O I N ,  
SYMBO L 5  C=WH I T E V= TR I ANG L E  I =NON E : 
SYIJ.80L6 C=WH I T E  V=C I RC L E I =NON E , 
FOOTNO T E  H= 2 F=XSW I S S  C= 
WH I T E " O B S E R V E D  T H E O R E T I C A L  0 P R E D I C T !:D X " , 
2 1 7 
COMM EN T : PROGRAM FOR ANOVA OF E F F EC T  OF D I F F ER E N T 
MH I COAG U L A N T S  ON pH OF P L ASMA AT Z ERO T I M E  
D o t o  c o o g ; 
i n p u t  c o o g p h  00 :  
C A R D S : 
1 7 2 9  1 7 . 2 8 1 7 .  3 
2 7 . 2 7 2 7 .  3 2 7 .  3 2  
3 7 . 4 2 3 7 . 50 3 7 . 52 
PROC ANOVA ; 
C LA S S E S  c o o g ;  
MOD E L  p H  = COAG ; 
1 7 2 9  
2 7 33 
3 7 . 5 2 
MEANS COAG! t u k e y  o l p h o� . 0 1 ; 
2 9  
. 3 1  
5 2  
T I T L E  " Z e r o  T i m e pH i n  V o c u t o i n e r s " ; 
COMMEN T : PROGRAM TO T E S T  FOR S I G  D I F F E R ENC E 
B ETWEEN B I ND HJG AT PH 7 . 4  VS P H 8 .  
D a t a  p h p b ; 
i n p u  t pH F R E E  Of) :  
CAR DS ; 
7 . 4  1 5 . 49 7 . 4  1 4 . 7 5 7 4 1 5 . 2 5 
8 . 0  1 4 . 7 5 8 0  1 4 . 5 7 8 . 0  " . 0 8  
PROC T T ES T ; 
C LASS pH ; 
VAR F R E E ; 
T I T L E  " B i n d i n g pH 7 . 4  v s  8 0 " ; 
COMMEN T : PROGRAM TO R E G R E S S  F R E E  F R A C T I ON OF PYR 
ON A LBUM I N  CON C E N T R A T I ON 
d a t a  s u m 4 5 ; 
I NP U T  a l b um i n  f r e e  c p t o t : 
CARDS ; 
4 5 . 5 6 4 . 9 1  3 6 3 . 3 1 6  
4 5 . 5 6 3 . 53 1 1 8  4 2 6  
14  1 3 . 5 1  3 0 1  
1 4 . 3 1 3 .  7 4  2 8 3 . 6 
1 3  8 1 3 . 2 8 3 1 9 . 3  
8 .  1 3  25 . 05 7 5  
8 1 3  2 0 . 2 1 2 5 8  
8 .  1 3  2 3 . 3 2  3 7 2  
8 1 3  2 2 . 3  3 8 2  
2 3 . 5  9 . 5 6 1  3 1 4 .  
2 J  5 1 2 . 6 64 202 
2 3  5 9 . 4 1 2  509 
T I TL E  " P E R C E N T  FR E E v S  A LB UM I N CONC E N T R A T I ON " ; 
PROC R EG ; 
MOD E L  F R E E= A L BUM I N/P R C L I  C LM ;  
O U T P U T  OU T �A LB P R ED I C T ED � P R D  R ES I DU A L = R E S ; 
PROC P LO T ; 
P LO T  F R E E - A LBUM I N� ' O '  P R D - A L8LJM I N� '  / O V E R L AY ;  
P LOT R E S - A LBUM I N ! V R E F = 0  
2 1 8 
COMM E N T  PROGRAM TO DO ANOVA ON E F F EC T  OF A N T l COAG U L A N T S  
ON P E R C E N T  F R E E  P Y R  
D o t o  f r e c oo g ; 
i n p u  t c o o g  F R E E  OQ ;  
C A R D S ; 
4 . 8 5 4  1 5 . 8 8 5  1 4 . 4 6 6 5  
7 . 9 3 4  2 4 . 6 4 1  2 7 . 34 1  
1 3 . 9 7 '  3 7 . 1 05 3 6 . 60 4  3 6 3 7 7  
P R OC  G LM ;  
C LA S S E S  c o o g ; 
MOD E L  FR E E  = COAG ; 
LSMEANS COAG ; 
T I T L E  " P e r c e n t  F r e e  PYR i n  D i f f e r e n t  T 1J b e s " ; 
COMM E N T ; PROGRAM TO DO T T ES T  ON P E R C E N T  F R E E  
A T  1 00 VS 4 0 0  N G  PYR/ML . .  
D o t a  f r e t h e r ;  
i n p u t  CONC F R E E  00 ;  
CARDS ; 
4 0 0 3 . 5 5 4 0 0 5 . 6 7 4eo 5 . 1 7  4 0 0  5 . 89 4 0 0  4 . 2 8 
1 00 4 . 0 6 1 00 4 . 08 l eO 3 . 2 6 1 00 3 . 0 8  1 00 3 . 1 8  
PROC T T ES T ; 
C LA S S  CONe ; 
VAR FR E E ;  
T I T L E  " B i n d i n g a t  1 00 V S . 4 0 0  n g/m l " ;  
COMMEN T ; PROGRAM TO DO T - T E S T  ON B I ND I NG A T  TWO p H s  
D o t a  f r e t h e r ;  
i n p u t  p h  F R E E  00 ;  
CARDS ; 
8 .  1 4 . 7 5 8 .  " . 5 7 8 .  1 4 . 0 8 
7 . 4  1 5 . 4 9 7 . 4  1 4 . 7 5 7 . 4  1 5 . 2 5 
P R QC  T T E S T  
C LASS P H  
V A R  F R E E  
T I T L E  " S i n  i n g a t  pH 7 . 4  V S . pH 8 . 0 " ;  
2 1 9 
COMMENT : PROGRAM TO T EST FOR S I G  D I F F E R E N C E  
B ETWEEN B I ND I NG AT PH 7 . 4  VS P H  8 
Do t o  p h p b ; 
i n p u t  p H  
CARDS ; 
7 . 4  1 5 . 49 
8 . 0  1 4 . 7 5 
PROC TTEST ; 
C LASS pH ; 
VAR FR E E ;  
F R E E  00 '  
7 . 4  1 4 . 75 7 .  4 1 5 .  
8 . 0  1 4 . 57 8 .  0 1 4 .  
T I T L E  " B i n d i n g p H  7 . 4  v s  8 . 0 " ;  
2 5  
08 
COMMENT : PROGRAM TO REGRESS FREE FRAC T I ON O F  PYR 
ON A LB UM I N  CONC ENTRAT I ON 
d a t a  s um4S ; 
I NPUT a l b um i n  f r e e  c p t o t ; 
CARDS ; 
45 . 5 6 4 . 9 1  3 63 . 3 1 6  
45 . 5 6 3 . 53 1 1 8 . 42 6  
1 4  1 3 . 5 1  3 0 1  
1 4 . 3  1 3 . 7 4 283 . 6  
1 3 . 8  1 3 . 28 3 1 9 . 3  
8 .  1 3  25 . 05 75 
8 . 1 3  20 . 2 1  2 5 8  
8 . 1 3  2 3 . 3 2 372 
8 . 1 3 2 2 . 3  382 
23 . 5 9 . 5 6 1  3 1 4 . 5  
23 . 5  1 2 . 66 4  2 0 2  
23 . 5  9 . 4 1 2  5 0 9  
T I TLE " P ERCENT FREE VS . A LBUM I N  CONCENTRAT I O N " ; 
PROC R EG ;  
MO D E L  FREE=AlBUM I N/P R C l i  C lM ; 
OUTPUT OUT=AlB P R ED I C T ED=PRD RES I DUAl=RES ; 
PROC P LOT , 
P LOT FR E E . A lBUM I N- · 0  PRD . A lBUM I N= ' . '  / OVER LAY ; 
P LOT R E S . A lBUM I N  / VREF=0 ; 
2 2 0  
COMMENT , F I L E WHONOR3 8 . SAS . l  f OR K LO T Z  F I T  OF DA T A  38 
GOP T I ONS HS I Z E=6 . 5  VS I ZE=5 NOD I SP LAY D Ev I C E- T EK 4 0 1 '  
GS FMO D E= r e p l o c e  GS FNAME= T EK 40 1 4  NOPROMP T ;  
d a t a  e d 3 8 ; 
I NP U T  B U F F ER P LASMA C E L L ;  
CARDS ; 
1 7 . 5 1 89 . 8 7 3 
29 . 3 1  2 3 1 . 45 4 
2 9 . 3 1  2 4 8 . 9 4 5 
33 . 2 5 347 . 7 5 6 
52 . 9 5 5 6 2 . 55 7 
49 5 4 8 . 72 8 
60 83 7 3 9 . 1 7  9 
52 . 95 5 8 1 . 5 1 0  
8 8 . 4 1 9 7 3 . 77 1 1  
9 2 . 35 1 2 4 2 . 6 2 1 2  
3 2 3 . 03 4 0 9 4 . 7 1 1 3  
3 2 3 . 03 3 6 6 3 . 3  1 4  
DATA C A LC ; 
S E T  ED38 ; 
BOUND - P LASMA - BUFFER ; 
DATA CALC2 ; 
S E T  CALC ; 
Db - BOUN D - 00000 1 /2 4 8 . 7 1 ; 
D f  = b u f f e r - . 00000 1 /248 . 7 1 ; 
[l a. T,A. C:.� LC3 : 
S E T  C A LC 2 , 
R = Db/3 4 0 8 6 9 5 7 E-0 4 ; 
Da t a  C o l c 4 ; s e t  c o l c .3 :  
r b o l b  = r iO t ; 
I f r e e  - l o g I 0 ( D f ) . 
p f r e e  = b u f f e r/ p ' a sma 
pbd = 1 0 - p f r e e ; 
R R - l /R . RD= I /D F . 
WT= I /BUFFER ; 
PROC N L I N  B E5 T=20 I T ER- ' 00 M E T HOD=DUD 
PARAM ET ERS HK 1 =3�000 HK2- 1 00 0 0 ; 
BOUNDS HK 1 > 1 000 ; 
_WE I GHT _-WT ; 
MOD E L  R - ( D f _ HK l  + ( 2 - ( D f  . .  2 ) - H K 1 o HK 2 » / ( 1 +D F - HK l  + ( D F  . .  2 ) - HK 1 _ H K2 ) ; 
OUTPUT OUT-LARS PRED ICT Eo-PRED R ES I DUA L=RES I D 
E SS-WRS S  PARMS-HK 1 HK2 ; 
PROC PR I NT ; 
T I T L E  H=2 F=XSW I SS C=WH I T E " K LOTZ F I T  OF PYR DATA 3 8 " ; 
PROC GP LOT ; 
LAB E L  RBA L8=" R/ALBUM I N " ; 
LABE L  R= " R " ; 
LAB E L  L F R E E= "  LOG FREE PYR " ; 
LAB E L  PRED= " PRED I C T ED " ; 
LAB E L  R ES I D- " R ES I DUA L " ; 
P LO T  R - L FR E E- l PRED- LFREE-2 / OVER LAY ; 
P LOT R ES I D - L FREE-3 / VRE F-0 ; 
SYMBO L I  C=WH I T E  V-TR I ANG LE I =NON E ;  
SYMBO L2 C-WH I T E  V-X I -JO I N ;  
SYMBO L3 C-WH I T E V-X I -NON E ; 
COMMENT ; F I LE WHONOR4 1 . SAS ; 2  FOR K LOTZ F I T  OF DATA 4 1  
GOP1 I ONS HS I Z E-6 . 5  VS I Z E-5 NOD I SP l ,\Y D EV I C E-TEK40 1 4  
G S FMOD E- r e p  l o c o  GSFNAME-T E K 40 1 4 NOPROMPT ; 
da t a  e d 4 1 : 
I NPUT BUFFER P LASMA C EL L ;  
CARD S ; 
2 2 1  
2 5 . 0 5 1 00 . 05 1 
2 5 . 0 5 9 6 . 55 2 
44 . 87 2 0 4 . 00 3 
50 . 75 2 0 2 . 2 1  4 
59 09 32 3 . 7 4 5 
55 . 42 3 2 3 . 7 4 6 
1 0 9 45 49 1 . 3 5  7 
1 1 3 . 1 2  485 . 0 1  8 
1 3 1 . 47 60 1 . 83 9 
1 4 1  . 9 5 605 . 84 1 0  
2 2 4 . 9  9 74 . 43 1 1  
2 3 2 . 1 6  1 034 . 8  1 2  
4 1 9 . 67 1 74 1 . 49 1 3  
4 7 7 . 38 1 9 84 . 1 2  1 4  
8 1  2 8 1  3 6 4 6 . 39 1 5  
D A T A  C A LC ; 
S E T  ED4 1 ; 
BOUND � P LASMA - B U F F E R ; 
DATA CA LC 2 ; 
S E T  CA LC ; 
Db - BOUND • .  000 0 0 1 /2 48 . 7 1 ; 
O f  � b u f f e r • .  0 0 0 0 0 1 /248 . 7 1 ; 
DA TA CALC3 : 
S E T  C A LC 2 : 
R � D b / 1 . 1 782 5 1 E-04 ; 
D a t a  C o l c 4 ; S e t  c o l c 3 ;  
r b o t b  r /O f ; 
I f  r e e  = l o g 1 0 ( O t ) 
p f r e e ":= b u f f e r/ p l a sm a ; 
p b d  = 1 . 0 - p f r e e  
RR� l I" : R D � l  I O F . 
W T � l /BU F F � R  . 
PRQC N U N  B E S h 2 0  : T ER� 1 00 M E T HOD�DUD : 
PARAMETERS �K l �3000e HK2� 1 00 0 0  
BOUNDS Hf< 1 >  1 000 : 
_WE I GHT _�WT :  
MOD E L  R = ( D f ' HK l  + ( 2 ' ( D f  • •  2 ) . HK 1 . H K 2 » / ( 1 +D F ' H K l  + ( D F  • •  2 ) . HK 1 . H K 2 ) : 
OUTPUT OUT�LARS PRED I C T ED�PRED R E S I DUA L�R ES I D  
E S S�WRSS PARMS�HK 1 HK2 . 
PRQC PR I N T ; 
T I T L E  H�2 F-XSW I SS C=WH I T E  " K LOTZ F I T  OF PYR DATA 4 1 " ;  
PRQC GP LOT ; 
LAB E L  RBALB="R/ALBUM I N " ; 
LAB E L  R=" R " : 
LAB E L  PRED= " PR E D I C T ED " ; 
LAB E L  L F R E E= " LOG F R E E  PYR" : 
LAI3 E L  R ES I D= " R ES I DUA L " ; 
P LOT R . L FR E E= l  P R ED - L FR E E=2 / OVER LAY ; 
P LOT R ES I D ' L F R E E=3 / VR E F=0 ; 
SYMBO L l  C=WH I T E  V-TR I ANG L E  I -NON E :  
SYMB O L 2  C=WH I T E  V-x I = J O I N :  
SYMBOLJ C-WH I T E V=X I -NONE ; 
C�ENT : F I LE WHONOR47 . SAS : 2  FOR K LOTZ F I T  OF DATA 47 
GOP T I ONS HS I ZE=6 . 5  VS I ZE=5 NOD I SP LAY D EV I C E=TEK40 1 4  
GSFMODE- r e p l c c e  GS FNAME= T EK40 1 4  NOPROMP T ; 
d o t a  e d 4 7 ; 
I NPUT B U FFER P LASMA C E L L ; 
CARDS : 
9 1 19 . 2 3 2 69 1 . 2 2 " 
8699 . 5  399 1 9  93 1 2  
2 7 8 6 . 3  1 56 9 9  89 1 3  
3088 . 3  ' 9 9 6 4  04 1 4  
2 2 2  
1 588 . 6 8 2 4 1  . 2 6 1 5  
1 65 0  8 8 9 4 3 . 25 6 
1 2 1 5  5 6 7 8 0  3 7 
1 1 0 8 . 9  5 3 8 2 . 7 8 
7 7 1 . 3  43 1 3  . 87 9 
7 7 1 . 3  6 2 8 3 . 1 5 1 0  
3 0 1 . 3  2 1 5 6 .  47 1 
2 8 5 . 7 1 1 30 .  55 2 
4 4 1  . 2  2 5 8 6  8 7  3 
4 1 2  . 3  3559 . 1 6  4 
3 8 3 . 4 3 3 7 0 . 2 8  5 
DATA CALC ; 
S E T  ED47 ; 
8 
BOUND � P LASMA - B U F F E R ; 
DATA CALC2 ; 
S E T  CALC ; 
D b  � BOUND • .  0 0 0 0 0  1 / 2 4 8 . 7 1  ; 
O f  � b u f f e r  • .  0 0 0 0 0 1 /2 48 . 7 1 ; 
DATA CALC3 ; 
S E T  CA LC2 ; 
R � O b/9 . 59 1 5 7 E-05 ; 
D o t e  C a l c 4 ; s e t  c o t c 3 ;  
r b o l b  r/O f ; 
I ( r eo "!  = 1 0'j 1 � ( 1) f ) ;  
p f r e e  = bu f f e r/p l a sma ; 
p b d  == 1 . 0 - p f r e e ; 
r r  ::: l / r ; 
r d  = 1 /0 f ; 
WT� 1 /BI) F F ER ; 
PROC N U N  BEST-20 I T ER� 1 00 METHOO�DUD ; 
PARAMET ERS HK 1 -30000 H K 2- 1 0 0 0 0 ; 
BOUNDS HK 1 > 1 000 ; 
_WE I GH T _�WT ; 
MOD E L  R � ( D f . HK l  + ( 2 . ( D f  • • 2 ) . HK 1 . H K2 ) ) / ( I +D F . HK l + ( D F " 2 ) . H K 1 .HK 2 ) ; 
OUTPUT OUT�LARS P R E D I C T ED�P R E D  R ES I DUAL�RES I O  
ESS�WRSS PARMS�HK '  H K 2 ; 
PROC PR I N T ; 
T I T L E  H=2 F�XSW I SS C�WH I T E " K LOTZ F I T  OF PYR DATA 4 7 " ; 
PROC GP LOT ; 
LAB E L  RBALB�" R/A LBUM I N " , 
LAB E L  R�" R " , 
LAB E L  L F R E E � "  LOG F R E E  P YR " ; 
LAB E L  P R E D-" PRED I C T ED " ; 
LAB E L  R ES I D� " R ES I DUA L " ; 
P LOT R . LFREE- l  P R ED . L FR E E=2 / OVER LAY ; 
P LOT RES I D . L FR E E-3 / V R E F-0 ; 
SYMBO L '  C-WH I T E V-TR I ANG L E  I -NON E ; 
SYMB O L 2  C-WH I T E  V-x I - J O I N ;  
SYMBOL3 C�WH I T E V�X I �NON E ;  
2 2 3  
CQM.4EN T : B LANCHARD F I T  OF F I RS T  ED DATA U S I NG N L l N  
d o l o  ed38 : 
I NPUT 8 U F F ER P LASMA C E L L ; 
CARDS ; 
1 7 . 5  1 89 . 87 3 
2 9 . 3 1 2 3 1 . 45 4 
2 9 . 3 1 248 . 9 4 5 
33 . 25 347 . 75 6 
5 2 . 95 5 6 2 . 55 7 
49 548 . 72 8 
6 0 . 83 739 . 1 7  9 
5 2 . 9 5 5 8 1 . 5  1 0  
8 8 . 4 1 9 7 3 . 77 1 1  
9 2 . 35 1 2 42 . 6 2 1 2  
3 2 3 . 03 4094 . 7 1 1 3  
3 2 3 . 03 3 6 6 3 . 3  1 4  
DATA C A LC ; 
S E T  ED38 ; 
80UND 2 P LASMA - 8 U F F ER ; 
DATA C A LC 2 ; 
S E T  C A LC ; 
Db 2 80UND ' . 0000e 1 /2 48 . 7 1 ; 
O f  = b u f f e r  • .  0000 0 1 /2 48 . 7 1 ; 
DATA CALC3 ; 
S E T  CALC2 ; 
R - D b/3 408 6 9 5 7 E-04 ; 
O c t o  C a l c 4 ; s e t  c o l c 3 :  
r b o l b  r/D f : 
! f r e e  ... l og 1 0 ( O n 
p f r e e  = b u f f e r / p l a s m a  
p b d  = 1 . 0 - p f r e e ; 
RR=1 /R ; Ro- l /D F ; 
PROC N U N  8 EST=20 I T ER= 1 00 METHOD=DUD ; 
PARAMETERS HK 1 -30000 . HN 1 = 1 . C=30000 . ;  
80UNDS HN 1 >0 . 00 1  . 
MO D E L  R8AL8 � « HN 1 . H K 1 )/ ( HHK 1 . D F ) )  + C ;  
OUTPUT OUTaLARS P R E D I C T ED=PR ED R ES I DUA L=R ES I D  
ESS-WRSS PARMS=HK l H N I  C 
PROC P R I NT ;  
T I T L E  " 8 LANCHARD F I T  O F  PYR DATA 3 8 " ; 
PROC P LOT . 
P LOT R 8 A L8 . R= · 0 ·  P R ED . R= · . ·  I OVER LAY ; 
P LOT R ES I D . R  I V R E F=0 ; 
P LOT R ES I D · R  I VREF=0 ; 
COMMENT : 8 LANCHARD F I T  OF S ECOND ED DATA U S I NG N U N  . . . . • . . • • . . • . • . .  
do t a  e d 4 1 ; 
I NPUT 8UFFER P LASMA C E L L ; 
CARDS ; 
2 5 . 06 1 00 . 05 1 
25 . 06 9 6 . 55 2 
44 . 87 204 . 00 3 
5 0 . 75 202 . 2 1  4 
6 9 . 09 323 . 74 5 
65 . 42 323 . 74 6 
1 09 . 45 49 1 . 35 7 
1 1 3 . 1 2 485 . 0 1 8 
1 3 1 . 47 6 0 1 . 83 9 
1 4 1 . 95 605 . 84 1 0  
224 . 9  974 . 43 1 1  
232 . 1 0  1 034 . 8  1 2  
4 1 9 . 67 1 74 1 . 49 1 3  
4 7 7 . 38 1 98 4 . 1 2  1 4  
2 2 4 
8 ' 2 . 8 ,  3 6 4 6 . 39 , 5  
DATA CA LC : 
S E T  ED4 ' : 
BOUND = P LASMA - B U F F ER : 
DATA CALC2 : 
S E T  CALC : 
Db = BOUND ' . 00000 ' /248 . 7 ' : 
0 1  = b u l l e r  • .  00000 ' /2 48 . 7 ' : 
DATA CALC3 : 
SET CALC2 : 
R = D b / 1 . ' 7826 ' E-0 4 : 
D a t a  C a l c 4 ; S e t  c o l c .3 ;  
r b o l b  = r/D I : 
I I r e e  = 1 0 9 , 0 ( 0 1 ) :  
p f r e e  = b u f f e r/p l a sm a ; 
p b d  = , . 0 - p l r e e : 
RR= ' !R : R D= ' /D F :  
PROC N L l N  B EST=20 I T ER= ' 00 METHOD=DUD : 
PARAMETERS HK , =30000 . HN ' = ' . C=30 0 0 0 . :  
BOUNDS HN ' >0 . 00 ' : 
MO D E L  RBALB - « H N '  . HK 1 ) / (  1 +HK h D F »  + C :  
OUTPUT OUT=LARS PRED I C T ED=P R ED R ES I D U A L=R E S I D  
ESS=WRSS PARMS=HK ' HN ' C :  
PROC PR I NT :  
T I T L E  " B LANCHARD F I T  O F  PYR DATA 4 ' '' :  
PRQC P LOT : 
P LOT RBALB . R= ' 0 '  P R E D . R= ' . '  / OVER LAY : 
P LOT R ES I D . R  / VR E F=0 ; 
COMM ENT . B LANCHARu F I T  or TH I RD ED DATA US I NG N U N .  
d a t a  e d 4 7 , 
I NPUT BUFFER P LASMA C E L L : 
CARDS : 
9 , 79 2 3269 ' 2 2  " 
8 6 9 9  5 399 ' 9  9 3  1 2  
2 7 8 6 . 3  1 5 699 8 9  , 3  
3088 . 3  ' 9 9 6 4 . 04 1 4 
, 588 . 6  8 2 4 ' 26 , 5  
, 65 0 . 8  8943 2 5  6 
' 2 ' 5 . 5  6780 . 3  7 
1 1 08 . 9  5382 . 78 8 
7 7 '  3 43 ' 3 . 87 9 
77 1 3 6283 . ' 5  , 0  
3 0 ' . 3  2 ' 5 6 . 47 , 
2 85 . 7  1 1 30 . 55 2 
44 ' . 2  2 5 8 6 . 87 3 
4 ,  2 . 3 3559 . ' 6 4 
383 . 4  3370 . 28 5 
DATA CA LC : 
S E T  ED47 : 
BOUND - P LASMA - BU FFER : 
DATA CA LC2 :  
SET CA LC : 
Db - BOUND • .  00000 ' /2 48 . 7 ' : 
0 1  - bu l l e r  • .  00000 ' /248 . 7 , : 
DATA CALC3 ; 
S ET CALC2 : 
R - Db/9 .  5 9 ,  5 7 E-0 5 : 
D o t o  C o l c4 ; se t  c o l c3 :  
· r bo t b  - rIO t ; 
I l r  •• - 1 09 , 0 (0 1 ) : 
p f ree  ... b u f f e r/p l a s m a ; 
pbd - ' . 0 - p f r e e ; 
2 2 5  
r r = l / r ; 
rd = l /D f ; 
PROC N L I N  B EST=20 I T ER= 1 00 M E T HOD=DUD ; 
PARAM E T E R S  HK 1 =J0000 . HN 1 = 1 . C=J0000 . ;  
BOUNDS HN 1 >0 . 00 l ; 
MOD E L  RBALB = « H N 1 . HK 1 ) / ( 1 +H K 1 . D F »  + C ;  
OUTPUT OUT=LARS P R E D I C T ED=P R E D  R ES I DUAL=RES I D  
ESS=WRSS PARMS=HK l H N l  C ;  
PROC P R I N T ;  
T I T L E  " B LANCHARD F I T  O F  PYR DATA 4 7 " ; 
PROC P LOT ; 
P LOT R BA L B . R= ' 0 '  P R ED · R= ' · '  I OVER LAY ; 
2 2 6  
2 2 7  
COMMENT : DATA FROM F I RS T  A T T EMPT T O  G E N ER A T E  SCATCHARD P LOT DATA . 
PROGRAMS FOR F I T S TO L A R S E N  AND DOUB L E  R EC I PROC A L  EQUAT I ON S  . .  
d a t a  e d 3 8 ; 
I NP U T  B U F F E R  P LA SMA C E L L ; 
CARDS ; 
1 7 . 5  1 89 . 87 3 
29 . 3 1  2 3 1 . 45 4 
2 9 . 3 1  2 4 8 . 9 4 5 
33 . 2 5 3 4 7 . 7 5 6 
5 2 . 9 5 5 6 2 . 5 5 7 
49 548 . 72 8 
50 . 83 7 3 9 . 1 7 9 
5 2 . 9 5 5 8 1 . 5  1 0  
8 8 . 4 1 9 7 3 . 77 1 1  
9 2 . 35 1 2 4 2 . 6 2 1 2  
3 2 3 . e3 4 0 9 4 , 7 1  1 3  
3 2 3 , e3 3 6 6 3 , 3  1 4  
DATA CALC ; 
S E T  ED38 ; 
BOUND = P LASMA - B U F F E R ; 
DATA CALC2 ; 
S E T  CALC ; 
Db = BOUND . , e e e e e l / 2 4 8 , 7 1 ; 
O f  = b u l l e r ' , 00 e e e l / 2 48 . 7 1 ; 
DATA CALC3 ; 
S E T  CALC2 ; 
R = D b/3 , 4 e 8 6 9 5 7 E-0 4 , 
D a t a  C o l c 4 ; s e t  c o l c J ;  
r b a  I b = r /0 I ; 
I l r e e  = l og I 0 ( D I ) ,  
p f r e e  = b u f f e r / p l o sm a  
p b d  = 1 . 0 - p f r e e ; 
RR= I /R ; RD= I /D F . 
T I T L E  · ' LAR S E N  � I T  OF p y �  DATA 3 8 " ;  
PROC N L I N  B EST-2e I T ER= 1 00 MET HOD=DUD ; 
PARAM ET ERS HK 1 = 2 e e e e e . HK2=30eee ; 
MO D E L  R= ( HK 1 / ( 2 . ( HK I -2 . HK 2 ) ) ) ' LOG ( 2 . ( HK I - 2 . H K 2 ) . D I + I ) ;  
OUTPUT OUT=LARS P R ED I C T ED=PR ED R E S I DUA L=R E S  
ESS=WRSS PARMS=HK l H K 2 ; 
PROC P R I NT ,  
T I T L E  " LA R S E N  F I T  O F  PYR DATA 3 8 " ; 
PROC P LOT ; 
P LOT R . l l r e .= e P R E D . L F R E E= ' . '  / OVER LAY ; 
P LOT R ES . L F R E E  / V R E F=0 ; 
PROC R EG ; 
T I T L E  " DOUB L E  R EC I PROCA L F I T  OF DATA 3 8 " ; 
MODEL r r= r d/P R e l l  e LM ;  
OUTPUT OUT=LARS 2  P R E D I CT ED=PRD R E S I DUAL=RES ; 
PROC P LOT ; 
P LOT R R . RD= ' 0 '  P R D . R D= ' . '  / OVER LAY ; 
P LOT R E S . R D  /VR E F=0 ; 
COMME N T : DATA G E N ER A T E D  I N  S ECOND A T T EM P T  TO G E N E R A T E  SCATCHARD P LO T  
F I TS TO LAR S EN EQUAT I ON AND DOUB L E  R EC I PROCA L EQUAT I ON ,  
1 a t o  e d 4 1 ; 
! NP U T  B U F F E R  P LASMA C E L L ; 
.:ARD S ; 
2 5 . e 6 l ee . 0 5 1 
2 5 , e 6 9 6 , 55 2 
4 4 , 87 2 0 4 , e0 3 
5'1 . 7 5  202 , 2 1  4 
5Q . e9 3 2 3 , 74 5 
65 . 42 3 2 3 . 7 4 6 
1 09 45 49 1 . 3 5  7 
1 1 3 1 2  4 8 5 . 0 1  8 
1 3 1 . 47 6 0 1 . 83 9 
1 4 1  . 9 5 6 0 5 . 8 4 1 0  
2 2 4 9 9 7 4 . 43 1 1  
232 1 6  1 03 4 . 8  1 2  
4 1 9 . 6 7 1 7 4 1 . 49 1 3  
4 7 7 . 38 1 9 8 4 . 1 2  1 4  
8 1 2 . 8 1 3 6 4 6 . 39 1 5  
DATA CALC ; 
S E T  ED 4 1 ; 
BOUND = P LASMA - B U F F ER ; 
DATA C A L C 2 ; 
S E T  CALC ; 
Db = BOUND ' . 00000 1 /2 48 . 7 1 ; 
D f  = b u f f e r ' . e00 0 0 1 /2 48 . 7 1 ; 
DATA CA LC3 ; 
S E T  C A L C 2 ; 
R = D b/ l . 1 7 8 2 6 1 E-0 4 ; 
D a t a  C o l c 4 : S e t  c a l c 3 ;  
r b o l b  r/D f ; 
1 f r e e  = l o g I 0 ( D I ) ; 
p f r e e  = b u f f e r/ p l a sm a ; 
p b d  = 1 . 0 - p f r e e ; 
RR= I /R ; RD= I /D F ;  
T I T L E  " LA R S E N  F I T  O F PYR D A T A  4 1 " ;  
PROC N L I N  B EST=20 I T ER= 1 00 M E T H OD=DUD ; 
PARAM E T ER S  H K 1 =2 0 0 0 0 0 . HK2=30000 ; 
MOD E L  R= ( HK 1 1 ( 2 .  ( HK 1 -2 - HK 2 ) ) ) - LOG ( 2 .  ( HK 1 -2 . H K 2 ) - D l + l  ) ; 
OUTPUT OUT=LARS P R E D I C T ED=P R ED R E S I DUA L=R ES 
ESS=WRSS PARMS=HK l H K 2 ; 
P R OC P R I NT ; 
T I T L E  " LA R S E N  F I T  OF PYR D A T A  4 1 " ;  
PROC P LOT ; 
P LOT R . l f r e e= · O '  P R ED ' L FR E E= ' - '  I OV E R LAY ; 
P LOT R ES - L F R E E  I V R E F=0 ; 
P R OC  R EG ;  
T I T L E  " DOUB L E  R EC I PROCA L F I T  O F  DATA 4 1 " ;  
MOD E L  r r= r d/P R C L I  C LM ;  
OUTPUT OUT= LARS2 P R E D  I C T ED=PRD R ES I D U A L=R ES ; 
PROC P LOT ; 
P LO T  R R - R D= ' O '  P R D . R D= ' . '  I OVER LAY ; 
P LOT R E S . R D  IV R E F=0 ; 
COMMEN T : DATA G E N ER A T E D  FOR T H I RD A T T EM P T  TO MAK E A SCATCHARD P LOT . 
F I TS TO LARSEN AND DOUB L E  R EC I PROCAL EOUAT I ONS . . . . . . . . . . . . . . . .  , 
d o t a  e d 4 7 : 
I NPUT B U F F ER P LAS�A C E L L ;  
CARDS ; 
9 1 79 . 2  32 69 1 . 22  1 1  
8 6 9 9 . 5  39 9 1 9 . 93 1 2  
2 7 8 6 . 3  1 5 6 9 9 . 89 1 3  
3088 . 3  1 9 9 6 4 . 0 4 1 4  
1 58 8 . 6  8 2 4 1 . 2 6 1 5  
1 6 5 0 . 8  8 9 4 3 . 2 5 6 
1 2 1 5 . 5  6 7 8 0 . 3  7 
1 1 0 8 . 9  5 3 8 2 . 7 8 8 
7 7 1 . 3 4 3 1 3 . 8 7 9 
7 7 1 . 3 6 2 83 . 1 5 1 0  
3 0 1 , 3  2 1 5 6 . 47 1 
2 8 5 . 7  1 1 3 0 . 5 5 2 
441 . 2  2586 . 87 3 
4 1 2 . 3 3 5 59 . 1 6 4 
2 2 8 
383 . 4  3370 . 28 5 
DATA CALC ; 
S E T  ED47 ; 
BOUND = P LASMA - B U F F E R ; 
DAT A CA LC2 ; 
SET CALC ; 
Db = BOUND • .  00000 1 /248 . 7 1 ; 
DI = b u l t e r o . 00000 1 /248 . 7 1 ; 
DATA CALC3 ; 
S E T  CALC2 ; 
R = D b/9 . 59 1 5 7 E-0 5 ; 
D a t a  C a l c 4 ; s e t  c a l c3 ;  
r bo l b  - r/D t ; 
I l r e e  = l og 1 0 ( D I ) ;  
p f r e e  = b u f f e r/p l a sm a ; 
pbd = 1 . 0 - p t r e e ; 
r r  = l / r ;  
r d = l /D I ; 
T I T L E  " LARSEN F I T  OF PYR DATA 4 7 " ; 
PROC N L I N  B EST=20 I T ER= 1 00 M ETHOD=DUD ; 
PARAMETERS HK1 =200000 . HK2=30000 ; 
MOD E L  R= ( HK 1 / ( 2 .  ( HK 1 -2 . H K 2 » ) ' LOG ( 2 .  ( HK l -2 . HK2)  ' D t + 1 ) ; 
�UT�UT CUT=�AR3 PRED r C T ED=PRED R E S i GUA L=R ES 
ESS=WRSS PARMS=HK 1 HK2 ; 
PROC PR I NT ; 
T I T L E  " LARSEN F I T  OF PYR DATA 47 " ;  
PROC P LOT ; 
P LOT R ' l l r e e= ' 0 '  P R ED . L F R E E= ' . '  / OVER LAY ; 
P LOT R E S . L FR E E  / VREF=0 ; 
PROC R EG ; 
T I T L E  " DOUB L E  REC I PROCAL F I T  OF DATA 4 7 " ; 
MOD E L  n = r d/P R C L I  C LM ;  
OUTPUT OUT=LARS2 P R E D I C T ED=PRD R E S I DUA L=RES ; 
PROC P L OT ;  
T I T L E  " DOUB L E  R EC I PROCA L F I T  O F  DATA 4 7 " ; 
P LOT R R . R D- ' a '  P R D . R D- ' . '  / OVER LAY ; 
P LOT RES.RD / VREF-0 ; 
2 2 9  
Append i x  B 
Resu l ts of F i ts to Add i t i o n a l  Mode l s 
BLANCHARD FIT OF STUDY 1 DATA 
3 7 0 0 0  i 
3 6 0 0 0  i 
3 5 0 0 0  i 
1 4 0 0 0  1 
3 3 0 0 0  
3 2 0 0 0  j 
; 3 1 0 0 0 j 
A 3 0 0 0 0  1 
� 2 9 0 0 0
. 
rN�)�(�.�)(���.�Jf�----------------�H��l: 
u 2 8 0 0 0  '" '" 
" 2 7 0 0 0  
� 2 6 0 0 0  
2 3 0 0 0 
2 2 0 0 0 6 
2 1 0 0 0 
;�;�� 1
2 0 0 0 0  'r� ��""'�������'-���"-'��---r 
o .  0 0 2  
���� j 6 0 0 0  5 0 0 0  
4 0 0 0  
3 0 0 0  
2 0 0 0  
1 0 0 0  
1 0 0 0  
- 2 0 0 0  
· 3 0 0 0  
- 4 0 0 0  �l 
- 5 0 0 0  
- 6 0 0 0  
- 7 000 
o .  a 1 2  a 0 2 2  
x 
0 . 0 3 2  0 4 2  0 . 0 5 2  
x 
x 
x 
x 
- 8 0 0 0  j 
-9000 �t,-.-__ �T-�_�';:'x ___ r-' __ �r-'�_"""" 
-e . o  - 7 . 5 -7 0 -6 . 5  -6 0 -5 5 
L OG F R E E  PYR 
2 3 0 
BLANCHARD FIT OF STUDY 2 DATA 
R 
3 4 0 0 0  I 3 3 0 0 0 3 2 0 0 0  
3 1 0 0 0  j 
� 3 0 0 0 0  
L 
6 2 9 00 0 
U 
\1 2 8 0 0 0 
N 
2 7 0 0 0  
2 6 0 0 0  
2 5 0 0 0  
2 � o o o iL-6 __ � __ � __ � __ � __ .-__ .-__ -. __ -r __ -' __ -. 
0 . 00 0 . 0 1  0 . 0 2 0 0 3  0 . 04 0 . 0 5 0 . 0 6 0 . 0 7 0 . 0 8 0 . 09 0 . 1 0  
6000 
5 0 0 0  
< 0 0 0  
3 0 0 0  
2 0 0 0  
1 0 0 0  
- 1 00: 1 
- 3 0 0 0  x x 
- 4 0 0 0  x 
x 
x 
x x 
X x  
x x 
- 2 0 0 0  I - 5 0 0 0  'r-----,r-___r�_,_---.--_,_�_,_�,______��___r-__, 
0 . 00 0 . 0 1  0 . 0 2 0 0 3  0 . 0 4 0 . 0 5 0 06  0 . 0 7 0 . 08 0 . 0 9 0 . 1 0  
2 3 1  
2 3 2  
BLANCHARD FIT OF STUDY 3 DATA 
9 0 0 0 0  
8 0 0 0 0  � 
� 
7 0 0 0 0  j 
5 0 0 0 0  1 '" 
� 
� 50000 '" '" '" 
d O O O O  � 
1 
3 0 0 0 0 1 '" 
1 '" 
2 0000  1 
I 
0 . 0  o 2 0 . 4 0 . 6  0 . 8  1 . 0 1 . 2 I . 4  
30000 1 
2 0 0 0 0  1 x x 
x 
R 1 0000 
E 
S x x I 
0 
U x A x x x L - 1 0 0 0 0  x x 
- 20000 
-30000 j x 
0 . 0  0 . 2  0 . 4 0 . 5  0 . 8  1 . 0 1 . 2 I . 4 
LAR S E N  F I T  OF PYR DATA 38 
NON- L I N EAR L EAST SQUAR ES SUMMARY STAT I ST I CS D E P E N D E N T  VAR I AB L E  R 
SOURCE DF SUM O F  SQUAR E S  MEAN SQUA R E  
REGRESS I ON 2 0 .  0040080 1 35 7  0 .  00200400679 
R E S I DUAL 1 0  0 .  000020 8 6 8 8 6  0 .  00000208689 
UNCOR R E C T ED TOTA L 1 2  0 00402888243 
( COR R EC T ED TOTAL ) ' 1 1 0 0 0 2 2 8 2 5 9 0 2 0  
PARAME T ER E S T I MA T E  ASYMPTO T I C  ASYMPTOT I C  9 5  7-
STD . ERROR CON F I D ENC E I NT ER V A L  
LOW ER U P P E R  
H K  1 30580 . 55 9 4 1  2 5 2 7 . 2 0 7 6 6 8  24949 . 55 4 3 9 9  3 6 2 1 1 . 5 6 4 4  1 
H K 2  3 5 6 8 2 . 577 1 1 2 9 5 9 4 9 8 0 6 6 3  -30259 . 5 6 3 8 7 4  1 0 1 6 2 4 7 1 809 
ASYMPTOT I C  COR R E LA T I ON MATR I X  O F  T H E  PARAM E T ER S  
CORR 
H K 1 
H K 2  
H K 1 
1 . 0000 
-0 9 5 7 8  
Da ta 38 S tudy 1 
H K 2  
-0 . 9 5 7 8  
1 . 0000 
2 3 3  
:J; < < 0 � s � z � � < 
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LARSEN f I T  Of PYR DA T A 4 1  
NON- L I  N EAR LEAST SQUAR E S  SUMMARY STAT I S T I CS D E P ENDENT VAR I AB L E  R 
SOURC E 
R EGRESS I ON 
R ES I DUAL 
UNCOR R E C T E D  TOTAL 
( COR R E C T E D  TOTAL ) 
Of SUM Of SQUARES MEAN SOUAR E 
2 0 . 0 1 6 4 6 7 7 1 7 1 5  0 . 0 0 8 2 3 3 8 5 8 5 8  
1 3  0 . 0 0 0 0 2 5 7 2 1 60 0 . 0 0 0 0 0 1 9 7 8 5 8  
1 5  0 . 0 1 6 4 9 3 4 3 8 7 6  
1 4  0 . 0089 2 7 1 3370 
PARAM E T E R  EST I MA T E  ASYMPTOT I C  ASYMPTOT I C  9 5  r. 
STD . ERROR CON F I D ENC E I NT ERVAL 
LOW ER UPPER 
HK l 2 6 6 9 3  5 6 3 5 4  7 7 1 . 4 4 7 4 5 0 9  2 5 0 2 6 . 9 53 6 4 7  2 8 3 6 0 . 1 73438 
HK2 2 6 433 . 62 6 1 6  4 3 53 . 9 1 1 1 64 1  1 7 0 2 7 . 5 7 8 5 8 1  3 5 8 3 9 . 6 7 3 7 4 1 
ASYMPTOT I C  COR R E LAT I ON MATR I X  OF T H E  PARAM E T E R S  
CORR 
HK l 
HK2 
HK l 
1 . 0000 
-0 . 9 1 2 0 
S tudy 2 Da ta 4 1  
HK2 
-0 9 1 2 0 
1 . 0 000 
N 
W 
0\ 
2
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LARSEN r l T  OF" PYR DATA 4 1  
P LOT O F"  R ES . L F"R E E  LEGEND : A .. , 08S , e .  2 085 , ETC . 
I • . •• 15 i 
8 . 00 1 0  + 
I • . ••• 5 i 
0 . 0000 �i----------- ---------------------------------- ---------------------------------
-• . ••• 5 i 
-. . .. , . i -• . •• 1 5  i 
-0 . 0020 + 
I 
-0 . 00 2 5  + 
I 
-0 . e0.}0 + 
I 
-e . 00J5 + 
I 
-0 . 0040 + 
--�,------+,----�+,�--�+-----��----�, ---7 . 0  -6 . B  -6 . 6 - 6 . 4  - 6 . 2  - 6 . 0  
L F R E E  
I I 
� . 8  � ,  � .  � 2  � ,  � . 8  I\J W 
(» 
LARS E N  F I T  OF PYR DATA 4 7  
NON- L I N EAR LEAST SQUAR ES SUMMARY STAT I S T I CS D E P ENDENT VAR I A B L E  R 
SOURC E O F  SUM O F  SQUA R E S  MEAN SQUAR E 
R EGRESS I ON 2 3 . 75 8 2 1 2 0 0 4 2  1 . 8 7 9 1 0 6 00 2 1  
RES I DUAL 1 3  0 . 1 0 1 1 8 1 85 7 8  0 . 0 0 7 7 8 3 2 1 98 
UNCORR ECTED TOTAL 1 5  3 . 8 5 9 3 9 3 8 6 2 0  
( CORRECTED TOTAL ) 1 4  . 9 2 9 8 1 2 9 7 2 9  
PARAM E T ER EST I MA T E  ASYMPTO T I C  ASYMPTOT I C  9 5  � 
S T D . ERROR CON F I D E N C E  I NT ERVA L 
LOWER U P P E R  
HK 1 6 4 2 7 9 . 90832 1 0080 . 6 3 2 7 9 3  4 2 5 0 2 . 038233 8 6 0 5 7 . 778403 
HK2 1 4 6 4 1 . 33 4 0 0  2808 . 9 2 6 1 2 0  8 5 7 3 . 02 1 68 1  20709 . 6463 1 0  
ASYMPTO T I C  CORR ELAT I ON MATR I X  O F  T H E  PARAM ETERS 
CORR 
H K 1  
HK2 
Da ta 47 
HK 1 
1 . 00 0 0  
-0 . 6 6 5 9  
S tudy 3 
H K 2  
-0 . 6659 
1 . 0 000 
2 3 9  
I 
1 . 5 .. 
I 
1 . 4 + 
I 
I . J + 
I 
1 .  2 + 
I 1 . 1  + 
I 
1 . 0 + 
I 
13 . 9 + 
I 
13 . 8  + 
I 
13 . 7  + 
I 
0 . 6  + 
I 
I 
13 . 5  + 
I 
0 . 4  + 
I 
0 . J  + 
I 
0 . 2  + 
I 
13 . 1  + 
I ; . 
0 . 13  + 
• •  
. . 
LARSEN F l l  O f  PYR DATA 4 7  
P LOI O F  R ' LfREE SYM80'_ U S E D  I S  0 
P L O l  O f  P R E D . L F R E E  SYMBO,- U S f.O  I S  • 
. . 
----+---�,.--�,'":-::---:+, :-::--�"-:---:+:--�''":-::---''---+----+---+---;---+----+---+--5 . 9 5 -5 . 85 -5 . 7 �  -5 . 65 -5 . 55 -5 . 4 5 -5 . J5 -5 . 2 5 -5 . 1 5 -:;' . 05 - 4 . 9 5 - 4 . 85 - 4 . 7 5 -4 . 6 5 -4 . 55 - 4 . 4 5 
L fREE 
NOTE :  4 OBS H I DDEN N "" 
o 
24
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OBS 
4 
5 
6 
7 
8 
9 
1 0  
1 1  
1 2  
DOUB L E  R E C I PROC A L  F I T  O F  D A T A  3 8  
D E P  VAR I AB L E : R R  
AC TUA L 
49 I . 8 35 
4 I 9 . 4 0 1  
386 0 0 2  
2 6 9  5 6 3  
1 66 . 3 6 1  
1 6 9 . 6 5 
1 2 4 . 9 7 8  
1 60 . 3 9 7  
9 5 . 7 5 5  
7 3 . 7 0 2 4  
2 2 . 4 7 7 4 
25 3805 
A N A L Y S I S  O F  VAR I AN C E  
SUM O F  MEAN 
SOURC E O F  SQUA R E S  SQUAR E F V A L U E  PROB>F 
MOD E L  I 2 5 2 4 3 0 . 5  2 5 2 43 0 . 5  1 3 7 . 3 3 1  0 . 0 00 1 
E R ROR 1 0  1 8 3 8 1 . 1 7  1 83 8 . 1 1 7  
C T O T A L  I I  2 7 0 8 1 1 . 7 
ROOT M S E  4 2 . 8 7 3 2 6  R- SQUA R E  o 9 3 2 1 
O E P  M EAN 2 0 0 . 4 5 8 6  A O J  R-SQ o 9 2 5 3  
C .  V .  2 1 . 3 8 7 5 9  
PARAM E T ER E S T  I MA T E S  
V A R  I AB L E  O F  
I N T E R C E P  
RD 
P R E D  I C T  S T D  E R R  
VA L U E  P R ED I C T 
55 I . 46 6  :12 4 08 7  
3 2 4 . 5 a 6  1 6  2 8 5 7  
3 2 4  s a 6  1 6  2 8 5 7  
2 8 4 . 6 5 4  1 4  3 1 0 7 
1 7 4 . 358 12 5 7 5 3  
1 8 9 365 1 2  4 1 2 6 
1 50 2 4 2  1 3  0 9 7 3  
1 7 4 . 358 1 2  5 7 5 3  
9 9 . 6 9 1 4  1 5  0 7 0 3  
9 4 . 9 34 6  1 5 . 3 0 5 6  
1 8 . 7 1 2  1 9 . 8 4 2  
1 8  7 1 2  1 9 . 8 4 2  
PARAM E T E R  
E S T  I MAT E 
- 1 1 . 8 0 2 8  
. 000039 6 3 3 3  I 
S T ANDARD 
ERROR 
2 1 . 9 3 7 4 5  
. 00000338202 
LOW E R 9 57. UPP E R 9 57. LOW E R 9 57. 
MEAN MEAN P R E D I C I  
4 7 9 . 2 5 4  6 2 3  6 7 7  4 3 1  . 7 1 5  
2 8 8  2 1 9  3 6 0  7 9 3  2 2 2 . 3 1 8  
2 8 8  2 1 9  3 6 0  7 9 3  2 2 2 . 3 1 8  
2 5 2 . 7 6 8  3 1 6  5 4 1  1 8 3 . 9 4 5  
1 46 338 2 0 2  3 7 7  7 4 . 805 1 
1 6 1 . 70 7  2 1 7 . 0 2 2  89 . 9 1 3 3 
1 2 1 . 0 6 1 7 9 . 4 2 5 50 . 3 5 6  
1 4 6 . 3 38 2 0 2 . 3 7 7  7 4 . 80 5 1  
6 6 . 1 1 2 4 1 3 3 . 2 7 - 1 . 5 6 6 6  
6 0 . 8 3 1 5  1 2 9 0 3 8  -6 . 4 9 8 4  
- 2 5 . 4 9 9  6 2 . 9 2 2 9  -86 . 5 5 1  
- 2 5 . 4 9 9  6 2 . 9 2 2 9  -86 . 5 5 1  
T FOR He : 
PARAM E T  ER�0 
- 0  538 
I I . 7 1 9  
UPP E R 9 5% 
P R E D I C T R ES I DUAL 
6 7  1 . 2 I 6 - 5 9 . 63 
4 2 6 . 6 9 4 9 4 . 8 9 5 2  
4 2 6 . 6 9 4  6 1 . 4 9 6 6  
38 5 . 3 6 4  - 1 5 . 09 1  
2 7 3 . 9 1  - 7 . 9 9 6 5  
2 8 8 . 8 1 6  - 1 9 . 7 1 4  
2 5 0 . 1 2 8 - 2 5 . 2 6 4  
2 7 3 . 9 1  - 1 3 . 9 6 1  
2 0 0 . 9 4 9  -3 . 9 3 6 3  
1 9 6 . 3 6 8  -2 1 . 2 3 2  
1 2 3 . 9 7 5  3 . 7 6 5 4 2  
1 2 3 . 9 7 5  6 . 6 6 8 4 7  
P R O B  > I T 1 
0 . 6 0 2 3  
0 . 000 1 
S T D  E R R  
R E S  I DUA L 
28 0 6 7 7  
3 9 . 6 5 9 7  
3 9  6 5 9 7  
4 0 . 4 1 4 4 
40 9 8 7 6  
4 1 . 03 7 1  
4 0  8 2 3 7  
4 0  9 8 7 6  
4 0 . 1 3 7 3  
4 0  0 4 8 2  
38 0 0 5 4  
38 0 0 5 4  
S T UD E N T  
R E S I D U A L  - 2 - 1 -0 I 2 
- 2 . 1 2 4 5  • • •  ' 1  
2 . 39 2 7 3  I ' " • 
1 . 5 5 0 6 1 I • • •  
- . 3 7 3 4 0 6  1 
- . 1 9 5 0 9 6  1 
- . 4 8 0 3 9 9  1 
- . 6 1 88 5 8  - I 
- . 3 4 0 6 1 6  1 
- . 0 9 8 0 7 2  1 
- . 53 0 1 6 5  ' 1  
. 0 9 9 0 7 5 7  I 
0 . 1 7 5 4 6 1  I 
N 
01> 
N 
COOK ' S  
OBS D 
1 3 . 0 0 9  
2 0 . 4 8 3  
3 0 . 2 0 3  
4 0 . 00 9  
5 0 . 00 2  
6 0 . 0 1 1 
7 0 . 0 2 0  
B 0 . 00 5  
COOK ' S  
OBS D 
9 o 0 0 1  
1 0  o 0 2 1  
1 1  o 0 0 1  
1 2  o 0 0 4  
S U M  O F  R ES I DU A L S  
SUM O F  SQUAR E D  R ES ! DU A L S  
P R E D I C T ED R ES I D  SS ( P R E S S ) 
- 1 . 4 6 9 9 4 E- 1 3  
1 8 38 1 . 1 7 
3 9 3 6 5 . 57 
N 
� 
w 
2 4
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OBS 
1 
2 
3 
4 
5 
6 
1 0  
1 1  
1 2  
1 3  
1 4  
1 5  
DOUB L E  R E C I PROC A L  F I T  O F  D A T A  4 1  
D E P  VAR I AB L E : RR ANAL Y S  I S O F  VAR l ANCE 
ACTUAL 
3 9 0 . 7 7 9  
409 . 9 1 1 
1 8 4 1 5 5 
1 9 3 . 48 
1 1 5 0 7 8  
1 1 3 . 4 4 3  
7 "  7 3 3 5  
7 8  7 9 8 9  
6 2  3 0 2 3  
6 3 . 1 '1 1 3  
3 9 . 09 7 2  
3 6 . 5 1 0 2 
2 2 . 1 69 8  
1 9 . 4 4 9  
1 0 . 3 4 1 9  
SUM O F  M E A N  
SOURC E O F  SQUAR E S  SQUA R E  F V A L U E  PROB>F 
MOD E L  1 2 1 9 4 7 7 . 2  2 1 9 4 7 7 . 2  1 0 1 5 . 7 3 1  0 . 00 0 1  
ERROR 1 3  2 8 0 9 . 0 1 5  2 1 6 . 0 7 8 1  
C T O T A L  1 4  2 2 2 2 8 6 . 2  
ROOT M S E  1 4 . 6 9 9 5 9  R-SQUAR E 0 . 9 8 7 4  
D E P  MEAN 1 2 1 . 0 2 8  ADJ R-S'l 0 . 9 8 6 4  
C . V .  1 2 . 1 4 5 6 2  
PARAME T E R  E S T  I M AT ES 
VAR I AB L E  O F  
I N T E R C E P  
RD 
P R E D I C T S T D  ERR 
VALUE P R ED I C T  
387 . 2 5 7  9 . 1 7 5 2 5 
3 8 7  2 5 7  9 .  1 7 5 2 5  
2 1 1 . 3 3 2  4 . 7 3 6 4 3  
1 8 5 . 5 4 7  4 30 1 5 7 
1 3 3 3 1 7  3 8 1 4 9 5  
1 4 1 42 5 3 . 8 4 9 
80 0 2 0 1 0 0 7 5 9  
7 7 . 0 6 0 2  0 3 8 3 7  
6 4  739 1 4 . 1 8 6 2 4  
5 9  1 3 1 5  4 . 2 6 3 4 5  
3 3 . 1 855 4 . 6 9 0 6 3  
3 1  . 7 9 7  4 . 7 1 6 3 6  
1 2 . 5 7 9  I 5 0 9 7 4 7  
9 7 0 2 6  5 . 1 5 8 1 6  
1 . 0 7028 5 . 3 4 5 3  
PARAM E T E R  
E S T  I MA T E  
- 1 1 . 2 1 5 1  
. 000040 1 49 9 8  
S T ANDARD 
ERROR 
5 . 6 2 3 3 9 7  
. 00000 1 2 5 9 7 8  
LOW E R 9 57. U P P E R 9 57. LOWER9 5'r. 
MEAN MEAN P R E D I C T  
3 6 7 . 4 3 5  4 0 7 . 0 7 8  3 4 9 . 8 2 1  
3 6 7 . 4 3 5  4 07 . 078 3 4 9  8 2 1 
2 0 1 . 1  2 2 1 . 5 6 5  1 7 7 9 6 8  
1 7 6 . 2 5 4  1 9 4 . 8 4 1 5 2 4 5 )  
1 2 5 . 07 5  1 4 1 . 5 58 1 00 5 0 8  
1 3 3 . 1 09 1 4 9 . 7 4 1 0 8 . 5 9 9  
7 1  . 3 623 88 . 678 4 7 . 1 04 6  
6 8 . 3 3 5 8  8 5 . 7 8 4 5  4 4 . 1 2 7  
5 5 . 6 9 5 3  7 3 . 7 8 2 9  3 1  . 7 1 9 g 
4 9 . 9 2 09 68 . 3 4 2 1 2 6 . 0 6 6 2  
2 3 . 05 2  4 3 . 3 1 9  - . 1 4 8 6 2 7  
2 1 . 6 08 41 . � 8 6 1 - 1 . 5 5 4  
1 . 5 6 6 6 4  2 3 . 5 9 1 5  -2 1 . 03 3  
- 1 . 4 4 0 9  2 0 . 8 4 6 1 - 2 3 . 9 5 2  
- 1 0 . 4 7 8  1 2 . 6 1 8 1  - 3 2 . 7 2 1  
T FOR H0 : 
PARAM E T ER=0 
- 1 . 9 9 4  
3 1 . 8 7 1  
U P P E R 9 57. 
P R E D I C T R ES I DU A L  
4 2 4  6 9 2  3 . 5 2 2 6  
4 2 4  6 9 2  2 2 . 6 5 4 3  
2 4 4  6 9 7  - 2 7 . 1 78 
2 1 8  6 3 6  7 . 9 3 2 8 7  
1 6 6 . 1 2 5 - 1 8 . 2 3 9  
1 7 4 2 5 2  - 2 7 . 9 8 2  
1 i 2 9 3 6  - 3 . 2 8 6 6  
1 09 . 9 9 3  1 . 7 3 8 7 5  
9 7  7 5 8 3  - 2 . 4 3 6 7  
9 2 . 1 9 68 4 . 03 9 8 1 
66 5 1 9 6 5 . 9 1 1 7  
6 5 . 1 4 8 1  4 . 7 1 3 1 5  
4 6 . 1 9 0 8  9 . 5 9 0 7 8  
4 3  3 5 7 5  9 . 7 4 6 3 7  
3 4  8 6 1 2  9 . 2 7 1 5 9 
PROB > I T I 
0 . 0 6 7 5  
0 . 000 1 
S T D  ERR 
R E S I D U A L  
1 1 . 4 8 4 5  
1 1  4 8 4 5  
1 3  9 1 5 6 
1 4  0 5 6 1 
1 4  1 9 59 
1 4 . 1 8 6 7  
1 4 . 1 4 2 7  
1 4 . 1 34 
1 4 . 09 0 9  
1 4 . 0 6 7 7  
1 3 . 9 3 1 1 
1 3 . 9 2 2 4  
1 3 . 7 8 7 5  
1 3 . 7 6 4 9  
1 3 . 6 9 3 3  
S T U D E N T  
R E S I D U A L  -2- 1 -0 1 2 
0 . 3 0 6 7 2 8  
1 . 9 7 2 6 1  I • • •  
- 1 . 9 5 3  
o 5 6 4 3 7 1 
- 1 . 2 8 4 8  
- 1 . 9 7 2 4  
-0 . 23239 
0 . 1 2 3 0 1 9  
- . 1 7 2 9 3 1  
0 . 2 8 7 1 68 
o 4 2 4 3 5 2  
o 3 3 8 5 2 9  
o 6 9 5 6 1 7  I :  o 7 0 8 0 6 1 
o 6 7 70 9 1  I '  N 
.,. 
0'1 
COOK ' S  
OBS D 
6 0 . 1 4 3 
7 0 . 00 2  
8 0 . 00 1  
9 0 . 00 1  
1 0  0 . 00 4  
1 1  0 . 0 1 0  
1 2  0 . 00 7  
1 3  0 . 03 3  
1 4  0 . 0 3 5  
1 5  0 . 0 3 5  
S U M  O F  R E S  I D U A L S  
S U M  O F  SQUA R E D  R E S  I D U A L S  
P R E D I C T ED R ES I D  S 5  ( P K E S S ) 
0 2 0 6 1 E- 1 4  
2 8 0 9 . 0 1 5  
4 1 60 . 7 7 
DOU8 L E  R E C I PROC A L  F I T  OF D A T A  4 1  
COOK ' S  
08S D 
o 030 
1 . 2 4 2  
0 . 2 2 1  
o 0 1 5  
o 0 6 0  
I\.) 
"" 
-..] 
2
4
8 
; 
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!� Ig i� 1* t8 I� u I: n: I"' t o 
D EP VAR I AB L E : R R  
085 AC T U A L  
1 . 0 1 4 6 
0 . 7 6 4 0 8 9  
1 8 4 7 2 9  
4 1 4 1 3 5 8  
5 3 . 5 8 5 8 1 
6 3 . 2 7 1 2 2 
7 4 . 2 8 6 8  
8 5 58 1 6 2 
9 6 . 7 3 3 8 7  
1 0  4 . 3 2 7 9 8  
1 1  1 2 . 8 588 
1 2 2 8 . 2 3 6  
1 3  1 1 . 1 1 7 8 
1 4  7 . 58063 
1 5  7 . 9 8 6 6 6  
DOU8 L E  R EC I F ROC A L  F I T  O F  D A T A  4 7  
ANALYS I S  O F  VAR I A N C E  
S U M  OF MEAN 
SOURC E D F  SQUA R E S  SQU A R E  F V A L U E  PR08 > F  
MO D E L  1 4 9 5 . 7 2 3 2  4 9 5 . 7 2 3 2  3 5 . 5 7 2  
ERROR 1 3  1 8 1 . 1 6 49 1 3 . 9 3 5 7 6  
C T O T A L  1 4  6 7 6 . 8 8 8 1 
ROOT M S E  3 . 7 3 3 0 6 4  R- SQUA R E  o 7 3 2 4  
D E P  MEAN 6 . 7 0 7 1 1 8 A D J  R-SQ 0 . 7 1 1 8  
C . V .  55 . 6 5 8 2 4  
PARAM E T E R  E S T  I MA T E S  
VAR I A8 L E  D F  
I NT ER C E P  
RD 
PR ED I C T S T D  ERR 
VA L U E  P R E D I C T  
0 . 2 0 9 8 5 3  1 . 4 5 4 5 7  
0 . 2 4 0 7 5 6  1 . 4 5 0 7  
1 . 4 9 5 7 4  1 . 3 0 0 G 7  
. 3 1 5 1 9  1 3 2 1 4 9 
8 8 7 7 5  1 . 1 5 7 2 1 
7 6 5 7 3  1 . 1 68 6 6  
88 1 7 6 1 . 0 7 3 9 9  
28862 1 . 0 4 5 7  
3 1 9 2 2  0 . 9 6 6 0 6 5  
6 . 3 1 9 2 2  0 . 9 6 6 0 6 5  
1 6 . 7 2 3 5  1 . 9 3 6 3 6  
1 7  6558 2 . 0 7 3 3 9  
1 1  3 0 9 5  1 . 2 3 4 7 1  
1 2 . 1 2 6 8  1 . 32 4 6 8  
1 3 . 0 6 7 3  1 . 4 3 7 4 4  
PARAM E T E R  
E S T  I M A T E  
-0 . 35059 1 
. 00 0 0 2 0 6 8 4 4 4  
S T ANDARD 
ERROR 
1 . 5 2 6 2 1 9  
. 00 0 0 0 3 4 6 8 0 8  
LOW ER 9 57. UP P ER 9 5% LOW E R 9 57. 
MEAN MEAN P R E D I C T  
- 2  9 3 2 6  3 . 3 5 2 2 6  -8 . 4 4 5 5  
- 2  8 9 3 3  3 . 3 7 4 7 9  -8 . 4 1 1 6  
- 1 . 3 1 48 4 . 30 63 2 - 7 . 0 4 4 8  
- 1 . 5 3 9 7  4 . 1 7 0 1  -7 . 2 4 
0 . 3 8 7 7 4 8  5 . 3 8 7 7 5  -5 . 5 5 5 6  
0 . 2 4 1 00 6  5 . 2 9 0 4 6  -5 . 6 8 5  
1 . 5 6 1 55 6 . 2 0 1 9 8 - 4 . 5 1 0 2 
2 . 0 2 9 5 4  6 . 5 4 7 7 1  - 4 . 0 8 6 6  
4 . 2 3 2 1 7  8 . 4 0 6 2 8  - 2 . 0 1 1 2  
4 . 2 3 2 1 7  8 .  1 0 6 2 8  - 2 . 0 1 1 2  
1 2 . 5 4 0 3  2 0 . 9 0 6 8  7 . 6 3 8 3 4  
1 3 . 1 7 6 5  2 2 . 1 35 1 8 . 4 3 0 5 8  
8 . 6 4 2 0 6  1 3 . 9 7 6 9  2 . 8 1 5 0 2  
9 . 2 6 5  1 4 . 9 8 8 6  3 . 5 6 9 3  
9 . 9 6 1 9 1 1 6 . 1 7 2 7  4 . 4 2 5 3 1 
T FOR H 0 : 
PARAM E T ER=0 
-0 2 3 0  
5 9 6 4  
U P P E R 9 57. 
P R E D I CT R ES I DU A L  
8 . 8 6 5 2 3  0 . 8 0 4 7 4 3  
8 . 89 3 1  0 . 5 2 3 3 3 3  
1 0 . 0 3 6 2  0 . 35 1 5 5 6  
9 . 8 7 0 3 8  . 09 8 3 9 1 
1 1 . 3 3 1 1 o 6 9 8 0 6 4  
1 1 . 2 1 6 5 o 5 0 5 4 8 6  
1 2 . 2 7 3 7  o 4 0 5 0 3 9  
1 2 . 6 6 3 8  1 . 2 9 3  
1 4 . 6 4 9 7  0 . 4 1 4 6 4 5  
1 4 . 6 4 9 7  - 1 . 9 9 1 2  
2 5 . 8 0 8 7  - 3 . 8 6 4 7  
2 6 . 8 8 1  1 0 . 58 0 2  
1 9 . 80 4  - . 1 9 1 6 58 
2 0 . 6 8 4 3  - 4 . 5 4 6 2  
2 1 . 70 9 3  - 5 . 0 8 0 7  
0 . 0 0 0 1  
PROS > I T I 
0 . 8 2 1 9  
0 . 000 1 
S T D  ERR 
R ES I DU A L  
3 4 3 8 0 2  
3 4 3 9 6 6  
3 . 4 9 9 0 3  
3 4 9 1 3 3 
3 5 4 9 1 7  
3 5 4 5 4 2  
3 . 5 7 5 2 3  
3 . 5 8 3 6 1 
3 . 6 0 5 9  
3 . 6 0 5 9  
3 . 1 9 1 6  
3 . 1 0 4 3 2  
3 . 5 2 2 9 6  
3 . 4 9 0 1 3  
3 . 4 4 5 2 2  
S T U D E N T  
R E S  I DU A L  - 2 - 1 -0 1 
0 . 2 3 4 0 7 2  I 
0 . 1 5 2 1 4 7 I 
0 . 1 00 4 7 2  I 
. 0 2 8 1 8 1 5  I 
0 . 1 9 6 6 8 4  I 
0 . 1 4 2 5 7 4  I 
0 . 1 1 3 2 9  • I 
0 . 3 6 0 8 0 9  I 
0 . 1 1 4 9 9 1  I 
- . 5 5 2 2 1 8  . : 1 - 1 . 2 1 09 
3 . 4 0 8 2 2  I · · · · · ·  
- . 0 5 4 4 0 3  I I 
- 1 . 3 0 2 6  " I I 
- 1 . 4 7 4 7  " I I 1\) U1 
0 
COOK ' S  
OBS D 
5 o 00 1 
7 o 00 1 
8 o 0 0 5  
9 o 000 
1 0  o 0 1 1 
1 1  o 2 7 0  
1 2  2 5 9 1 
1 3  o 000 
1 4  0 . 1 2 2 
1 �  0 . 1 89 
SUM or R E S  I DUALS 
SUM or SQUAR ED R E S  I DUALS 
PRED I C T ED R ES I D  S S  ( P R E S S ) 
33 1 4 7 E- 1 5  
1 8 1 . 1 6 4 9  
3 3 4 . 0 0 4 5  
DOUB L E  R EC I PROCAL F I T  O F  DATA 4 7  
OBS 
1 
2 
3 
4 
5 
COOK ' S  
D 
o 005 
o 0 0 2  
o 0 0 1  
o 000 
o 002 
N 
U1 
I-' 
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2 5 4  
vita 
2 5 5  
2 5 6  
